

## **SCIENTIFIC REFERENCES FOR INTEGRATIVE ONCOLOGY**

### I- Scientific articles

- Alkylglycerols, Alpha lipoic acid, Acetyl-L-carnitine p.2
- Anti-oxidants & nutraceuticals in chemotherapy p. 4
- Artemisinin & Artesunate p. 12
- Ashwagandha (Withania) p. 13
- Avemar, Boswellia p.14
- Breast cancer p. 15
- Butyrate, Cannabis p.16
- Chinese medicine (TCM) herbs & acupuncture p. 19
- Co-enzyme Q-10 p. 22
- Curcumin & Inflammation p. 23
- Diet & general integrative oncology (miscellany) p. 28
- Ginger, Grape seed extract & Resveratrol p. 34
- Green tea EGCG & polyphenols p. 38
- Indole-3-carbinol p. 41
- L-Glutamine, Low-dose Naltrexone p. 43
- Melatonin p. 45
- Milk thistle p. 48
- Mistletoe lectins p. 50
- Mitochondria, Dichloroacetate DCA p. 52
- Modified citrus pectin p. 57
- Mushrooms (Reishi, button mushrooms, etc.) p. 58
- Omega 3 oils p. 59
- Phytoestrogens and Soy p. 62
- Pomegranate & Ellagic acid, Prevention p. 64
- Quercitin p. 65
- Radiation p. 67
- Stem cells & immune cells p. 69
- Sugar, Insulin, IGF-1, Metformin p. 71
- Surgery p. 74
- Vitamin C p. 76
- Vitamin D p. 79
- Vitamin K p. 81

### II – Bibliography p. 82

### II – Journals p. 86

## ALKYLGLYCEROLS

[Effect of High Doses of Shark Liver Oil Supplementation on T cell Polarization and Peripheral Blood Polymorphonuclear Cell Function], Lewkowicz, Banasik, Głowacka, et al., **Pol. Merkur. Lekarski.** 2005; 18 (108): 686-692.

[The Assessment of the Effectiveness of the Shark Liver Oil in Recurrent Aphthous Stomatitis Treatment: Clinical and Immunological Studies], Gurańska, Lewkowicz, Urbaniak, et al., **Pol. Merkur. Lekarski.** 2001; 11 (63): 233-238.

An Update on the Therapeutic Role of Alkylglycerols, Iannitti & Palmieri, **Marine Drugs** 2010; 8: 2267-2300.

## ALPHA LIPOIC ACID & ACETYL-L-CARNITINE

Increased ROS Generation and p53 Activation in Alpha Lipoic Acid-induced Apoptosis of Hepatoma Cells, Simbula, Columbano, Ledda, et al., **Apoptosis** 2007; 12 (1): 113-123.

Uptake, Recycling, and Antioxidant Actions of Alpha-Lipoic Acid in Endothelial Cells, Jones, Li, Qu, et al., **Free Radic. Biol. Med.** 2002; 33 (1): 83-93.

Alpha-Lipoic Acid Inhibits TNF-alpha Induced NF-kappa B Activation Through Blocking of MEKK1-MKK4-IKK Signalling Cascades, Lee, Lee, Kim, et al., **Int. Immunopharmacol.** 2008; 8 (2): 362-370.

Reactive Oxygen Species Mediate Caspase Activation and Apoptosis Induced by Alpha Lipoic Acid in Human Lung Epithelial Cancer Cells Through Bcl-2 Down-Regulation, Moungiaroen, Nimmannit, Callery, et al., **J. Pharmacol. Exp.** 2006; 319 (3): 1062-1069.

R-lipoic Acid Inhibits Mammalian Pyruvate Dehydrogenase Kinase, Korotchkina, Sidhu,& Patel, **Free Radic. Res.** 2004; 38 (10): 1083-1092.

Alpha Lipoic Acid Induces Apoptosis in Human Colon Cancer Cells by Increasing Mitochondrial Respiration with a Concomitant O<sub>2</sub>\* Generation, Wenzel, Nickel & Daniel, **Apoptosis** 2005; 10 (2): 359-368.

Reactive Oxygen Species Mediate Caspase Activation and Apoptosis Induced by Lipoic Acid in Human Lung Epithelial Cells Through Bcl-2 Down-Regulation, Moungiaroen, Nimmannit, Callery, et al., **J. Pharmacol. Exp. Ther.** 2006; 319 (3): 1062-1069.

Differential Activity of Lipoic Acid Enantiomers in Cell Culture, Smith, Thiagaraj, Seaver & Parker, **J. Herb Pharmacother.** 2005; 5 (3): 43-54.

Selective Inactivation of Alpha-ketoglutarate Dehydrogenase and Pyruvate Dehydrogenase: Reaction of Lipoic Acid with 4-hydroxy-2-nonenal, Humphries & Szweda, **Biochemistry** 1998; 37 (45): 15835-15841.

Interaction of Alpha-lipoic Acid Enantiomers and Homologues with the Enzyme Components of the Mammalian Pyruvate Dehydrogenase Complex, Löffelhardt, Bonaventura, Locher , et al., **Biochem. Pharmacol.** 1995; 50 (5): 637-646.

The Long-term Survival of a Patient with Pancreatic Cancer with Metastases to the Liver after Treatment with the Intravenous Alpha-Lipoic Acid/Low-dose Naltrexone Protocol, Berkson, Rubin & Berkson, **Integr. Cancer Ther.** 2006; 5 (1): 83-89..

Effects of Alpha Lipoic Acid on Transforming Growth Factor beta 1-p38 Mitogen-activated Protein Kinase-Fibronectin Pathway in Diabetic Nephropathy, Lee, Kang, Ryu, et al., **Metabolism** 2009; 58 (5): 616-623.

*The Natural Antioxidant Alpha-Lipoic Acid Induces p27(Kip1) Dependent Cell Cycle Arrest and Apoptosis in MCF-7 Human Breast Cancer Cells*, Dozio, Ruscica , Passafaro, et al., **Eur J Pharmacol.** 2010; 641 (1): 29-34.

*Treatment of Symptomatic Diabetic Polyneuropathy with the Antioxidant α-Lipoic Acid. A 7-Month Multicenter Randomized Controlled Trial (ALA-DIN III Study)*, Ziegler, Hanefeld, Ruhnau, et al., **Diabetes Care** 1999; 22: 1296-1301.

*Attenuation of Mitochondrial Apoptosis by Alpha Lipoic Acid Through Suppression of Mitochondrial Oxidative Stress to Reduce Diabetic Cardiomyopathy*, Li, Zhang, Li, et al., **Chin. Med. J. (Engl.)** 2009; 122 (21): 2580-2586.

*Mitochondrial Decay in the Aging Rat Heart: Evidence for Improvement by Dietary Supplementation with Acetyl-L-Carnitine and/or Lipoic Acid*, Hagen, Moreau, Suh & Visioli, **Ann. NY Acad. Sci.** 2002; 959: 491-507.

*Memory Loss in Old Rats is Associated with Brain Mitochondrial Decay and RNA-DNA Oxidation: Partial Reversal by Feeding Acetyl-L-Carnitine and/or R-Alpha Lipoic Acid*, **Proc. Natl. Acad. Sci. USA** 2002; 99 (4): 2356-2361.

*Acetyl-L-Carnitine for the Treatment of Chemotherapy-Induced Peripheral Neuropathy: A Short Review*, De Grandis, **CNS Drugs**. 2007; 21 S 1:39-43; discussion 45-46.

*(R)-Alpha Lipoic Acid-Supplemented Old Rats Have Improved Mitochondrial Function, Decreased Oxidative Damage and Increased Metabolic Rate*, Hagen, Ingersoll, Lykkesfeldt, et al., **FASEB J.** 1999; 13 (2): 411-418.

*Increased ROS Generation and p53 Activation in Alpha Lipoic Acid-Induced Apoptosis of Hepatoma Cells*, Simbula, Columbano, Ledda, et al., **Apoptosis** 2007; 12 (1): 113-123.

*Uptake, Recycling, and Antioxidant Actions of Alpha-Lipoic Acid in Endothelial Cells*, Jones, Li, Qu, et al., **Free Radic. Biol. Med.** 2002; 33 (1): 83-93.

*Alpha-Lipoic Acid Inhibits TNF-Alpha Induced NF-κappa B Activation Through Blocking of MEKK1-MKK4-IKK Signalling Cascades*, Lee, Lee, Kim, et al., **Int. Immunopharmacol.** 2008; 8 (2): 362-370.

*Reactive Oxygen Species Mediate Caspase Activation and Apoptosis Induced by Alpha Lipoic Acid in Human Lung Epithelial Cancer Cells Through Bcl-2 Down-regulation*, Moungjaroen, Nimmannit, Callery, et al., **J. Pharmacol. Exp.** 2006; 319 (3): 1062-1069.

*R-lipoic Acid Inhibits Mammalian Pyruvate Dehydrogenase Kinase*, Korotchkina, Sidhu & Patel, **Free Radic. Res.** 2004; 38 (10): 1083-1092.

*Alpha Lipoic Acid Induces Apoptosis in Human Colon Cancer Cells by Increasing Mitochondrial Respiration with a Concomitant O<sub>2</sub>\* Generation*, Wenzel, Nickel & Daniel, **Apoptosis** 2005; 10 (2): 359-368.

*Reactive Oxygen Species Mediate Caspase Activation and Apoptosis Induced by Lipoic Acid in Human Lung Epithelial Cells Through Bcl-2 Down-regulation*, Moungjaroen, Nimmannit, Callery, et al., **J. Pharmacol. Exp. Ther.** 2006; 319 (3): 1062-1069.

*Differential Activity of Lipoic Acid Enantiomers in Cell Culture*, Smith, Thiagaraj, Seaver & Parker, **J. Herb Pharmacother.** 2005; 5 (3): 43-54.

*Selective Inactivation of Alpha-ketoglutarate Dehydrogenase and Pyruvate Dehydrogenase: Reaction of Lipoic Acid with 4-Hydroxy-2-Nonenal*, Humphries & Szweda, **Biochemistry** 1998; 37 (45): 15835-15841.

*Interaction of Alpha-lipoic Acid Enantiomers and Homologues with the Enzyme Components of the Mammalian Pyruvate Dehydrogenase Complex*, Löffelhardt, Bonaventura, Locher , et al., **Biochem. Pharmacol.** 1995; 50 (5): 637-646.

*The Long-term Survival of a Patient with Pancreatic Cancer with Metastases to the Liver After Treatment with the Intravenous Alpha-Lipoic Acid/Low-Dose Naltrexone Protocol*, Berkson, Rubin & Berkson, **Integr. Cancer Ther.** 2006; 5 (1): 83-89.

*Effective Treatment of Oxaliplatin-Induced Cumulative Poly-Neuropathy with Alpha-Lipoic Acid*, Gedlicka, Scheithauer, Schull & Kornek, **J. Clin. Oncol.** 2002; 20 (5): 3359-3361.

*Effects of Alpha Lipoic Acid on Transforming Growth Factor beta 1-p38 Mitogen-Activated Protein Kinase-Fibronectin Pathway in Diabetic Nephropathy*, Lee, Kang, Ryu, et al., **Metabolism** 2009; 58 (5): 616-623.

*The Natural Antioxidant Alpha-Lipoic Acid Induces p27(Kip1) Dependent Cell Cycle Arrest and Apoptosis in MCF-7 Human Breast Cancer Cells*, Dozio, Ruscica , Passafaro, et al., **Eur. J. Pharmacol.** 2010; 641 (1): 29-34.

*Antiplatelet Activity of Alpha-Lipoic Acid*, Lai, Shih, Huang & Chou, **J. Agric. Food Chem.** 2010; 58 (15): 8596-8603.

*Lipoic Acid Inhibits Cell Proliferation of Tumor Cells in vitro and in vivo*, Feuerecker,Pirsig, Seidl, et al., **Cancer Biol Ther.** 2012; 13 (14): 125-1435.

*The Anti-Neoplastic Effects of Alpha Lipoic Acid: Clinical Benefits in System Tumors Besides Lung Carcinomas*, Kapoor, **Kor. J. Thorac. Cardiovasc. Surg.** 2013; 46 (2): 162-163.

*Metabolic Treatment of Cancer. Intermediate Results of a Prospective Case Series*, Schwartz, Buhler, Icard, et al., **Anticancer Res.** 2014; 34 (2): 973-980.

*Symptomatic and Neurophysiological Responses of Paclitaxel or Cisplatin-Induced Neuropathy to Oral Acetyl-L-Carnitine*, Bianchi, Vitali, Garaceni, et al., **Eur. J. Cancer** 2005; 41 (12): 1746-1750.

*Acetyl-L-Carnitine Monograph*, **Alt. Med. Rev.** 2010; 15 (1): 76-83.

#### ANTI-OXIDANTS & NUTRACEUTICALS IN CHEMOTHERAPY

*The Contribution of Cytotoxic Chemotherapy to 5-Year Survival in Adult Malignancies*, Morgan, Ward & Barton, **Clin. Oncol.** 2004; 16: 549-560.

*A Pilot Study on the Effect of Acetyl-L-Carnitine in Paclitaxel and Cisplatin-Induced Peripheral Neuropathy*, Maestri, De Pasquale Ceratti, Cundari, et al., **Tumouri** 2005; 9 (12): 135-138.

*Symptomatic and Neurophysiological Responses of Paclitaxel or Cisplatin-Induced Neuropathy to Oral Acetyl-L-Carnitine*, Bianchi, Vitali, Garaceni, et al., **Eur. J. Cancer** 2005; 41 (12): 1746-1750.

*Paclitaxel and Cisplatin-Induced Neuropathy: A Protective Role for Acetyl-L-Carnitine*, Pisano, Pratesi, Camerini, et al., **Clin. Cancer Res.** 2003; 9: 5756-5767.

*L-Carnitine Reduces Doxorubicin-Induced Apoptosis Through a Prostacyclin-Mediated Pathway in Neonatal Rat Cardiomyocytes*, Chao, Hong, Liu, et al. **Int. J. Cardiol.** 2011; 146 (2): 145-152.

*A Pilot Study on the Effect of Acetyl-l-Carnitine in Paclitaxel and Cisplatin-Induced Peripheral Neuropathy*, Maestri, De Pasquale Ceratti, Cdari et al., **Tumouri** 2005; 91 (2): 135-138.

*Potential Role of Levo-Carnitine Supplementation for the Treatment of Chemotherapy-Induced Fatigue in Non-Anaemic Cancer Patients*, Graziano, Bisonni, Catalano, et al., **Br. J. Cancer** 2002; 86 (12): 1854-1857.

*Carnitine Plasma Levels and Fatigue in Children/Adolescents Receiving Cisplatin, Ifosfamide, or Doxorubicin*, Hockenberry, Hooke, Gregurich & McCarthy, **J. Pediatr. Hematol. Oncol.** 2009; 31 (9): 664-669.

*L-Carnitine Reduces Doxorubicin-Induced Apoptosis Through a Prostacyclin-Mediated Pathway in Neonatal Rat Cardiomyocytes*, Chao, Liu, Hong, Lin et al., **Int. J. Cardiol.** 2009; 16 (2): 506-513.

*Cisplatin-Induced Kidney Injury in the Rat: L-Carnitine Modulates the Relationship Between MMP-9 and TIMP-3*, Martinez, Costantino, Clementi, et al., **Exp. Toxicol. Pathol.** 2009; 61 (3): 183-188

*Differential Expression of HSP70 and Ultrastructure of Heart and Liver Tissues of Rats Treated with Adriamycin: Protective Role of L-Carnitine*, Strauss & Porras, **Invest. Clin.** 2007; 48 (1): 33-43.

*Acetyl-L-Carnitine for the Treatment of Chemotherapy-Induced Peripheral Neuropathy: A Short Review*, De Grandis, **CNS Drugs** 2007; 21 (Suppl 1): 39-43; discussion 45-46.

*Prevention by L-Carnitine of Interleukin-2 Related Cardiotoxicity During Cancer Chemotherapy*, Lissoni, Galli, Tancini & Barni, **Tumouri** 1993; 79 (3): 202-204.

*Acetyl-l-Carnitine Prevents and Reduces Paclitaxel-Induced Painful Peripheral Neuropathy*, Flatters, Xiao & Bennett, **Neurosci. Lett.** 2006; 397 (3): 219-223.

*Reversal of Doxorubicin-Induced Cardiac Metabolic Damage by L-Carnitine*, Sayed-Ahmed, Shaarawy, Shouman & Osman, **Pharmacol Res.** 1999; 39 (4): 289-295

*Dietary Antioxidants During Cancer Chemotherapy: Impact on Chemotherapeutic Effectiveness and Development of Side-effects*, Conklin, **Nutr. Can.** 2000; 37 (1): 1-18.

*Impact of Antioxidant Supplementation on Chemotherapeutic Efficacy: a Systematic Review of the Evidence from Randomized Controlled Trials*, Block, Koch, Mead, et al., **Cancer Treat. Rev.** 2007; 33 (5): 407-418.

*Antioxidants and Other Nutrients Do Not Interfere with Chemotherapy or Radiation Therapy and Can Increase Kill and Increase Survival, Part 2*. Simone, Simone, Simone & Simone, **Altern. Ther. Health Med.** 2007; 13 (2): 40-47

*Chemotherapy-Associated Oxidative Stress*, Conklin, **Integr. Cancer Ther.** 2004; 3 (4): 294-299.

*High Doses of Multiple Antioxidant Vitamins: Essential Ingredients in Improving the Efficacy of Standard Cancer Therapy*, Prasad, Kumar,et al, **J. Amer. Coll. Nutr.**, 1999; 18: 13-25.

*Supplements During Chemotherapy*, McKinney, **Alive - Canadian Journal of Health & Nutrition**, April 2004; #258: 36.

*To Combine or Not to Combine: Natural Health Products and Chemotherapy?*, Lemmo, **Townsend Letter** Aug.- Sept. 2006; #277/78: 76-77.

*Oxidants, Antioxidants and the Current Incurability of Metastatic Cancers*, Watson, J., **Open Biol.** 2013; 120144, published online 8 January 2013.

*Reduction of Paclitaxel-Induced Peripheral Neuropathy with Glutamine*, Vahdat, Papadopoulos, Lange, et al, **Clin. Cancer Res.** 2001; 7 (5): 1192-1197.

*Glutamine Protects Against Doxorubicin-Induced Cardiotoxicity*, Cao, Kennedy & Klimberg, **J. Surg. Res.** 1999; 85 (1) 178-182.

*Prevention of Chemotherapy and Radiation Toxicity with Glutamine*, Savarese, Savy, Vahdat, et al., **Cancer Treat. Rev.** 2003; 29 (6): 501-513

*Baseline Nutritional Status is Predictive of Response to Treatment and Survival in Patients Treated by Definitive Chemo-Radiotherapy for a Locally Advanced Esophageal Cancer*, Di Fiore, Leclaire, Pop, et al., **Am. J. Gastroenterol.** 2007; 102 (11): 2557-63. Epub 2006 Aug 4.

*Antioxidants and Cancer Therapy; Their Actions and Interactions with Oncologic Therapies*, Lamson & Brignall **Alt. Med. Rev.** 1999; Vol. 4 No.5: 304-329.

*Antioxidants and Cancer Therapy: A Systematic Review*, Ladas, Jacobson, Kennedy, et al., **Oncol.** 2004; 22 (3): 517-528.

*Antioxidants and Cancer Therapy II – Quick reference Guide*, Lamson & Brignall, **Alt. Med. Rev.** 2000; Vol. 5 No. 2: 152-163.

*Antioxidants and Cancer III – Quercitin*, Lamson & Brignall, **Alt. Med. Rev.** 2000; Vol. 5 No. 6: 196-208.

*Orthomolecular Oncology Review: Ascorbic Acid & Cancer 25 Years Later*, Gonzalez, Riordan, et al, **Integr. Cancer Ther.** 2005; 4 (1): 32-44.

*Antioxidants and Cancer Therapy Integr. Cancer Ther.* Special Edition 2004; 3 (4): 277-383.

- *Multiple Dietary Antioxidants Enhance the Efficacy of Standard and Experimental Cancer Therapies & Decrease Their Toxicity*, Prasad.: 310-321.
- *Chemotherapy-Associated Oxidative Stress: Impact on Chemotherapeutic Effectiveness*, Conklin: 294-300.
- *Dietary Antioxidants & Human Cancer*, Borek: 333-341.
- *Antioxidants & Cancer Therapy: Furthering the Debate*, Block: 342-348.

*The Use of Vitamin C and Other Antioxidants with Chemotherapy and Radiotherapy in Cancer Treatment*, Gunn, Hoffer & Stoute **J. Orthomolec. Med.** Special Issue 2004; Vol. 19 No.4: 194-255.

- *Editorial: The Use of Vitamin C and Other Antioxidants with Chemotherapy and Radiotherapy in Cancer Treatment*, Hoffer & Gunn: 195-197.
- *The Use of Vitamin C with Chemotherapy in Cancer Treatment: An Annotated Bibliography*: Stoute: 198-245.
- *The Use of Antioxidants with Chemotherapy & Radiotherapy in Cancer Treatment: A Review*, Gunn: 246-255.

*All-Trans Retinoic Acid Potentiates Tamoxifen-Induced Cell Death Mediated by Jun N-terminal Kinase in Breast Cancer Cells*, Wang and Weider, **Oncogene** 2004; 23 (2): 426-433.

*Retinoic Acid Enhances the Cytotoxic Effects of Gemcitabine and Cisplatin in Pancreatic Adenocarcinoma Cells*, Pettersson, Colston & Dalgleish, **Pancreas** 2001; 23 (3): 273-279.

*Antioxidant Levels Tied to Treatment Toxicities in ALL*, Kelly, et. al. **Paediat. Blood Cancer** 2005; 44: 1-8.

*Low Antioxidant Vitamin Intakes are Associated with Increases in Adverse Effects of Chemotherapy in Children with Acute Lymphoblastic Leukemia*, Kennedy, et al., **J. Clin. Nutr.** 2004; 79 (6): 1029-1036.

*Antioxidant Status Decreases in Children with Acute Lymphoblastic Leukemia During the First Six Months of Chemotherapy Treatment*, Tapani, Nissinen, et al., **Br. J. Nutr.** 2004; 92: 665-669.

*Antioxidants and Other Nutrients Do Not Interfere with Chemotherapy or Radiation Therapy and Can Increase Kill and Increase Survival, Part 1*, Simone, et al., **Altern Ther. Health Med.** 2007; 13: 22-28.

*Chemotherapy Alone vs. Chemotherapy Plus High-dose Multiple Antioxidants in Patients with Advanced Non-Small Cell Lung Cancer*, Pathak, et al., **J. Am. Coll. Nutr.** 2005; 24 (1): 16-21.

*Adjvant Immunotherapy with Oral Tegafur/Uracil Plus PSK in Patients with Stage II or III Colorectal Cancer: A Randomized Controlled Study*, Ohwadea, et al., **Br. J. Cancer** 2004; 90 (%): 1003-1010

*Vitamin E May Protect Against Chemotherapy-Induced Neuropathy*, Argyriou, et al, **Neurology** 2005; 64: 26-31.

*Vitamin E and N-Acetyl-Cysteine as Antioxidant Adjvant Therapy in Children with Acute Lymphoblastic Leukemia*, Al-Tonbary, Al-Haggar, EL-Ashry, et al., **Adv. Hematol.** 2009; Article ID 689639, 5 pages  
doi:10.1155/2009/689639

*Tocopherol-Associated Protein-1 Accelerates Apoptosis Induced by Alpha-Tocopherol Succinate in Mesothelioma Cells*, Neuzil, Dong, Wang & Zingg, **Biochem. Biophys. Res. Commun.** 2006; 343 (4): 1113-1117.

*A Randomized Controlled Trial Evaluating the Efficacy and Safety of Vitamin E Supplementation for Protection Against Cisplatin-Induced Peripheral Neuropathy: Final Results*, Argyriou, Chroni, Koutras, et al, **Support. Care Cancer** 2006; 14 (11): 1134-1140.

*Vitamin E Neuroprotection for Cisplatin Neuropathy: A Randomized, Placebo-Controlled Trial*, Pace, Giannarelli, Galiè, et al., **Neurology** 2010; 74 (9): 762-766.

*Antioxidants Against Cancer*, Moss, 2000, Equinox Press.

*Augmented Efficacy of Tamoxifen in Rat Breast Tumourigenesis When Gavaged Along With Riboflavin, Niacin and CoQ10: Effects on Lipid Peroxidation and Antioxidants in Mitochondria*, Perumal, Shanti & Sachdanandam, **Chem. Biol. Interact.** 2005; 152 (1): 49-58.

*Supplementation with Antioxidant Micronutrients and Chemotherapy-induced Toxicity in Cancer Patients Treated with Cisplatin-based Chemotherapy: A Randomized, Double-blind, Placebo-controlled Study*, Weijl, Elsendoorn, Lentjes, et al., **Eur. J. Cancer**, 2004; 40: 1713-1723.

*Selenium as an Element in the Treatment of Ovarian Cancer in Women Receiving Chemotherapy*, Selja, & Talerczyk, **Gynec. Oncol.** 2004; 93: 320-327.

*Selenium (Se) Deficiency in Women with Ovarian Cancer Undergoing Chemotherapy and the Influence of Supplementation with this Micro-element on Biochemical Parameters*, Sieja, **Pharmazie** 1998; 53 (7): 473-476.

*The Protective Role of Selenium on the Toxicity of Cisplatin-Contained Chemotherapy Regimen in Cancer Patients*, Hu, Chen, Zhang, et al., **Biol. Trace Elem. Res.** 1997; 56 (3): 331-341.

*Apoptosis Induced by Selenomethionine and Methionine is Superoxide Mediated and p53 dependent in Human Prostate Cancer Cells*, Zhao, Domann & Zhong, **Mol. Cancer Ther.** 2006; 5 (12): 3275-3284.

*A Pilot Study on the Relation Between Cisplatin Neuropathy and Vitamin E*, Bove, Picardo, Maresca, et al., **J. Exp. Clin. Cancer Res.** 2001; 20: 277-280.

*Neuroprotective Effect of Vitamin E Supplementation in Patients Treated with Cisplatin Chemotherapy*, Pace, Savarese, Picardo, et al., **J. Clin. Oncol.** 2003; 21:927-931.

*Neuroprotective Effect of Reduced Glutathione on Oxiplatin-based Chemotherapy in Advanced Colorectal Cancer: A Randomized Double-Blind Placebo-controlled Trial*, Cascinu, et al., **J. Clin. Oncol.** 2002; 20 (16): 3478-3483.

*High Curative Resection Rate with Weekly Cisplatin, 5-Fluorouracil, Epidoxorubicin, 6S-Leukovorin, Glutathione & Filgastrim in Patients with Locally Advanced, Unresectable Gastric Cancer: A Report from the Italian Group Study of Digestive Tract Cancer*, Cascinu, **Br. J. Cancer** 2004; 90 (8): 1521-1525.

*Glutathione Reduces the Toxicity and Improves Quality of Life of Women Diagnosed with Ovarian Cancer: Results of a Double-Blind Randomized Trial*, Smyth, Bowman, Perren, et al., **Ann. Oncol.** 1997; 8 (6): 569-573.

*Dose Intensification of Platinum Compounds with Glutathione Protection as Induction Chemotherapy for Advanced Ovarian Carcinoma*, Bohm, et al., **Oncology** 1999; 57 (2): 115-120.

*Role of Cystine Transport in Intracellular Glutathione Level and Cisplatin Resistance in Human Ovarian Cancer Cell Lines*, Okuno, Sato, Kuriyama-Matsumura, et al., **Br. J. Cancer** 2003; 88 (6): 951–956.

*Synergy Between Paclitaxel Plus an Exogenous Methyl Donor in the Suppression of Murine Demyelinating Diseases*, Mastronardi, Tsui, Winer, et al., **Mult. Scler.** 2007; 13 (5): 96-609.

*The Use of Antioxidants with First-Line Chemotherapy in Two Cases of Ovarian Cancer*, Drisko, Chapman & Hunter, **J. Am. Coll. Nutr.** 2003; 22 (2): 118-123.

*Coenzyme Q10 for Prevention of Anthracycline-Induced Cardiotoxicity*, Conklin, **Integr. Canc. Ther.**, 2005; 4 (2): 110-130.

*Protective Effect of Coenzyme Q10 in Cardiotoxicity Induced by Adriamycin*, Okuma, Furuta & Ota, **Gan To Kagaku Ryoho** 1984; 11 (3): 502-508.

*Use of Antioxidant Supplements During Breast Cancer Treatment: A Comprehensive Review*, Greenlee, Hershman & Jacobson, **Breast Cancer Res Treat** 2008 Oct. 7, (epub ahead of print – PMID 18839308).

*Methylseleninic Acid [Selenium] Synergizes with Tamoxifen to Induce Caspase-Mediated Apoptosis in Breast Cancer Cells*, Li, et al., **Mol. Cancer Ther.** 2008; 7 (9): 3056-3063.

*Ascorbic Acid and Adriamycin Toxicity*, Shimpko, et al., **Am. J. Clin. Nutr.** 1991; 54 (Suppl. 6): 1298S-1301S.

*Impact of Antioxidant Supplementation on Chemotherapeutic Efficacy: A Systematic Review of the Evidence from Randomized Controlled Trials*, Block, Koch, Mead, et al., **Cancer Treat. Rev.** 2007; 33 (5): 407–418.

*Drug Resistance Against Gemcitabine and Topotecan Mediated by Constitutive hsp70 Over-expression in vitro: Implication of Quercetin as Sensitiser in Chemotherapy*, Sliutz, Karlseder, Tempfer, et al., **Br. J. Cancer** 1996 ; 74 (2): 172-177.

*Quercetin Potentiates the Effect of Adriamycin in a Multidrug-Resistant MCF-7 Human Breast Cancer Cell Line: P-Glycoprotein as a Possible Target*, Scambia, Ranelletti, Panic, et al., **Cancer Chemother. Pharmacol.** 1994; 34 (6): 459-464.

*The Synergistic Reversal Effect of Multi-Drug Resistance by Quercetin and Hyperthermia in Doxorubicin-Resistant Human Myelogenous Leukemia Cells*, Shen, Zhang, Wu & Zhu, **Int. J. Hyperthermia** 2008; 24 (2): 151-159.

*Potential Synergism of Natural Products in the Treatment of Cancer*, Hemaiswarya & Doble, **Phytother. Res.** 2006; 20: 239-249.

*Tyrosinase Overexpression Promotes ATM-dependent p53 Phosphorylation by Quercitin and Sensitizes Melanoma Cells to Dacarbazine*, Thangasamy, Sittadjody, Lanza-Jacoby, et al., **Cell Oncol.** 2008; 30: 371-387

*Effects of Quercetin on the Cell Growth and the Intra-Cellular Accumulation and Retention of Adriamycin*, Asaum, Matsuzaki, Kawasak, et al., **Anticancer Res.** 2000; 20 (4): 2477-2483.

*The Synergistic Reversal Effect of Multidrug Resistance by Quercetin and Hyperthermia in Doxorubicin-Resistant Human Myelogenous Leukemia Cells*, Shen, Zhang, Wu & Zhu, **Int. J. Hyperthermia** 2008 ;24 (2): 151-159.

*Enhancement of the Anti-Proliferative Activity of Cis-Diamminedichloroplatinum-II (Cisplatin) by Quercitin*, Hoffmann, Fiebig, Winterhalter, et al., **Int. J. Cancer** 1990; 45: 536-539.

*Inhibitory Effect of Quercitin on Primary Ovarian and Endometrial Cancers and Synergistic Activity with Cis-Diamminedichloroplatinum-II (Cisplatin)*, Scambia, Ranelletti, Bendetti-Panici, et al., **Gynec. Oncol.** 1992; 45: 13-19.

*Drug Resistance Against Gemcitabine and Topotecan Mediated by Constitutive HSP70 Overexpression in vitro: Implication of Quercitin as Sensitiser in Chemotherapy*, Sliutz, Karlseder, Temfer, et al., **Br. J. Cancer** 1996; 74 (2): 172-177.

*Molecular Pathways in the Chemosensitization of Cisplatin by Quercitin in Human Head and Neck Cancer*, Sharma, Sen & Singh, **Cancer Biol. Ther.** 2005; 4 (9): 949-955.

*Temozolomide, Quercitin and Cell Death in the MOGGCCM Astrocytoma Cell Line*, Jakubowicz-Gil, Langner, Wertel, et al., **Chemico-Biol. Interact.** 2010; 188: 190-203.

*Effects of Quercetin on the Bioavailability of Doxorubicin in Rats: Role of CYP3A4 and P-gp Inhibition by Quercetin*, Choi, Piao & Kang, **Arch. Pharm. Res.** 2011; 34 (4): 607-613.

*Synergistic Anti-Cancer Effects of Grapeseed Extract and Conventional Cytotoxic Agent Doxorubicin Against Human Breast Carcinoma Cells*, Sharma, Tyagi, Singh, et al., **Breast Cancer Res. Treat.** 2004; 85 (1): 1-12.

*Amelioration of Doxorubicin-Induced Myocardial Oxidative Stress and Immunosuppression by Grapeseed Extract Proanthocyanidins in Tumour-bearing Mice*, Zhang, Wang, Song, et al., **J. Pharm. Pharmacol.** 2005; 57 (8): 1043-1052.

*Resveratrol Confers Resistance Against Taxol Via Induction of Cell Cycle Arrest in Human Cancer Cell Lines*, Mao, Bai, Lin, et al., **Mol. Nutr. Food Res.** 2010; 54 (11): 1574-1584.

*Five Years Survival in Metastatic Non-small Cell Lung Cancer Patients Treated with Chemotherapy Alone or Chemotherapy and Melatonin: A Randomized Trial*, Lissoni, Chilelli, Villa, et al., **J. Pineal Res.** 2003; 35 (1): 12-15.

*Bio-modulation of Cancer Chemotherapy for Metastatic Colorectal Cancer: A Randomized Study of Weekly Low-dose Irinotecan Alone versus Irinotecan Plus the Oncostatic Pineal Hormone Melatonin in Metastatic Colorectal Cancer Patients Progressing on 5-Fluorouracil-Containing Combinations*, Cerea, Vaghi, Ardizzoia, et al., **Anticancer Res.** 2003; 23 (2C): 1951-1954.

*Melatonin, A Promising Role in Taxane-Related Neuropathy*, Nahleh, et al. **Clin. Med. Insights Oncol.** 2010; 4: 35-41.

*Melatonin: Reducing the Toxicity and Increasing the Efficacy of Drugs*, Reiter, Tan, Sainz, et al., **J. Pharm. Pharmacol.** 2002; 54 (10): 1299-321.

*Reduction of Cisplatin-Induced Anemia by the Pineal Indole 5-Methoxytryptamine in Metastatic Lung Cancer Patients*, Lissoni, Malugani, Bukovec, et al., **Neuro. Endocrinol. Lett.** 2003; 24 (1-2): 83-85.

*Oxidant-Antioxidant Status in Relation to Survival Among Breast Cancer Patients*, Saintot, Mathieu-Daude, Astre, et al., **Int. J. Cancer** 2002; 97 (5): 574-579.

*A Phase II Study of Chemo-Neuroimmunotherapy with Platinum, Subcutaneous Low-Dose Interleukin-2 and the Pineal Neurohormone Melatonin (P.I.M.) as a Second-Line Therapy in Metastatic Melanoma Patients Progressing on Dacarbazine Plus Interferon-Alpha*, Lissoni, Vaghi, Ardizzoia, et al., **In Vivo.** 2002; 16(2): 93-96.

*Decreased Toxicity and Increased Efficacy of Cancer Chemotherapy Using the Pineal Hormone Melatonin in Metastatic Solid Tumour Patients with Poor Clinical Status*, Lissoni, Barni, Mandalà, et al., **Eur. J. Cancer** 1999; 35 (12): 1688-1692.

*Chemoneuroendocrine Therapy of Metastatic Breast Cancer with Persistent Thrombocytopenia with Weekly Low-Dose Epirubicin Plus Melatonin: A Phase II Study*, Lissoni, Tancini, et al., **J. Pineal Res.** 1999; 26 (3): 169-173.

*Treatment of Cancer Chemotherapy-Induced Toxicity with the Pineal Hormone Melatonin*, Lissoni, Tancini, Barni, et al., **Support. Care Cancer** 1997; 5 (2): 126-129.

*Use of Herbs and Supplements by Chemotherapy Patients Attending an Integrative Cancer Clinic*, Block, Gyllenhaal, Koch, et al., Presented at annual meeting of the **Society for Integrative Oncology**, San Francisco CA, Nov. 21 2007.

*Oral Glutamine is Effective for Preventing Oxaliplatin-Induced Neuropathy in Colorectal Cancer Patients*, Wang Lin, Lin et al., **Oncologist** 2007; 12 (3): 312-319.

*Oral Glutamine Reduces the Duration and Severity of Stomatitis After Cytotoxic Cancer Chemotherapy*, Anderson, Schroeder & Skubitz, **Cancer** 1998; 83 (7): 1433-1439.

*Glutamine Supplementation in Cancer Patients*, Yoshida, Kaibara, Ishibashi & Shirouzu, **Nutrition** 2001; 17 (9): 766-768.

*Clinical Use of Glutamine Supplementation*, Wernerman, **J. Nutr.** 2008; 138 (10): 2040S-2044S.

*The Effect of Glutamine Supplementation on Hematopoietic Stem Cell Transplant Outcome in Children: A Case-control Study*, Kuskonmaz, Yalcin, Kucukbayrak, et al., **Pediatr. Transplant.** 2008; 12 (1): 47-51.

*Glutamine Supplementation in Cancer Patients Receiving Bone Marrow Transplantation and High-dose Chemotherapy*, Ziegler, **J. Nutr.** 2001; 131 (9 Supplement): 2578S-2584S; discussion: 2590S.

*Nutrition Support for Bone Marrow Transplant Patients*, Murray & Pindoria, **Cochrane Database Syst. Rev.** 2008; (4): CD002920.

*Effects of Oral Glutamine Supplementation on Children with Solid Tumours Receiving Chemotherapy*, Okur, Ezgu, Tumer, et al., **Pediatr. Hematol. Oncol.** 2006; 23 (4): 277-285.

*Exogenous Glutamine: the Clinical Evidence*, Bongers, Griffiths & McArdle, **Crit. Care Med.** 2007; 35 (9 Supplement): 545S-552S.

*Bolus Oral Glutamine Protects Rats Against CPT-11-induced Diarrhea and Differentially Activates Cytoprotective Mechanisms in Host Intestine But Not Tumour*, Xue, Sawyer, Field, et al., **J. Nutr.** 2008; 138 (4): 740-746.

*Oral Glutamine to Prevent Chemotherapy Induced Stomatitis: A Pilot Study*, Skubitz & Anderson, **J. Lab. Clin. Med.** 1996; 127( 2): 223–228.

*Effect of Low-Dose Oral Glutamine on Painful Stomatitis During Bone Marrow Transplantation*, Anderson, Ramsay, Shu, et al., **Bone Marrow Transplant** 1998; 22 (4): 339–344.

*A Double-Blind Randomized Placebo-Controlled Study of Oral Glutamine in the Prevention of Mucositis in Children Undergoing Hematopoietic Stem Cell Transplantation: A Pediatric Blood and Marrow Transplant Consortium Study*, Aquino, Harvey, Garvin, et al., **Bone Marrow Transplant** 2005; 36 (7): 611–616.

*Oral Glutamine for the Prevention of Oral Mucositis Associated with High-dose Paclitaxel and Melphalan for Autologous Bone Marrow Transplantation*, Cockerham, Weinberger & Lerchie, **Pharmacother.** 2000; 34 (3): 300–303.

*Phase III Controlled Evaluation of Glutamine for Decreasing Stomatitis in Patients Receiving Fluorouracil (5-FU)-Based Chemotherapy*, Okuno, Woodhouse, Loprinzi, et al., **Am. J. Clin. Oncol.** 1999; 22 (3): 258–261.

*Reduction of Paclitaxel-Induced Peripheral Neuropathy with Glutamine*, Vahdat, Papadopoulos, Lange, et al., **Clin. Cancer Res.** 2001; 7: 1192-1197.

*Glutamine as a Neuroprotective Agent in High-Dose Paclitaxel-Induced Peripheral Neuropathy: A Clinical and Electrophysiologic Study*, Stubblefield, Vahdat, Balmaceda, et al., **Clin. Oncol. (R. Coll. Radiol.)** 2005; 17(4): 271-6.

*Prevention of Chemotherapy and Radiation Toxicity with Glutamine*, Savarese, Savy, Vahdat, et al., **Cancer Treat. Rev.** 2003; 29 (6): 501-513.

*Oral Glutamine for the Prevention of Chemotherapy-Induced Peripheral Neuropathy*, Amara, **Ann. Pharmacother.** 2008; 42 (10): 1481-1485.

*Oral Glutamine Ameliorates Chemotherapy-Induced Changes of Intestinal Permeability and Does Not Interfere with the Antitumour Effect of Chemotherapy in Patients with Breast Cancer: A Prospective Randomized Trial*, Li, Yu, Liu, et al., **Tumouri**, 2006; 92 (5): 396-401.

*L-Glutamine Decreases the Severity of Mucositis Induced by Chemoradiotherapy in Patients with Locally Advanced Head and Neck Cancer: A Double-Blind, Randomized, Placebo-Controlled Trial*, Tsujimoto, Yamamoto, Wasa, et al., **Oncol. Rep.** 2015; 33: 33-39.

*Oleic Acid, the Main Monounsaturated Fatty Acid of Olive Oil, Suppresses Her-2/neu (erbB-2) Expression and Synergistically Enhances the Growth Inhibitory Effects of Trastuzumab (Herceptin) in Breast Cancer Cells with Her-2/neu Oncogene Amplification*, Menendez, Vellon, Colomer & Lupu, **Ann. Oncol.** 2005; 16 (3): 359-371.

*Clinical Corner: Herb-drug Interactions in Cancer Chemotherapy: Theoretical Concerns Regarding Drug Metabolizing Enzymes*, Block & Gyllenhaal, **Integr. Cancer Ther.** 2002; 1 (1): 83-89.

*Treatment with Antioxidant and Other Nutrients in Combination with Chemotherapy and Irradiation in Patients with Small-cell Lung Cancer*, Jaakkola, Lähteenmäki, Laakso, et al., **Anticancer Res.** 1992; 12 (3): 599-606.

*Neuroprotective Effect of Reduced Glutathione on Cisplatin-based Chemotherapy in Advanced Gastric Cancer: A Randomized Double-blind Placebo Controlled Trial*, Cascinu, Cordella, Del Ferro E, et al., **J. Clin. Oncol.** 1995; 1: 26-32.

*Glutathione Improves the Therapeutic Index of Cisplatin and Quality of Life for Patients with Ovarian Cancer*, Smyth, Bowman, Perren, et al., **Proc. ASCO** 1995; 14: 761.

*Anti-tumour Activity of Gemcitabine and Oxaliplatin is Augmented by Thymoquinone in Pancreatic Cancer*, Banerjee, Kaseb, Wang, et al., **Cancer Res.** 2009; 69 (13): 5575-5583.

*Weekly Cisplatin and Glutathione in Relapsed Ovarian Carcinoma*, Colombo, Bini, Miceli, et al., **Int. J. Gynecol. Cancer** 1995; 5: 81-86.

*Effect of Green Tea on Pharmacokinetics of 5-FluoroUracil in Rats and Pharmacodynamics in Human Cell Lines In Vitro*, Qiao, Gu, Shang, Du, et al., **Food Chem. Toxicol.** 2011 Mar 31. [Epub ahead of print] PMID: 21440026

*Efficacy of Venlafaxine for the Prevention and Relief of Oxaliplatin-Induced Acute Neurotoxicity: Results of EFFOX, a Randomized, Double-Blind, Placebo-Controlled Phase III Trial*, Durand, Deplanque, Montheil, et al., **Ann. Oncol.** 2011 Mar 22; [Epub Ahead of Print],

*Putative Chemopreventive Molecules Can Increase Nrf2-Regulated Cell Defense in Some Human Cancer Cell Lines, Resulting in Resistance to Common Cytotoxic Therapies*, Hu, Miao, Loignon, Kandouz, Batist, **Cancer Chemother Pharmacol.** 2010; 66 (3): 467-474. Epub 2009 Nov 26. PMID: 19940992

*Theanine and Glutamate Transporter Inhibitors Enhance the Antitumour Efficacy of Chemotherapeutic Agents*, Sugiyama & Sadzuka, **Biochim. Biophys. Acta.** 2003; 1653 (2): 47-59.

*An Approach to the In Vitro Evaluation of Potential for Cytochrome P450 Enzyme Inhibition from Herbals and Other Natural Remedies*, Strandell, Neil & Carlin, **Phytomedicine** 2004; 11: 98–104.

*Either Called "Chemobrain" or "Chemofog," the Long-Term Chemotherapy-Induced Cognitive Decline in Cancer Survivors Is Real*, Argyriou, Assimakopoulos, Iconomou, et al., **J. Pain Symptom Manage.** 2011;41(1): 126-139.

*Intravenous Calcium and Magnesium For Oxaliplatin-Induced Sensory Neurotoxicity in Adjuvant Colon Cancer: NCCTG N04C7*, Grothey, Nikcevich, Sloan, et al., **J. Clin. Oncol.** 2010 Dec 28; [Epub Ahead of Print].

*Presentation, Impact and Prevention of Chemotherapy-Induced Hair Loss*, Breed, van den Hurk & Peerbooms, **Expert Rev. Dermatol.** 2011; 6 (1): 109-125.

*Metformin, B-12, and Enhanced Breast Cancer Response to Chemotherapy*, Garcia & Tisman, **J. Clin. Oncol.** 2010; 28 (2): e19.

*The Contribution of Cytotoxic Chemotherapy to 5-year Survival in Adult Malignancies*, Morgan, Wardy & Barton<sup>2</sup>, **Clin. Oncol.** 2004; 16: 549-560.

#### ARTEMESININ / ARTESUNATE

*Clinical Pharmacology of Artemisinin-Based Combination Therapies*, German & Aweeka, **Clin. Pharmacokinet.** 2008; 47 (2): 91-102.

*Artemesinin and the Anti-Malarial Endoperoxides: from Herbal Remedy to Targeted Chemotherapy*, Meshnick, Taylor & Kamchonwongpaisan, **Microbiol. Rev.** 1996; 60 (2): 301-315

*Pharmacokinetics and Pharmacodynamics of Endoperoxide Antimalarials*, Gautam, Anirudh, Ahmed, et al., **Curr. Drug Metab.** 2009; 10 (3): 289-306.

*Artemisinin Blocks Prostate Cancer Growth and Cell Cycle Progression by Disrupting Sp1 Interactions with the Cyclin-dependent Kinase-4 (CDK4) Promoter and Inhibiting CDK4 Gene Expression*, Willoughby, Sundar, Cheung, et al., **J. Biol. Chem.** 2009; 284 (4): 2203-2213.

*The Anti-Malarial Artesunate is Also Active Against Cancer*, Efferth, Dunstan, Sauerberry et al., **Int. J. Oncol.** 2001; 18: 767-773.

*Synergistic Cytotoxicity of Artemisinin and Sodium Butyrate on Human Cancer Cells*, Lai & Singh, **Anticancer Res.** 2005; 25: 4325-4332.

*Dihydroartemisinin Enhances Radiosensitivity of Glioma Cells in vitro*, Kim, Kim, Lee et al., **J. Cancer Res. Clin. Oncol.** 2007; 132 (2): 129-135.

*Molecular Pharmacology and Pharmacogenomics of Artemisinin and Its Derivatives in Cancer Cells*, Efferth, **Current Drug Targets** 2006; 7: 407-421.

*Dihydroartemisinin Downregulates Vascular Endothelial Growth Factor Expression and Induces Apoptosis in Chronic Myeloid Leukemia K562 Cells*, Lee, Zhou & Wu, **Cancer Chemother. Pharmacol.** 2006; 57 (2): 213-220.

*Dihydroartemisinin Induces Apoptosis by a Bak-Dependent Intrinsic Pathway*, Handrick, Ontikatze, Bauer, et al., **Mol Cancer Ther.** 2010 Sep;9(9):2497-510. Epub 2010 Jul 27. PMID: 20663933

*Anticancer Properties of Artemesinin Derivatives and Their Targeted Delivery by Transferrin Conjugation*, Nakase, Lai, Singh & Sasak, **Int. J. Pharmaceutics** 2008; 354 (1-2): 28-33.

*Gene Expression Profiling Identifies Novel Key Players Involved in the Cytotoxic Effect of Artenusate on Pancreatic Cells*, Efferth, **Biochem. Pharm.** 2009; 78: 273-283.

*Dihydroartemisinin Improves the Efficiency of Chemotherapeutics in Lung Carcinomas in vivo and Inhibits Murine Lewis Lung Carcinoma Cell Line Growth in vitro*, Zhou, Zhang, Li et al., **Cancer Chemother. Pharmacol.** 2007; 66 (1): 21-29.

*Dihydroartemisinin is an Inhibitor of Ovarian Cancer Cell Growth*, Jiao, Ge, Meng et al., **Acta Pharmacologica Sinica** 2007; 28: 1045-1056.

*Dihydroartemisinin Exerts Cytotoxic Effects and Inhibits Hypoxia Inducible Factor-1 $\alpha$  Activation in C6 Glioma Cells*, Huang, Ma, Zhang et al., **J. Pharm. Pharmacol.** 2007; 59 (6): 849-856.

*Ferroportin and Iron Regulation in Breast Cancer Progression and Prognosis*, Torti, Pinnix, Miller, et al., **Sci. Transl. Med.** 2010; 2 (43): 43-56.

*A Randomised, Double Blind, Placebo-Controlled Pilot Study of Oral Artesunate Therapy for Colorectal Cancer*, Krishna, Ganapathi, Ster, et al., **EBioMedicine** 2015; 2 (1): 82-90.

#### ASHWAGANDHA

*Antitumour and Radiosensitizing Effects of Withania somnifera (Ashwagandha) on a Transplantable Mouse Tumour, Sarcoma -180*. Devi & Solomon **Ind. J. Exp. Biol.** July 1993; 31 (7): 607-611.

*In vivo Growth Inhibitory Effect of Withania somnifera (Ashwagandha) on a Transplantable Mouse Tumour Sarcoma-180*, Devi, Sharada, Solomon, et al., **Ind. J. Exp. Biol.** 1992; 30: 169-172.

*Withania somnifera dunal: Potential Plant Source of a Promising Drug for Chemotherapy and Radiosensitization*, Devi, **Ind. J. Exp. Biol.** 1996; 34 (10): 927-932.

*In vivo growth Inhibitory and Radiosensitizing Effects of Withaferin A on Mouse Erlich Ascites Carcinoma in vivo*, Devi, Sharada & Solomon, **Acat. Oncol.** 1996; 35: 95-100.

*Modulation of TCA Cycle Enzymes and Electron Transport Chain Systems (by Withania) In Experimental Lung Cancer*, Senhilnathan, Padmavathi, Magesh & Sakthisekaran, **Life Sci.** 2006; 78 (9): 1010-1014.

*Immunoprotection by Botanical Drugs in Cancer Chemotherapy*, Diwanay, Chitre & Patwardhan, **J. Ethnopharmacol.** 2004; 90 (1): 49-55

*The Protective Effect of a Purified Extract of Withania somnifera Against Doxorubicin-induced Cardiac Toxicity in Rats*, Hamza, Amin & Daoud, **Cell Biol. Toxicol.** 2008; 24 (1): 63-73.

*Enhancement of the Response of B16F1 /Melanoma to Fractionated Radiotherapy and Prolongation of Survival by Withaferin and/or Hyperthermia*, Kalthur & Pathirissery, **Integr. Cancer Ther.** 2010; 9 (4): 370-377.

*Recent Changes in Concepts of Antioxidant Treatment*, Matkovics, **Orv Hetil** 2006; 147 (16): 747-752. [NAC]

## AVEMAR / METOPROL

*Fermented Wheat Germ Extract (Avemar) in the Treatment of Cancer and Autoimmune Diseases*, Boros, Nichelatti & Shoenfeld, **Ann. N.Y. Acad. Sci.** 2005; 1051: 529-542.

*Antimetastatic Effect of Avemar in High-Risk Melanoma Patients*, Demidov, Manzuk, Kharkevitch, et. al., **18<sup>th</sup> UICC International Cancer Congress**, 2002; P868 - Oslo, Norway.

*A Medical Nutriment Has Supportive Value in the Treatment of Colorectal Cancer*, Jakab, Schoenfeld, Balogh, et al., **Br. J. Cancer** 2003; 89 (3): 465-469.

*Adjuvant Fermented Wheat Germ Extract (Avemar) Nutraceutical Improves Survival of High Risk Skin Melanoma Patients: A Randomized, Pilot, Phase II Clinical Study with a 7-Year Follow-Up*, Demidov, Manziuk, Kharkevitch, et al., **Cancer Biother. Radiopharm.** 2008; 23 (4): 477-482.

*Fermented Wheat Germ Extract Reduces Chemotherapy-Induced Febrile Neutropenia in Pediatric Cancer Patients*, Garami, Schuler, Babosa, et al., **J. Pediatr. Hematol. Oncol.** 2004; 26 (10): 631–635.

*Promising Cytotoxic Activity Profile of Fermented Wheat Germ Extract (Avemar®) in Human Cancer Cell Lines*, Mueller, Jordan & Voigt, **J. Exp. Clin. Cancer Res.** 2011; 30: 42.

*Fermented Wheat Germ Extract in the Supportive Therapy of Colorectal Cancer*, Farkas E., **Orv Hetil.** 2005;146 (37): 1925-312015: 570785.

*Adjuvant Fermented Wheat Germ Extract (Avemar™) Nutraceutical Improves Survival of High-Risk Skin Melanoma Patients: A Randomized, Pilot, Phase II Clinical Study with a 7-Year Follow-Up*, Demidov, Manziuk, Kharkevitch, et al., **Cancer Biother. Radiopharm.**, 2008; 23 (4): DOI: 10.1089/cbr.2008.0486

*Preclinical Evaluation on the Tumor Suppression Efficiency and Combination Drug Effects of Fermented Wheat Germ Extract in Human Ovarian Carcinoma Cells*, Wang, Wang, Chang, et al., **Evid. Based Complement Alternat Med.** 2015; 570785. PMCID: PMC4359848.

*Inhibitory Effects of AVEMAR on Proliferation and Metastasis of Oral Cancer Cells*, Yanga, Changa, Tsaiia, et al., **Nutr. Cancer** 2016; 0 (0):1-8.

Garami, Schuler, Babosa, et al., *Fermented Wheat Germ Extract Reduces Chemotherapy-Induced Febrile Neutropenia in Pediatric Cancer Patients*, **J. Pediatr. Hematol. Oncol.** 2004; 26( 10): 631-635.

*A Medical Nutriment Has Supportive Value in the Treatment of Colorectal Cancer*, Jakab, Schoenfeld, Balogh, et al., **Br. J. Cancer** 2003; 89 (3): 465-469.

*Metabolic Profiling of Cell Growth and Death in Cancer: Applications in Drug Discovery*, Boros, Cascante & Lee, **Drug Discovery Today** 2002; 7 (6): 18-26.

## BOSWELLIA

*Analysis of Frankincense from Various Boswellia Species with Inhibitory Activity on Human Drug Metabolising Cytochrome P450 Enzymes Using Liquid Chromatography Mass Spectrometry After Automated On-line Extraction*, Frank & Unger, **J. Chromatogr. A.** 2006; 1112 (1-2): 255-262.

*Boswellic Acids and Malignant Glioma: Induction of Apoptosis but No Modulation of Drug Sensitivity*, Glaser, Winters, Groscurth, et. al., **Br. J. Cancer** 1998; 80 (5-6): 756-765.

*Boswellic Acids Inhibit Glioma Growth: A New Treatment Option?*, Winking, Sarikaya, et. al., **J. Neurooncol** 2000; 46: 97-103.

*Boswellic Acids in the Palliative Therapy of Children with Progressive or Relapsed Brain Tumours*, Janssen, Bode, Breu, et. al., **Klin. Paediatr.** 2000; 212: 189-195.

*Response of Radio-Chemotherapy-Associated Cerebral Edema to a Phytotherapeutic Agent H15*, Streffer, Bitzer, Schabet, et al., **Neurology** 2001; 56: 1219-1221.

*Boswellic Acid Acetate Induces Differentiation and Apoptosis in Leukemia Cell Lines*, Jing, Nakato, et al., **Leuk. Res.** 1999; 23: 43-50.

*Boswellic Acids: Novel, Specific, Non-redox Inhibitors of 5-lipoxygenase*, Safayhi, Mack, Sabieraj, et al., **J. Pharmacol. Exp. Ther.** 1992; 261 (3): 1143-1146.

*[Boswellia] A Lipoxygenase Inhibitor in Breast Cancer Brain Metastases*, Flavin, **J. Neurooncol.** 2007; 82 (1): 91-93. Epub 2006 Sep 26.

#### BREAST CANCER

*Survival Impact of Integrative Cancer Care in Advanced Metastatic Breast Cancer*, Block, Gyllenhaal, Tripathy, et al., **Breast J.** 2009; 154: 357-366.

*Apparent Partial Remission of Breast Cancer in "High-Risk" Patients Supplemented with Nutritional Antioxidants, Essential Fatty Acids and Coenzyme Q10*, Lockwood, Moesgaard, Hanioka, et. al., **Mol. Aspects. Med.** 1994; Suppl. 15: 231-240.

*Progress on Therapy of Breast Cancer with Vitamin Q10 and the Regression of Metastases*, Lockwood, Moesgaard, Yamamoto & Folkers, **Biochem. Biophys. Res. Commun.** 1995; 212 (1): 172-177.

*The Israeli Breast Cancer Anomaly*, Westin & Richter, **Annals N.Y. Acad. Sci.** 1989; 609: 269-279.

*Alteration of the Effects of Cancer Therapy Agents on Breast Cancer Cells by the Herbal Medicine Black Cohosh*, Rockewewll, Liu & Higgins, **Breast Cancer Res. Treat.** 2005; 90: 233-239.

*Fibroblasts Isolated from Common Sites of Breast Cancer Metastasis Enhance Cancer Cell Growth Rates and Invasiveness in an Interleukin-6-Dependent Manner*, Studebaker, Storci, Werbeck, et al., **Cancer Res.** 2008; 68 (21): 9087-9095.

*Psychologic Intervention Improves Survival for Breast Cancer Patients: A Randomized Clinical Trial*, Andersen, Yang, Farrar, et al., **Cancer** 2008; 113:3450-3458.

*Perspectives on the Soy-Breast Cancer Relation*, Messina & Wu, **Am. J. Clin. Nutr.** 2009; 895: 1673S-1679S.

*Co-enzyme Q10, Riboflavin and Niacin Supplementation on Alteration of DNA Repair Enzyme and DNA Methylation in Breast Cancer Patients Undergoing Tamoxifen Therapy*, Premkumar, Yuvaraj & Sachdanandam, **Br. J. Nutr.** 2008; 1006: 1179-1182.

*Ferroportin and Iron Regulation in Breast Cancer Progression and Prognosis*, Torti, Pinnix, Miller, et al., **Sci. Transl. Med.** 2010; 2 (43): 43-56.

*Suppression of Proliferation and Invasive Behavior of Human Metastatic Breast Cancer Cells by Dietary Supplement Breast Defend*, Wojnowski, Jaing, Jedinak & Sliva, **Integr. Cancer Ther.** 2010; Oct 6. DOI: 10.1177/1534735410386953

*Vitamin Supplement Use During Breast Cancer Treatment and Survival: A Prospective Cohort Study*, Nechuta, Wei Lu, Zhi Chen, et al., **Cancer Epidemiol Biomarkers Prev.** Published online first December 21, 2010.  
doi:10.1158/1055-9965.EPI-10-1072.

*Vitamin Supplements Beneficial in Patients With Breast Cancer*, Nelson, [www.medscape.com/viewarticle/735088](http://www.medscape.com/viewarticle/735088)

*Enzyme Therapy in the Treatment of Lymphedema in the Arm After Breast Carcinoma Surgery*, Adamek, Prausova, Wald, **Chirurgicka Klinika FN Motol, Praha. Rozhl Chir.** 1997; 76 (4): 203-204. [Article in Czech]

*Influence of Pre- and Post-Diagnosis Physical Activity on Mortality in Breast Cancer Survivors: The Health, Eating, Activity and Lifestyle Study*, Irwin, Smith, McTiernan, et al., **J. Clin. Oncol.** 2008; 26 (24): 3958-3964.

*Does the Effect of Weight Lifting on Lymphedema Following Breast Cancer Differ by Diagnostic Method: Results from a Randomized Controlled Trial*, Hayes, Speck, Reimet, et al. **Breast Cancer Res Treat.** 2011; 1301: 227-234.

*Improving Lymphatic Drainage with Herbal Preparations: A Potentially Novel Approach to Management of Lymphedema*, Wheat, Currie, Kiat & Bone, **Austral. J. Med. Herb.** 2009; 21 (3): 66-70.

*A Series of Case Reports: Clinical Evaluation of a Complex Homeopathic Injection Therapy in the Management of Pain in Patients After Breast Cancer Treatment*, Alverellos, Ruiz de Vianaspre Alvear, Kaszkin-Bettag, **Altern. Ther. Health Med.** 2010; 16 (1): 54-59.

*RRR-Gamma-Tocopherol Induces Human Breast Cancer Cells to Undergo Apoptosis Via Death Receptor 5 (DR5)-Mediated Apoptotic Signaling*, Yu, Park, Jia, et al., **Cancer Lett.** 2008; 259 (2): 165-176.

*IBIS-I Tamoxifen Update: Maturity Brings Questions*, Chlebowski, **Lancet Oncol.** 2015; 16 (1): 7-9.

*Risk of Breast Cancer Recurrence Associated with Carbohydrate Intake and Tissue Expression of IGF-1 Receptor*, Emond, Pierce, Natarajan, et al., **Cancer Epidemiol. Biomarkers Prev.** 2014; 23 (7): 1273-1279.

## BUTYRATE

*Sodium Butyrate Inhibits Cell Growth and Stimulates P21 Protein in Human Colonic Adenocarcinoma Cells Independently of P53 Status*, Kobayashi, Tan & Fleming, **Nutr. & Cancer** 2003; 46 (2): 202-211.

*Butyrate Induces Glutathione S-Transferase in Human Colon Cells and Protects from Genetic Damage by 4-Hydroxy-2-Nonenal*, Ebert, et al., **Nutr. & Cancer** 2001; 41 (1): 156-164.

*Topical Butyrate for Acute Radiation Proctitis: Randomised, Cross-over Trial*, Vernia, Fracasso, Casale, et al., **Lancet** 2000; 356 (9237): 1232-1235

## CANNABIS

*Cannabinoid-Opioid Interaction in Chronic Pain*, Abrams, Couey, Shade, et al., **Clin. Pharmacol. Ther.** 2011; 90: 844-851.

*Cannabis Smoking and Risk of Lung Cancer in Men: a Pooled Analysis of Three Studies in Maghreb*, Berthiller, Straif, Boniol, et al. **J. Thorac. Oncol.** 2008; 3: 1398-1403.

*Inhibition of Tumour Angiogenesis by Cannabinoids*, Blazquez, Casanova, Planas, et al., **FASEB** 2003; 17: 529-531.

*Cannabinoids Inhibit the Vascular Endothelial Growth Factor Pathway in Gliomas*, Blázquez, González-Feria, Álvarez, Haro, Casanova, Guzmán, **Cancer Res.** 2004; 64: 5617-5623.

*Cannabinoid Receptors as Novel Targets for the Treatment of Melanoma*, Blázquez, Carracedo, Barrado, et al. **FASEB**. 2006; 20: 2633–2635.

*Down-Regulation of Tissue Inhibitor of Metalloproteinases-1 in Gliomas: A New Marker of Cannabinoid Antitumoural Activity?* Blázquez, Carracedo, Salazar, et al. **Neuropharmacol.** 2008; 54: 235–243.

*Pharmacologic and Clinical Effects of Medical Cannabis*, Borgelt, Franson, Nussbaum & Wang, **Pharmacotherapy** 2013; 33:195-209.

*Cannabinoids Reduce Erb-2-Driven Breast Cancer Progression Through Akt Inhibition*, Caffarel, et al., **Mol. Cancer** 2010; 9: 196.

*Marijuana Use and Risk of Lung Cancer: A 40-Year Cohort Study*, Callaghan, Allebeck, Sidorchuk, **Cancer Causes Control**. 2013; Jul 12. [Epub ahead of print]

*Are Cannabinoids an Effective and Safe Treatment Option in the Management of Pain? A Qualitative Systematic Review*, Campbell, Tramèr, Carroll, et al. **BMJ**. 2001;323: 13-16.

*Cannabinoids Induce Apoptosis of Pancreatic Tumour Cells Via Endoplasmic Reticulum Stress-Related Genes*, Carracedo, Gironella, Lorente, et al. **Cancer Res.** 2006; 66: 6748–6755.

*The Stress-Regulated Protein P8 Mediates Cannabinoid-Induced Apoptosis of Tumour Cells*, Carracedo, Lorente, Egia, et al. **Cancer Cell** 2006; 9: 301–312.

*Inhibition of Skin Tumour Growth and Angiogenesis in vivo By Activation of Cannabinoid Receptors*, Casanova, Blázquez, Martínez-Palacio, et al. **J. Clin. Invest.** 2003; 111: 43–50.

*Cannabinoid Receptor Activation Induces Apoptosis Through Tumour Necrosis Factor Alpha-Mediated Ceramide de novo Synthesis in Colon Cancer Cells*, Chianchi, Fabio, et al., **Clin. Cancer Res.** 2008; 14: 7691-7700.

*Medical Marijuana: The Conflict Between Scientific Evidence and Political Ideology. Part One of Two*. Cohen, **J. Pain Palliat. Care Pharmacother.**2009; 23: 4-25.

*Medical Marijuana: The Conflict Between Scientific Evidence and Political Ideology. Part Two of Two*. Cohen, **J. Pain Palliat. Care Pharmacother.**2009; 23: 120-140.

*Comparison of the Analgesic Effects of Dronabinol and Smoked Marijuana in Daily Marijuana Smokers*, Cooper, Comer, Haney, **Neuropsychopharmacol.** 2013; Apr 22. doi: 10.1038/npp.2013.97. [Epub ahead of print]bl Int. 2012;109:495-501.

*Prevention and Therapy of Cancer by Dietary Monoterpenes*, Crowell, **J. Nutr.** 1999; 129 (3): 775S-778S.

*Plant, Synthetic, and Endogenous Cannabinoids in Medicine*, Di Marzo, De Petrocellis. **Ann. Rev. Med.** 2006; 57: 553–574.

*Medical Use of Marijuana*, Doblin & Kleiman, **Ann. Intern. Med.** 1991; 114: 809-810.

*Anti-Tumoural Action of Cannabinoids: Involvement of Sustained Ceramide Accumulation and Extracellular Signal-Regulated Kinase Activation*, Galve-Roperh, Sánchez, Cortés, et. al., **Nat. Med.** 2000; 6: 313–319.

*De novo-Synthesized Ceramide is Involved in Cannabinoid-Induced Apoptosis*, Gómez del Pulgar, Velasco, Sánchez, Haro, Guzmán, **Biochem. J.** 2002; 363: 183–188.

*Cancer Cachexia and Cannabinoids*, Gorter, **Forsch Komplementarmed.** 1999; 6 Suppl 3: 21-22

*Cancer Chemoprevention and Therapy by Monoterpenes*, Gould, **Environ. Health Persp.** 1997; 105 Suppl. 4: 977-979.

*Anandamide Inhibits Adhesion and Migration of Breast Cancer Cells*, Grimaldi, Pisanti, Laezza, et al., **Exp. Cell Res.** 2006; 312: 363-373.

*The Therapeutic Potential of Cannabis and Cannabinoids*, Grotenhuis, Müller-Vahl, **Dtsch Arzte Int.** 2012; 109 (29-30): 495-501.

*Expression of Cannabinoid Receptors Type 1 and Type 2 in Non-Hodgkin Lymphoma: Growth Inhibition by Receptor Activation*, Gustafsson, et al., **Int. J. Cancer** 2008; 123: 1025-1033.

*Cannabinoids: Potential Anticancer Agents*, Guzmán, **Nat. Rev. Cancer** 2003; 3: 745-755.

*A Pilot Clinical Study of Δ<sup>9</sup>-TetraHydroCannabinol in Patients with Recurrent Glioblastoma Multiforme*, Guzmán, Duarte, Blázquez, et al. **Br. J. Cancer** 2006; 95: 197-203.

*Cannabinoids and Cancer: Causation, Remediation, and Palliation*, Hall, Christie, Currow, **Lancet Oncol.** 2005; 6: 35-42.

*The Dual Effects of Delta-9-TetraHydroCannabinol on Cholangiocarcinoma Cell: Anti-Invasion Activity at Low Concentration and Apoptosis Induction at High Concentration*, Lellawat, et al., **Cancer Investig.** 2010; 28 (4): 196.

*A Population-Based Case Control Study of Marijuana Use and Head and Neck Squamous Cell Carcinoma*, Liang, et al., **Cancer Prev. Res.** 2009; 2: 759-768.

*Cannabinoid Receptors as Therapeutic Targets*, Mackie, **Annual Rev. Pharmacol. Toxicol.** 2006; 46: 101-122.

*Cannabidiol Enhances the Inhibitory Effects of Delta-9-TetrahydroCannabinol on Human Glioblastoma Cell Proliferation and Survival*, Marcu, et al., **Mol. Cancer Ther.** 2010; 9: 180-189.

*Systematic Review and Meta-Analysis of Cannabis Treatment for Chronic Pain*, Martín-Sánchez, Furukawa, Taylor & Martin, **Pain Med.** 2009; 10: 1353-1368.

*Cannabidiol as a Novel Inhibitor of Id-1 Gene Expression in Aggressive Breast Cancer Cells*, McAllister, et al., **Mol. Cancer Ther.** 2007; 6: 2121.

*Anticancer Activity of Cannabinoids*, Munson, Harris, Friedman et al., **J. Nat. Cancer Inst.** 1975; 5: 597.

*Inhibition of Human Tumour Prostate PC3 Cell Growth by Cannabinoids R(+)-Methanandamide and JWH-015: Involvement of CBD*, Olea-Herrero, et al., **Brit. J. Cancer** 2009; 101: 940-950.

*The Molecular Logic of Endocannabinoid Signalling*, Piomelli, **Nat. Rev. Neurosci.** 2003; 4: 873-884.

*AntiAngiogenic Activity of the Endocannabinoid Anandamide: Correlation to Its Tumour-Suppressor Efficacy*, Pisanti, Borselli, Oliviero, et al., **J. Cell Physiol.** 2007; 211: 495-503.

*Inhibitory Effects of Cannabinoid CB1 Receptor Stimulation on Tumour Growth and Metastatic Spreading: Actions on Signals Involved in Angiogenesis and Metastasis*, Portella, Laezza, Laccetti, et al., **FASEB J** 2003; 17: 1771-1773.

*Cannabis-Induced Cytotoxicity in Leukemic Cell Lines: The Role of the Cannabinoid Receptors and the MAPK Pathway*, Powles, te Poele, Shamash, et al., **Blood** 2005; 105 (3): 1214-1221.

*Δ<sup>9</sup>-TetraHydroCannabinol Inhibits Epithelial Growth Factor-Induced Lung Cancer Cell Migration in vitro As Well As Its Growth and Metastasis in vivo.* Preet, Ganju, Groopman, **Oncogene** 2008; 27: 339–346.

*Inhibition of Cancer Cell Invasion by Cannabinoids via Increased Expression of Tissue Inhibitor of Matrix MetalloProteinases-1,* Ramer & Heinz, **J. Nat. Cancer Inst.** 2007; 100: (1): 59-69.

*Delta-9-THC Induces Apoptosis in Human Prostate PC-3 Cells Via a Receptor-Independent Mechanism,* Ruiz, et al., **FEBS Letters** 1999; 458: 400-404.

*Inhibition of Glioma Growth in vivo by Selective Activation of the CB<sub>2</sub> Cannabinoid Receptor,* Sánchez, de Ceballos, Gómez del Pulgar, et al. **Cancer Res.** 2001; 61: 5784–5789.

*Comparison of Orally Administered Cannabis Extract and Delta-9-TetraHydroCannabinol in Treating Patients with Cancer-Related Anorexia-Cachexia Syndrome: A Multicenter, Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial from the Cannabis-In-Cachexia-Study-Group,* Strasser, Luftner, Possinger, et al. **J. Clin. Oncol.** 2006; 24: 3394-3400.

*Loss of Cannabinoid Receptor 1 Accelerates Intestinal Tumour Growth,* Wang, Wang Ning, et al., **Cancer Res.** 2008, 68 (15): 6468-6476.

*Cannabinoids Inhibit Cellular Respiration of Human Oral Cancer Cells,* Whyte, et al., **Pharmacol.** 2010; 85: (6): 328-335.

*Cannabidiol for the Prevention of Graft-versus-Host-Disease after Allogeneic Hematopoietic Cell Transplantation: Results of a Phase II Study,* Yeshurun, Shpilberg, Herscovici, et al., **Biol Blood Marrow Transplant** 2015; S1083-8791 (15): 00375-4. doi: 10.1016/j.bbmt.2015.05.018.

*The Use of Medical Marijuana in Cancer,* Birdsall, Birdsall & Tims, **Curr. Oncol. Rep.** 2016; 18:40. Doi: 10.1007/s11912-016-0530-0.

#### CHINESE MEDICINE (TCM) HERBS & ACUPUNCTURE

*Traditional Chinese Medicine In Cancer Symposium,* Vanc. Gen. Hosp. Sept. 21, 2003

*Astragalus-Based Chinese Herbs and Platinum-based Chemotherapy for Advanced Non-Small-Cell Lung Cancer: Meta-analysis of Randomized Trials,* McCulloch, See, Shu, et al., **J. Clin. Oncol.** 2006; 24 (3): 419-430.

*Traditional Chinese Medicine Astragalus Reverses Predominance of Th2 Cytokines and Their Up-stream Transcript Factors in Lung Cancer Patients,* Wei, Sun, Xiao, et al., **Oncol. Rep.** 2003; 10 (5): 1507-1512.

*Shi-Quan-Da-Bu-Tang (Ten Significant Tonic Decoction), SQT. A Potent Chinese Biological Response Modifier in Cancer Immunotherapy, Potentiation and Detoxification of Anticancer Drugs,* Zee-Cheng, **Methods Find Exp Clin Pharmacol.** 1992; 14 (9): 725-736

*Immunotherapy with Chinese Medicinal Herbs. I. Immune Restoration of Local Xenogeneic Graft-versus-host Reaction in Cancer Patients by Fractionated Astragalus membranaceus in vitro,* Chu, Wong & Mavligit, **J. Clin. Lab. Immunol.** 1988; (3): 119-123.

*Clinical Study on Effect of Astragalus in Efficacy Enhancing and Toxicity Reducing of Chemotherapy in Patients of Malignant Tumour,* Duan & Wang, **Zhongguo Zhong Xi Yi Jie He Za Zhi.** 2002; 22 (7): 515-517.

*Effect of Astragalus Polysaccharides in Promoting Neutrophil-Vascular Endothelial Cell Adhesion and Expression of Related Adhesive Molecules,* Hao, Qiu & Wu, **Zhongguo Zhong Xi Yi Jie He Za Zhi.** 2004; 24 (5): 427-430.

*The Radioprotective Effects of Bu-Zhong-Yi-Qi-Tang: A Prescription of Traditional Chinese Medicine Astragalus*, Kim, Lee, Oh, et al. **J. Chin. Med.** 2002; 30 (1): 127-137.

*A Study on the Immune Receptors for Polysaccharides from the Roots of Astragalus membranaceus, a Chinese Medicinal Herb*, Shao, Xu, Dai, et al. **Biochem. Biophys. Res. Commun.** 2004; 320 (4): 1103-1111.

*Astragalus-Based Chinese Herbs and Platinum-Based Chemotherapy for Advanced Non-Small-Cell Lung Cancer: Meta-Analysis of Randomized Trials*, McCulloch, See, Shu, et al., **J. Clin. Oncol.** 2006; 24 (3): 419-430.

*Effect of Chinese Drugs Combining with Chemotherapy on Quality of Life in 146 Children with Solid Tumour*, Shi, Tian, Zhu, et al., **Chin. J. Integr. Med.** 2011; 17 (1): 31-34.

Effects of Large Dose of Astragalus Membranaceus on the Dendritic Cell Induction of Peripheral Mononuclear Cell and Antigen Presenting Ability of Dendritic Cells in Children with Acute Leukemia, Dong , Gu, Ma, et al., **Zhongguo Zhong Xi Yi Jie He Za Zhi** 2005; 25 (10): 872-875.

*Chinese Medical Herbs for Chemotherapy Side-Effects on Colorectal Cancer Patients*, Taixiang, Munro & Guanjian, **Cochrane Database Syst. Rev.** 2005; (1): CD004540.

*Cohort Study on the Effect of a Combined Treatment of Traditional Chinese Medicine and Western Medicine on the Relapse and Metastasis of 222 Patients with Stage II and III Colorectal Cancer After Radical Operation*, Yang, Ge, Wu, et al., **Chin. J. Integr. Med.** 2008; 144: 251-256.

*Clinical Observation on Treatment of Colonic Cancer with Combined Treatment of Chemotherapy and Chinese Herbal Medicine*, Zhou, Shan & You, **Chin. J. Integr. Med.** 2009; 152: 107-111.

*Immune System Effects of Echinacea, Ginseng and Astragalus: A Review*, Block & Mead, **Integr. Cancer Ther.** 2003; 2 (3): 247-267.

*Chinese Medicinal Herbs Reverse Macrophage Suppression Induced by Urological Tumours*, Rittenhouse, Lui & Lau, **J. Urol.** 1991; 146 (2): 486-490.

*Integrating Chinese & Conventional Medicine in Colorectal Cancer Treatment*, Lahans, **Integr. Cancer Ther.** 2007; 6 (1): 89-94.

*Chinese Herbal Medicine and Chemotherapy in the Treatment of Hepatocellular Carcinoma: A Meta-Analysis of Randomized Controlled Trials*, Shu, McCulloch, Xiao, et al., **Integr. Cancer Ther.** 2005; 4 (3): 219-229.

*“And What Other Medications Are You Taking?”*, Gordan, Chay, Kelly, et al., **J. Clin. Oncol.** 2011; 29 (11): 288-291. {Reishi for primary liver HCC}

*Traditional Chinese Medicine Herbal Treatment May Have a Relevant Impact on the Prognosis of Patients with Stage IV Adenocarcinoma of the Lung Treated with Platinum-Based Chemotherapy or Combined Targeted Therapy and Chemotherapy*, Guo, Liu, Xu, et al., **Integr. Cancer Ther.** 2011; 10 (2): 127-137.

*Chinese Herbal Medicine for Cancer Pain*, Xu, Lao, Ge, et al., **Integr. Cancer Ther.** 2007; 6 (3): 208-234.  
*Cancer Chemo-Preventative and Therapeutic Activities of Red Ginseng*, Xiaoguang, Hongyan, Xiaohong, et al., **J. Ethnopharmacol.** 1998; 60 (1): 71-78.

*Current Evaluation of the Millennium Phytomedicine- Ginseng (II): Collected Chemical Entities, Modern Pharmacology, and Clinical Applications Emanated from Traditional Chinese Medicine*, Jia, Zhao & Liang, **Curr. Med. Chem.** 2009; 16 (22): 2924-2942.

*Sensitization of a Tumour, But Not Normal Tissue, to the Cytotoxic Effect of Ionizing Radiation Using Panax Notoginseng Extract*, Chen ,Wu, Wang , et al., **Am. J. Chin. Med.** 2001; 29 (3-4): 517-524.

*Honokiol, a Multifunctional Antiangiogenic and Antitumour Agent*, Fried & Arbiser, **Antioxid. Redox Signal.** 2009; 11 (5): 1139–1148.

*Mitochondrial-Mediated Apoptosis in Lymphoma Cells by the Diterpenoid Lactone Andrographolide, the Active Component of Andrographis paniculata*, Yang, Evens, Prachand, et al., **Clin Cancer Res.** 2010; 16 (19): 4755-4768.

*Pilot Testing of Methods for Evaluation of Acupuncture for Emesis During Radiotherapy: A Randomised Single Subject Experimental Design*, Enblom, Tomasson, Hammar, et al. **Acup.Med.** 2011; 292: 94-102.

*The Effects of P6 Acupressure in the Prophylaxis of Chemotherapy-Related Nausea and Vomiting in Breast Cancer Patients*, Molassiotis, Helin, Dabbour, et al., **Complement. Ther. Med.** 2007; 15 (1): 3-12.

*Acupuncture: Role in Comprehensive Cancer Care – A Primer for the Oncologist and Review of the Literature*, Cohen, Menter & Hale, **Integr. Cancer Ther.** 2005; 4 (2): 131-143.

*Is There a Role for Acupuncture in the Symptom Management of Patients Receiving Palliative Care for Cancer? - A Pilot Study of 20 Patients Comparing Acupuncture With Nurse-Led Supportive Care*, Lim; Wong & Aung **Acup. Med.** 2011; 29 (3): 173-179.

*The Management of Cancer Related Fatigue After Chemotherapy with Acupuncture and Acupressure: A Randomized Controlled Trial*, Molassiotis, Sylt & Diggins, **Complement. Ther. Med.** 2007; 154: 228-237.

*Acupuncture to Alleviate Chemotherapy-Induced Nausea and Vomiting in Paediatric Oncology – A Randomized Multicenter Crossover Pilot Trial*, Gottschling, Reindl, Meyer, et al., **Klin. Paediatr.** 2008; 220 (6): 365-370.

Acupunct Med. 2012 Mar;30(1):4-7. doi: 10.1136/acupmed-2011-010034. Epub 2011 Dec 5.

*Acupuncture for Chemotherapy Induced Peripheral Neuropathy (CIPN): A Pilot Study Using Neurography*, Schroeder, Meyer-Hamme & Epplée, **Acup. Med.** 2012; 30 (1): 4-7.

*Acupuncture Versus Venlafaxine for the Management of Vasomotor Symptoms in Patients with Hormone Receptor-Positive Breast Cancer: A Randomized Controlled Trial*, Walker, Rodrigues, Kohn, et al., **J. Clin. Oncol.** 2009; Epub ahead of print PMID: 20038728.

*Acupuncture in the Rehabilitation of Women After Breast Cancer Surgery- A Case Series*, Alem & Gurgel, **Acup. Med.** 2008; 262: 86-93.

*Monitoring of Neuromuscular Blockade at the P6 Acupuncture Point Reduces the Incidence of Post-operative Nausea and Vomiting*, Arnberger, Stadelmann, Alischer, et al., **Anesthesiology** 2007; 107 (6): 903-908.

*Acupuncture for the Treatment of Vasomotor Symptoms in Breast Cancer Patients Receiving Hormone Suppression Treatment*, Walker, et al., **Int. J. Rad. Oncol. Biol. Phys.** 2008; Abstract No. 228. Volume 72, Number 1. See also **J. Clin. Oncol.** 2009; published online dec. 28, 2009.

*Clinical Observations on Post-Operative Vomiting Treated by Auricular Acupuncture*, Kim, Kim & Kim, **Am. J. Chin. Med.** 2003; 31 (3): 475-480.

*Clinical Uses of P6 Acupuncture Anti-Emesis*, Dundee & McMillan, **Acupunct. Electrother. Res.** 1990; 15 (3-4): 211-215.

*Acupuncture for Nausea and Vomiting: An Update of Clinical and Experimental Studies*, Streitberger, Ezzo & Schneider, **Auton. Neurosci.** 2006; 129( 1-2): 107-117.

*Effect of Acupressure on Nausea and Vomiting Induced by Chemotherapy in Cancer Patients*, Gardani, Cerrone, Biella, et al., **Minerva Med.** 2006; 97 (5): 391-394.

*Acupuncture-Point Stimulation for Chemotherapy-Induced Nausea or Vomiting*, Ezzo, Richardson, Vickers, et al., **Cochrane Database Syst. Rev.** 2006; 2: CD002285. DOI: 10.1002/14651858.CD002285.pub2.

*Electroacupuncture for Refractory Acute Emesis Caused by Chemotherapy*, Choo, Kong, Lim, et al., **J. Altern. Complement. Med.** 2006; 12 (10): 963-969.

*The Effect of Acupuncture on Salivary Flow Rates in Patients with Xerostomia*, Blom, Dawidson, Angmar-Måansson, **Oral Surg. Oral Med. Oral Pathol.** 1992; 73 (3): 293-298.

*Cochrane Review Summary for Cancer Nursing: Acupuncture-Point Stimulation for Chemotherapy-Induced Nausea or Vomiting*, Konno, **Cancer Nurs.** 2010; 33 (6): 479-480.

*Effects of Electro-Acupuncture on T-Cell Subpopulations, NK Activity, Humoral Immunity and Leukocyte Count in Patients Undergoing Chemotherapy*, Ye, Liu, Wang & Xu, **J. Trad. Chin. Med.** 2007; 271: 19-21.

*Acupuncture for the Treatment of Hot Flashes in Breast Cancer Patients, a Randomized, Controlled Trial*, Hervik & Mjaland, **Breast Cancer Res. Treat.** 2009; 1162: 311-316.

*Electroacupuncture Versus Gabapentin for Hot Flashes Among Breast Cancer Survivors: A Randomized Placebo-Controlled Trial*, Mao, Bowman, Xie, et al., **J. Clin. Oncol.** 2015; 60.9412; pub.online Aug.24, 2015.

*Acupuncture for Dysphagia After Chemo-Radiation Therapy in Head and Neck Cancer: A Case Series Report*, Lu, Posner, Wayne, et al., **Integr. Cancer Ther.** 2010; 9 (3): 284-290.

*Acupuncture versus Metoclopramide in the Treatment of Postoperative Gastroparesis Syndrome in Abdominal Surgical Patients: A Randomized Controlled Trial*, Sun, Luo, Wu, et al., **J. Chin. Integr. Med.** 2010; 8 (7): 641.

*Self Administered Acupuncture for Treatment of Chemotherapy Associated Nausea: A Pilot Study*, Adler & Hansen, **BMC Compl. Alt. Med.** 2012; Research Congress on Integrative Medicine and Health: Conferencenteratona.

*Phase 2 Results from Radiation Therapy Oncology Group Study 0537: A Phase 2/3 Study Comparing Acupuncture-Like Transcutaneous Electrical Nerve Stimulation Versus Pilocarpine in Treating Early Radiation-Induced Xerostomia*, Wong, James, Sagar, et al., **Cancer** 2012; 11817: 4244 - 4252.

## CO-ENZYME Q10

*Coenzyme Q10 Plasma Levels Predict Melanoma Metastasis*, Rusciani, et al, **J. Am. Acad. Dermatology**, 2006; 54: 234-241.

*Coenzyme Q Differentially Modulates Phospholipid Hydroperoxide Glutathione Peroxidase Gene Expression and Free Radicals Production in Malignant and Non-malignant Prostate Cells*, Quiles, Farquharson, Ramirez-Tortosa, et al., **Biofactors** 2003; 18 (1-4): 265-270.

*Clinical Response of Myelodysplastic Syndromes Patients to Treatment with Coenzyme Q10*, Galili, Sechman, Cerny, et al., **Leuk Res.** 2007 J; 31 (1): 19-26.

*Coenzyme q10 for Prevention of Anthracycline-Induced Cardiotoxicity*, Conklin, **Integr Cancer Ther.** 2005; 4 (2): 110-130.

*CoQ10: Could It Have a Role in Cancer Management?*, Hodges, Hertz, Lockwood & Lister, **BioFactors** 1999; 9: 365-370.

*An Analysis of the Role of Coenzyme Q in Free Radical Generation and As an Antioxidant*, Beyer, **Biochem. & Cell Biol.** 1992; 70 (6): 390-403.

*The Mode of Action of Lipid-Soluble Antioxidants in Biological Membranes. Relationship Between the Effects of Ubiquinol and Vitamin E as Inhibitors of Lipid Peroxidation in Submitochondrial Particles*, Ernster, Forsmark & Nordenbrand, **J. Nutr. Sci. & Vitamin.** 1992; Spec No: 548-551.

*Improved Survival in Patients with End-Stage Cancer Treated with Coenzyme Q10 and Other Antioxidants*, Hertx & Lister, **J. Int. Med. Res.** 2009; 37: 1961-1971.

#### CURCUMIN & INFLAMMATION

*Curcumin and Green Tea Polyphenols: Synergistic Anticancer Compounds*, Yarnell, **Quart. Rev. Nat. Med.** 1998; Fall: 218-220.

*Curcumin Inhibits Prosurvival Pathways in Chronic Lymphocytic Leukemia B Cells and May Overcome Their Stromal Protection in Combination with EGCG*, Ghosh, Kay, Secreto & Shanafelt, **Clin. Cancer Res.** 2009; 15 (4): 1250-1258.

*Antioxidant and Anti-Inflammatory Properties of Curcumin*, Menon & Sudheer, **Adv. Exp. Med. Biol.** 2007; 595: 105-125.

*Curcumin and Resveratrol Inhibit Nuclear Factor-kappaB-Mediated Cytokine Expression in Adipocytes*, Gonzales & Orlando, **Nutr. Metab. (Lond.)** 2008; 5 (1): 17.

*Curcumin Dually Inhibits Both mTOR and NF-{kappa}B Pathways Through a Crossed PI3K/Akt/IKK Signaling Axis in Adenoid Cystic Carcinoma*, Sun, Chen, Zhang, et al., **Mol. Pharmacol.** 2010; [Epub ahead of print] PMID: 20959361

*Regulation of COX and LOX by Curcumin*, Rao, **Adv. Exp. Med. Biol.** 2007; 595: 213-226.

*Induction of Apoptosis by Curcumin and its Implications for Cancer Therapy*, Karunagaran, Rashmi & Kumar, **Curr. Cancer Drug Targets** 2005; 5 (2): 117-129.

*Curcumin Inhibits Human Colon Cancer Cell Growth by Suppressing Gene Expression of Epidermal Growth Factor Receptor Through Reducing the Activity of the Transcription Factor Egr-1*, Chen, Xu & Johnson, **Oncogene** 2005; Sept. 19, Epub.

*Biological Effects of Curcumin and its Role in Cancer Chemoprevention and Therapy*, Singh & Khar, **Anticancer Agents Med.Chem.** 2006; 6 (3): 259-270.

*Chemotherapeutic Potential of Curcumin for Colorectal Cancer*, Chauhan, **Curr. Pharm. Des.** 2002; 8 (19): 1695-1706.

*Synergistic Inhibitory Effects of Curcumin and 5-FluoroUracil on the Growth of the Human Colon Cancer Cell Line HT-29*, Du, Jiang, Xia & Zhong, **Chemotherapy** 2006; 52 (1): 23-28.

*Molecular Targets of Curcumin*, Lin, **Adv. Exp. Med. Biol.** 2007; 595: 227-243.

*Curcumin, an Anti-Oxidant and Anti-Tumour Promoter, Induces Apoptosis in Human Leukemia Cells*, Kuo, Huang & Lin, **Biochem Biophys Acta** 1996; 131 (7): 95-100.

*Curcumin, a Dietary Component, Has Anti-Cancer, Chemo-Sensitization, and Radio-Sensitization Effects by Down-Regulating the MDM2 Oncogene Through the PI3K/mTOR/ETS2 Pathway*, Zhang, Hill, Wang & Zhang, **Cancer Res.** 2007; 67 (5): 1988-1996.

*Cellular Foundation of Curcumin-Induced Apoptosis in Follicular Lymphoma Cell Lines*, Skommer, Wlodkowic & Pelkonen, **Exp. Hematol.** 2006; 34 (4): 463-474.

*Curcumin Inhibits Human Colon Cancer Cell Growth by Suppressing Gene Expression of Epidermal Growth Factor Receptor Through Reducing the Activity of the Transcription Factor Egr-1*, Chen, Xu & Johnson, **Oncogene** 2006; 25: 278-287.

*Therapeutic Potential of Curcumin in Human Prostate Cancer-1. Curcumin Induces Apoptosis in Both Androgen-Dependent and Androgen-Independent Prostate Cancer Cells*, Dorai, Gehani & Katz, **Prost. Cancer Prost. Dis.** 2000; 3: 84-93.

*Dietary Curcumin Inhibits Chemotherapy-Induced Apoptosis in Models of Human Breast Cancer*, Somasundaram, Edmund, Moore, et al., **Cancer Res.** 2002; 62 (13): 3868-3875.

*Can a Common Spice be Used to Treat Cancer?*, Witter, **Oncolog.** 2007; 52 (9): 4-5.

*Curcumin and Colorectal Cancer: Add Spice to Your Life*, Kunnumakarra, Guha & Aggarwal, **Curr. Colorectal Cancer Rep.** 2009; 5: 5-14.

*Curcumin Inhibits GPVI-Mediated Platelet Activation by Interfering with the Kinase activity of Syk and the Subsequent Activation of PLCgamma2*, Mayanglambam, Dangelmaier, Thomas, et al., **Platelets** 2010; 21 (3): 211-220.

*Curcumin as Chemosensitizer*, Limtrakul, **Adv. Exp. Med. Biol.** 2007; 595: 269-300.

*Dietary Curcumin Inhibits Chemotherapy-Induced Apoptosis in Models of Human Breast Cancer*, Somasundaram, Edmund, Moore, et al., **Cancer Res.** 2002; 62 (13): 3868-3875.

*Modulation of Function of Three Drug Transporters, P-Glycoprotein (ABCB1), Mitoxantrone Resistance Protein (ABCG2) and Multi-Drug Resistance Protein 1 (ABCC1) by Tetrahydrocurcumin, a Major Metabolite of Curcumin*, Limtrakul, Chearwae, Shukla, et al., **Mol. Cell Biochem.** 2007; 296 (1-2): 85-95.

*Aspirin, COX-2 Inhibitors Effective as Adjuvant Therapy in Stage III Colon Cancer*, Fuchs, **Amer. Soc. Clin. Onc.**, AGM May 16, 2005; Abstract 3530, as reported by Schuster, Medscape Medical News, May 2005; article 504976.

*Helicobacter Infection, Chronic Inflammation and the Development of Malignancy*, Crowe, **Curr. Opin. Gastroenterol.** 2005; 21 (1): 32-38.

*Nutritional and Botanical Modulation of the Inflammatory Cascade – Eicosanoids, Cyclooxygenases and Lipoxygenases – As an Adjunct in Cancer Therapy*, Wallace, **Integr. Cancer Ther.** 2002; 1 (1): 7-37.

*Inflammation, COX-2 Inhibitors, & Cancer*, Block, **Integr. Cancer Ther.** 2005; 4 (1): 3-4.

*Inflammation and Cancer: An Ancient Link with Novel Potentials*, Pervez Hussain & Harris, **Int. J. Cancer** 2007; 121 (11): 2373-2380.

*NF-kappaB: A Stress-Regulated Switch for Cell Survival*, Piva, Belardo & Santoro, **Antioxid. Redox Signal.** 2006; 8 (3-4): 478-486.

*Cancer Cachexia and Targeting Chronic Inflammation: A Unified Approach to Cancer Treatment and Palliative/Supportive Care*, MacDonald, **J. Support. Oncol.** 2007; 5 (4): 157-162.

*Inflammation and Cancer*, Coussens & Werb, **Nature** 2002; 420 (6917): 860-867.

*Significance and Relationship Between Infiltrating Inflammatory Cell and Tumour Angiogenesis in Hepatocellular Carcinoma Tissues*, Peng, Deng, Yang, et al., **World J Gastroenterol.** 2005; 11 (41): 6521-6524.

*Inflammatory Cell Infiltration of Tumours: Jekyll or Hyde*, Talmadge, Donkor, & Scholar, **Cancer Metastasis Rev.** 2007; 26 (3-4): 373-400.

- Bioavailability of Curcumin: Problems and Promises*, Anaand, Kunnumakkara, Newman, et al., **Molec. Pharm.** 2007; 4 (6): 807-818.
- Phase II Trial of Curcumin in Patients with Advanced Pancreatic Cancer*, Dhillon, Aggarwal, Newman, et al., **Clin. Cancer Res.** 2008; 14 (14): 4491-4499.
- Prevention and Treatment of Pancreatic Cancer by Curcumin in Combination with Omega-3 Fatty Acids*, Swamy, Citineni, et al, **Nutr. Cancer** 2008; 60 Suppl. 1: 81-89.
- Curcumin Inhibits Human Colon Cancer Cell Growth by Suppressing Gene Expression of Epidermal Growth Factor Receptor Through Reducing the Activity of the Transcription Factor Egr-1*, Chen, Xu & Johnson, **Oncogene** 2006; 25 (2): 278-287.
- Curcumin Induces Apoptosis of Triple-Negative Breast Cancer Cells by Inhibition of EGFR Expression*, Sun, Liu & Huang, **Mol. Med. Report** 2012; 6 (6): 1267-1270.
- Phase II Trial of Curcumin in Patients with Advanced Pancreatic Cancer*, Dhillon, Aggarwal, Newman, et al., **Clin. Cancer Res.** 2008; 14 (14): 4491-4499.
- Inhibitory Effect of Curcumin, a Food Spice from Turmeric, on Platelet-Activating Factor and Arachidonic Acid-Mediated Platelet Aggregation Through Inhibition of Thromboxane Formation and Ca<sup>2+</sup> Signalling*, Shah, Nawaz, Pertani, et al., **Biochem. Pharmacol.** 1999; 58 (7): 1167-1172.
- Combination Treatment with Curcumin and Quercetin of Adenomas in Familial Adenomatous Polyposis*, Cruz-Correia, Shoskes, Sanchez, et al., **Clin. Gastroenterol. Hepatol.** 2006; 4 (8): 1035-1038.
- Curcumin Inhibits Proliferation, Invasion, Angiogenesis and Metastasis of Different Cancers Through Interaction with Multiple Cell Signaling Proteins*, Kunnumakkara, Anand & Aggarwal, **Cancer Lett.** 2008; [Epub ahead of print].
- Curcumin (Diferuloylmethane) Down-Regulates Expression of Cell Proliferation and Anti-Apoptotic and Metastatic Gene Products Through Suppression of I-kappaB-alpha Kinase and Akt Activation*, Aggarwal, Ichikawa, Takada, et al., **Mol. Pharmacol.** 2006; 69 (1): 195-206.
- Curcumin Down-Regulates the Multidrug-Resistance Mdr1b Gene by Inhibiting the PI3K/Akt/NF kappa B Pathway*, Choi, Kim, Lim, et al., **Cancer Lett.** 2008; 259 (1): 111-118.
- Amelioration of Immune Cell Number Depletion and Potentiation of Depressed Detoxification System of Tumour-Bearing Mice by Curcumin*, Pal, Bhattacharyya, Choudhuri, et al., **Cancer Detect. Prev.** 2005; 29 (5): 470-478
- Vitamin Antioxidants, Lipid Peroxidation, Tumour Stage, the Systemic Inflammatory Response and Survival in Patients with Colorectal Cancer*, Leung, Crozier, Talwar, et al., **Int. J. Cancer** 2008; 12310: 2460-2464.
- Evaluation of Anti-Inflammatory Property of Curcumin (Diferuloyl methane) in Patients with Postoperative Inflammation*, Satoskar, Shah & Shenoy, **Int. J. Clin. Pharmacol. Ther.** 1986; 24: 651-654.
- Biological Effects of Curcumin and its Role in Cancer Chemoprevention and Therapy*, Singh & Khar, **Anticancer Agents Med. Chem.** 2006; 6 (3): 259-270.
- Suppression of the Nuclear Factor-kappaB Activation Pathway by Spice-Derived Phytochemicals: Reasoning for Seasoning*, Aggarwal & Shishodia, **Ann. N. Y. Acad. Sci.** 2004; 1030: 434-441.
- Phase I Dose Escalation Trial of Docetaxol Plus Curcumin in Patients with Advanced and Metastatic Breast Cancer*, Bayet-Robert, Kwiatkowski, Leheurteur, et al., **Cancer Biol. Ther.** 2010, 9 (1): [Epub ahead of print]. PMID 19901561.

*Curcumin in Combination with Bortezomib Synergistically Induced Apoptosis in Human Multiple Myeloma U266 Cells*, Park, Ayyappan, Bae, et al., **Molecular Oncology** 2009; 2 (4): 317-326.

*Curcumin Circumvents Chemoresistance in vitro and Potentiates the Effect of Thalidomide and Bortezomib Against Human Multiple Myeloma in Nude Mice Model*, Sung, Kunnumakkara, Sethi, et al., **Mol. Cancer Ther.** 2009; 8 (4): 959-970.

*Curcumin as an Anti-Cancer Agent: Review of the Gap Between Basic and Clinical Applications*, Bar-Sela, Epelbaum & Schaffer, **Curr. Med. Chem.** 2010; 17 (3): 190-197(8).

*Aromatase Inhibitor Letrozole in Synergy with Curcumin in the Inhibition of Xenografted Endometrial Carcinoma Growth*, Liang, Hao, Wu, et al., **Int. J. Gynecol. Cancer** 2009; 19 (7): 1248-1252.

*Phase I/II Study of Gemcitabine-Based Chemotherapy Plus Curcumin for Patients with Gemcitabine-Resistant Pancreatic Cancer*, Kanai, Yoshimura, Asada, et al., **Cancer Chemother. Pharmacol.** 2010; published online Sept. 22, 2010: DOI 10.1007/s00280-010-1470-2A.

*Elimination of Colon Cancer Stem-Like Cells by the Combination of Curcumin and FOLFOX*, Yu, Kanwar, Patel, et al., **Transl. Oncol.** 2009; 2 (4): 321-328.

*Comparison of Systemic Availability of Curcumin with that of Curcumin Formulated with Phosphatidylcholine*, Marczylo, Verschoyle, Cooke, et al., **Cancer Chemother. Pharmacol.** 2007; 60 (2):171-177.

*Curcumin Dually Inhibits Both mTOR and NF- $\kappa$ B Pathways Through a Crossed PI3K/Akt/IKK Signaling Axis in Adenoid Cystic Carcinoma*, Sun, Chen, Zhang, et al., **Mol. Pharmacol.** 2010; [Epub ahead of print] PMID: 20959361.

*Chemopreventive and Therapeutic Effects of Curcumin [Mini-Review]*, Duvoix, Blasius, Delhalle, et al., **Cancer Letters** 2005; 223: 181–190.

*Curcumin: A Novel Nutritionally Derived Ligand of the Vitamin D Receptor with Implications for Colon Cancer Chemoprevention*, Bartika, Whitfielda, Kaczmarskaa, et al., **J. Nutr. Biochem.** 2010; 21: 1153–1161.

*Novel STAT3 Phosphorylation Inhibitors [from Curcumin ]Exhibit Potent Growth-Suppressive Activity in Pancreatic and Breast Cancer Cells*, Lin, Hutzen, Zuo, et al., **Cancer Res.** 2010; 70 (6): 2445-2454.

*Protective Effect of Curcumin in Cisplatin-Induced Oxidative Injury in Rat Testis: Mitogen-Activated Protein Kinase and Nuclear Factor- $\kappa$ B Signaling Pathways*, Ilbey, Ozbek, Cekmen, et al., **Human Reproduction** 2009; 24 (7): 1717–1725.

*Curcumin Inhibits Pro-Survival Pathways in Chronic Lymphocytic Leukemia B Cells and May Overcome Their Stromal Protection in Combination with EGCG*, Ghosh, Kay, Secreto & Shanafelt, **Clin. Cancer Res.** 2009; 15 (4): 1250-1258.

*Curcumin Induces Downregulation of E2F4 Expression and Apoptotic Cell Death in HCT1116 Human Colon Cancer Cells: Involvement of Reactive Oxygen Species*, Kim & Lee, **Korean J. Physiol. Pharmacol.** 2010; 14 (6): 391-397  
*Curcumin in Cancer Chemoprevention: Molecular Targets, Pharmacokinetics, Bioavailability, and Clinical Trials*, Shehzad, Wahid & Lee, **Arch. Pharm.** (Weinheim). 2010; 343 (9): 489-499.

*Pharmacokinetics and Pharmacodynamics of Curcumin*. Sharma, Steward & Gescher, **Adv. Exp. Med. Biol.** 2007; 595: 453-470.

*Curcumin Suppresses Human Papillomavirus Oncoproteins, Restores p53, Rb, and PTPN13 Proteins and Inhibits Benzo[a]pyrene-induced Upregulation of HPV E7*, Maher, Bell, O'Donnell, et al., **Mol. Carcinog.** 2011; 50 (1): 47-57.

*Curcumin Counteracts the Proliferative Effect of Estradiol and Induces Apoptosis in Cervical Cancer Cells*, Singh & Singh, **Mol. Cell Biochem.** 2011; 347 (1-2):1-11.

*Molecular Mechanism of Curcumin Induced Cytotoxicity in Human Cervical Carcinoma Cells*, Singh & Singh, **Mol. Cell Biochem.** 2009; 325 (1-2):107-119.

*Upregulation of p53 Expression in Patients with Colorectal Cancer by Administration of Curcumin*, He, Shi, Wen, et al., **Cancer Inv.** 2011; 29: 208–213.

*Turmeric and Green Tea: A Recipe for the Treatment of B-Chronic Lymphocytic Leukemia*, Angelo & Kurzrock, **Clin Cancer Res.** 2009; 15 (4): 1123-1125.

*Synergistic Role of Curcumin with Current Therapeutics in Colorectal Cancer: Minireview*, Patel & Majumdar, **Nutr. Cancer** 2009; 61: 842-846. {+ with 5FU, oxaliplatin & gemcitabine chemo}

*Adjuvant Therapy with Bioavailability-Enhanced curcuminoids Suppresses Systemic Inflammation and Improves Quality of Life in Patients with Solid Tumours: A Randomized Double-Blind Placebo-Controlled Trial*, Panahi, Saadat, Beiraghda & Sahebkar, **Phytother. Res.** 2014; published online – Wiley Online Library – doi: 10.1002/ptr.5149.

*Curcumin Potentiates Antitumour Activity of L-Asparaginase via Inhibition of the AKT Signaling Pathway in Acute Lymphoblastic Leukemia*, Wang, Geng, Wang & Lu, **Leuk Lymphoma** 2012; Jan. 25. [Epub ahead of print]

*Impact of Curcumin, Raspberry Extract, and Neem Leaf Extract on Rel Protein-Regulated Cell Death /Radiosensitization in Pancreatic Cancer Cells*. Veeraraghavan, Natarajan, Lagisetty , et al., **Pancreas** 2011; [Epub ahead of print]

*Effects of Curcumin on Stem-Like Cells in Human Esophageal Squamous Carcinoma Cell Lines*, Almanaa, Geusz & Jamasbi, **BMC Compl. Alt.]Med.** 2012; 12:195.

*Curcumin and EGCG Suppress Apurinic/Apyrimidinic Endonuclease 1 and Induce Complete Remission in B-Cell Non-Hodgkin's Lymphoma Patients* , Bassiouny, Atteya, El-Rashidy & Neenaa, **Funct. Foods Health Dis.** 2011; 12: 525-544.

*Effect of a Herbal Extract Containing Curcumin and Piperine on Midazolam, Flurbiprofen and Paracetamol (Acetaminophen) Pharmacokinetics in Healthy Volunteers.*, Volak, Hanley, Masse, et al., **Br. J. Clin. Pharmacol.** 2013; 75 (2): 450-462. doi: 10.1111/j.1365-2125.2012.04364.

*Curcumin for Radiation Dermatitis: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Thirty Breast Cancer Patients*, Ryan, Heckler, Ling, et al., **Radiat. Res.** 2013; 180 (1): 34-43.

*Curcumin Modulates the Radiosensitivity of Colorectal Cancer Cells by Suppressing Constitutive and Inducible NF- $\kappa$ B Activity*, Sandur, Deorukhkar, Pandey, et al., **Int J Radiat Oncol Biol Phys.** 2009; 75 (2): 534–542.

*Potential Applications of Curcumin and Its Novel Synthetic Analogs and Nanotechnology-Based Formulations in Cancer Prevention and Therapy*, Mimeault & Batra, **Chin. Med.** 2011; 6 (31): 1-19.

*Curcumin and Its Formulations: Potential Anti-Cancer Agents*, Ji, Huang, Zhu, **Anticancer Agents Med Chem.** 2012;12 (3): 210-218. PMID: 22044005

*Chemopreventive and Chemotherapeutic Potential of Curcumin in Breast Cancer*, Sinha, Biswas, Sung et al., **Curr. Drug Targets.** 2012; 13 (14): 1799-1819.

*Recent Progress in Studying Curcumin and Its Nano-Preparations for Cancer Therapy*, Liu, Chen, Lv, et al., **Curr. Pharm. Des.** 2013; 19 (11):1974-1993.

*Curcumin Inhibits Cancer Stem Cell Phenotypes In ex vivo Models of Colorectal Liver Metastases, And Is Clinically Safe and Tolerable in Combination with FOLFOX Chemotherapy*, James, Iwuji, Irving, et al., **Cancer Lett.** 2015; 364 (2): 135-141.

*Antagonistic Role of Natural Compounds in mTOR-Mediated Metabolic Reprogramming*, Cerella, Gaigneaux, Dicato & Diederich, **Cancer Letters** 2014; doi Feb 19, CAN 11802, 2014.canlet 4.02.008.

*Regression of Follicular Lymphoma with Devil's Claw: Coincidence or Causation?*, Wilson, **Curr. Oncol.** 2009; 16 (4): 67-70.

#### DIET & GENERAL INTEGRATIVE ONCOLOGY

*Natural Health Products and Cancer Treatment*, Hal Gunn, Complementary Corner, Summer 2003 Vol. 4 No. 3 www.abreastinthewest.ca (BCCA policy re: natural agents)

*Use of Complementary / Integrative Nutritional Therapies During Cancer Treatment: Implications in Clinical Practice*, Kumar et al., **Cancer Control** 2002; 9 (3): 236-243.

*Complementary Therapies for Cancer-Related Symptoms*, Deng, Cassileth & Yeung, **J. Support Oncol.** 2004; 2: 419-429.

*Complementary and Alternative Therapies for Cancer*, Cassileth & Deng, **Oncologist** 2004; 9: 80-89. *Integrative Oncology: Complementary Therapies in Cancer Care*, Cassileth, Heitzer & Gubili, **Cancer Chemother. Rev.** 2008; 3 (4): 204-211.

*Lifestyle Changes and the 'Spontaneous' Regression of Cancer: An Initial Computer Analysis*, Foster, **Int. J. Biosoc. Res.**, 1988; 10 (1): 17-33.

*(Gamma)γ-Tocopherol Traps Mutagenic Electrophiles Such As NOx and Complements (Alpha)α-Tocopherol: Physiological Implications*, Christen, Woodall, Shigenaga, et al., **Proc. Natl. Acad. Sci.** 1997; 94: 3217-3222.

*Synergistic Effects of Multiple Natural Products in Pancreatic Cancer Cells*, Wang, Desmoulin, Banerjee, et al., **Life Sci.** 2008; 83 (7-8): 293–300. doi:10.1016/j.lfs.2008.06.017.

*The Effect of Thiamine Supplementation on Tumour Proliferation: A Metabolic Control Analysis Study*, Comăneanu-Anduix, Boren, Martinez, et al., **Eur. J. Biochem.** 2001; 268: 4177- 4182.

*Exercise in Prevention and Management of Cancer*, Newton & Galvao, **Curr. Treat. Opt. Oncol.** 2008; 92 (3): 135-146.

*Molecular Targets of Dietary Agents for Prevention and Therapy of Cancer*, Aggarwal & Shishodia, **Biochem. Pharmacol.** 2006; 71: (10): 1397-1421.

*Analysis of Botanicals and Dietary Supplements for Antioxidant Capacity: A Review*, Prior & Cao, **J. AOAC Int.** 2000; 83 (4): 950-956.

*Dietary Fat, Fiber, Vegetable, and Micronutrients are Associated with Overall Survival in Postmenopausal Women Diagnosed with Breast Cancer*, McEligot, Largent, Ziogas, Peel & Anton-Culver, **Nutr. Cancer.** 2006; 55 (2): 132-140.

*Dietary Influences on Survival After Ovarian Cancer*, Nagle, Purdie, Webb, et al., **Int. J. Cancer** 2003; 106 (2): 264-269.

*Association of Dietary Patterns with Cancer Recurrence and Survival in Patients with Stage III Colon Cancer*, Meyerhardt , Niedzwiecki , Hollis, et al., **J. Amer. Med. Assoc.** 2007; 298 (7):754 -764.

*Greater Survival After Breast Cancer in Physically Active Women with High Vegetable-Fruit Intake Regardless of Obesity*, Pierce, Stefanick, Flatt, et al., **J. Clin. Oncol.** 2007; 25 (17): 2345-2351.

*Influence of a Diet Very High in Vegetables, Fruit and Fiber and Low in Fat on Prognosis Following Treatment for Breast Cancer*, **J. Amer. Med. Assoc.** 2007; 298 (3): 289-298.

*Baseline Nutritional Status is Predictive of Response to Treatment and Survival in Patients Treated by Definitive Chemoradiotherapy for a Locally Advanced Esophageal Cancer*, Di Fiore, Leclaire, Pop, et al., **Am. J. Gastroenterol.** 2007; 102 (11): 2557-2563.

*Is Voluntary Vitamin and Mineral Supplementation Associated with Better Outcome in Non-Small Cell Lung Cancer Patients? Results from the Mayo Clinic Lung Cancer Cohort*. Jatoi, Williams, Nichols, et al., **Lung Cancer**. 2005; 49 (1): 77-84.

*Mind-Body Therapies for the Management of Pain*, Astin, **Clin. J. Pain** 2004; 20 (1): 27-32.

*Multivitamin Use and Breast Cancer Incidence in a Prospective Cohort of Swedish Women*, Laarson, Akesson, Bergkvist & Wolk, **Am. J. Clin. Nutr.** 2010; 91 (5): 1268-1272.

*Survival Impact of Integrative Cancer Care in Advanced Metastatic Breast Cancer*, Block, Gyllenhaal, Tripathy, et al., in press, **The Breast Journal** 2009; 15 (4).

*Survival Impact of Integrative Care in Advanced Prostate Cancer*, Block, Gyllenhaal, Chodak, et al., **Proc. Am. Soc. Clin. Oncol.** 2003; 22: abstract 1746.

*The Healing Journey: Incorporating Psychological and Spiritual Dimensions Into the Care of Cancer Patients*, Cunningham, **Curr. Oncol.** 2008; 15 Suppl.2: S37-S41

*Pilot Crossover Trial of Reiki vs. Rest for Treating Cancer-Related Fatigue*, Tsang, Carlson & Olson, **Integr. Cancer Ther.** 2007; 6 (1): 25-35.

*Randomized Placebo-Controlled Trial of Cognitive Behavioral Therapy and Armodafinil for Insomnia After Cancer Treatment*, Roscoe, Garland, Heckler, et al., **J. Clin. Oncol.** 2014 Dec 1. pii: JCO.2014.57.6769. [Epub ahead of print]

*The Hoxsey Treatment: Cancer Quackery or Effective Physiological Adjuvant?*, Brinker, **J. Naturopathic Med.** 1996; 6(1): 9-23.

*Broad in vitro Efficacy of Plant-Derived Betulinic Acid Against Cell Lines Derived from the Most Prevalent Human Cancer Types*, Kessler, Mullauer, de Roo & Medema, **Cancer Lett.** 2007; 251 (1): 132-145.

*Complementary & Alternative Medicine*, Larson, **Trustee Mag.** 2006, Sept.

*Genetic Program Linking Cancer to Hemostasis Identified*, Boccaccio, et al., **Nature** 2005; 434: 396-400.

*Metastasis: A Therapeutic Target for Cancer*, Steeg & Theodorescu, **Nat. Clin. Pract. Oncol.** 2008; 5 (4): 206-219.

*Effect of Gamma-Linolenic Acid on the Transcriptional Activity of the Her-2/neu (erbB-2) Oncogene*, Menendez, Vellon, Colomer & Lupu, **J. Natl. Cancer Inst.** 2005; 97 (2): 1611-1615.

*Therapeutic Applications of Whey Protein*, Marshall, **Altern. Med. Rev.** 2004; 9 (2): 136-156.

*Herb-Drug Interactions in Oncology: Focus on Mechanisms of Induction*, Meijerman, Beijnen and Schellens, **Oncologist** 2006; 11: 742-752.

*L-Glutamine Use in the Treatment and Prevention Mucositis and Cachexia: A Naturopathic Perspective*, Noé, **Integr. Cancer Ther.** 2009; 8 (4): 409-415.

*Bringing Evidence to Complementary and Alternative Medicine in Children with Cancer: Focus on Nutrition-Related Therapies*, Kelly, **Pediatr. Blood Cancer** 2008; 50 (2 Suppl): 490-493; discussion 498.

*The Use of a Whey Protein Concentrate in the Treatment of Patients with Metastatic Carcinoma: A Phase I-II Clinical Study*, Kennedy, **Anticancer Res.** 1995; 15 (6B): 2643-2649.

*Energy-Modulating Vitamins – A New Combinatorial Therapy Prevents Cancer Cachexia in Rat Mammary Carcinoma*, Perumai, Shanthi & Sachdanandam, **Br. J. Nutr.** 2005; 93(6): 901-909.

*P13 Kinase /Akt Pathway as a Therapeutic Target in Multiple Myeloma*, Harvey & Lonial, **Future Oncol.** 2007; 3(6): 639-647.

*Starvation-Dependent Differential Stress Resistance Protects Normal But Not Cancer Cells Against High-Dose Chemotherapy*, Raffaghello, Lee, Sadfie, et al., **Proc Natl Acad Sci USA** 2008; 105 (24): 8215-8220.

*Targeting Energy Metabolism in Brain Cancer Through Calorie Restriction and the Ketogenic Diet*, Seyfried, Kiebish, Marsh & Mukherjee, **J. Can. Res. Ther.** 2009; 5: 7-15. PMID: 20009300

*Adherence to Mediterranean Diet and Health Status: Meta-Analysis*, Sofe, Cesari, Abbate, et al., **BMJ** 2008; 337: a1344.

*Early Hormonal Data from a Multicentre Phase II Trial Using Transdermal Oestrogen Patches as a First-Line Hormonal Therapy in Patients with Locally Advanced or Metastatic Prostate Cancer*, Langley, Godsland, Kynaston, et al., **BJU Int** 2008; 102 (4): 442-445.

*Dietary Alpha-, Beta-, Gamma- and Delta-Tocopherols in Lung Cancer Risk*, Mahabir, Schendel, Dong, et al., **Int. J. Cancer** 2008; 123: 1173-1180.

*Allergic Pulmonary Inflammation Promotes the Recruitment of Circulating Tumour Cells to the Lung*, Taranova, Maldonado, Vachon, et al., **Cancer Res.** 2008; 68 (20): 8582-8589.

*Interaction of Warfarin with Drugs, Natural Substances, and Foods*, Greenblatt & von Moltke, **J. Clin. Pharmacol.** 2005; 45 (2): 127-132.

*Intensive Lifestyle Changes May Affect the Progression of Prostate Cancer*, Ornish, Weidner, Fair, et al., **J Urol.** 2005; 174 (3): 1065-1069.

*High Casein-Lactalbumin Diet Accelerates Blood Coagulation in Rats*, Chan, Lou & Hargrove, **J. Nutr.** 1993; 123 (6): 1010-1016.

*Dairy Products, Calcium, and Vitamin D and Risk of Prostate Cancer*, Chan & Giovannucci, **Epidemiol. Rev.** 2001; 23 (1): 87-92.

*Lycopene and Apo-12- Lycopenal Reduce Cell Proliferation and Alter Cell Cycle Progression in Human Prostate Cancer Cells*, Ford, Elsen, Zuniga, et al., **Nutr. Cancer** 2011; 63 (2): 256–263.

*Serum Phospholipid Fatty Acids and Prostate Cancer Risk: Results From the Prostate Cancer Prevention Trial*, Brasky, Till, White, et al., **Am. J. Epidemiol.** 2011; doi: 10.1093/aje/kwr027

*Testosterone Therapy in Men With Untreated Prostate Cancer*, Morgentaler, Lipshultz, Bennett, et al., **J. Urol.** 2011; 185 (4): 1256-1260.

*Radical Prostatectomy Versus Watchful Waiting in Early Prostate Cancer*, Bill-Axelson, Holmberg, Ruutu, et al., **N. Engl. J. Med.** 2011; 364: 1708-1717, 1770-1772.

*A High Ratio of Dietary n-6/n-3 Polyunsaturated Fatty Acids is Associated with Increased Risk of Prostate Cancer*, Williams, Whitley, Hoyod, et al., **Nutr. Res.** 31 2011; 31: 1–8.

*The Effects of Virgin Coconut Oil (VCO) as Supplementation on Quality of Life (QOL) Among Breast Cancer Patients*, Law, Azman, Omar, et al., **Lipids Health Dis.** 2014 Aug 27;13:139.

*Choline. A Nutrient That is Involved in the Regulation of Cell Proliferation, Cell Death, and Cell Transformation*, Zeisel, **Adv. Exp. Med. Biol.** 1996; 399: 131-141.

*Potent Activation of Mitochondria-Mediated Apoptosis and Arrest in S and M Phases of Cancer Cells by a Broccoli Sprout Extract*, Tang, Zhang, Jobson, et al., **Mol. Cancer Ther.** 2006; 5 (4): 935-944.

*Dairy Products and Breast Cancer: the IGF-I, Estrogen, and bGH Hypothesis*, Outwater, Nicholson & Barnard, **Med. Hypotheses** 1997; 48 (6): 453-461.

*Prospective Study of Grapefruit Intake and Risk of Breast Cancer in Postmenopausal Women: the Multi-ethnic Cohort Study*, Monroe, Murphy, Kolonel & Pike, **Br. J. Cancer** 2007; 697 (3): 440-445.

*Paraneoplastic Syndromes: An Approach to Diagnosis and Treatment*, Pelosof & Gerber, **Mayo Clin. Proc.** 2010; 85 (9): 838-854.

*The Tumour Lysis Syndrome*, Howard, Jones, & Pui, **N. Engl. J. Med.** 2011; 364: 1844-1854.

*Does Grapefruit Juice Increase the Bioavailability of Orally Administered Sex Steroids?* Fingerová, Oborná, Petrová, et al., **Ceska Gynekol.** 2003; 68 (2): 117-121.

*Gamma-Linolenic Acid Therapy of Human Glioma- A Review of in vitro, in vivo, and Clinical Studies*, Das, **Med. Sci. Monit.** 2007; 13 (7): RA119-131.

*Gamma Linolenic Acid: An Antiinflammatory Omega-6 Fatty Acid*, Kapoor & Huang, **Curr. Pharm. Biotechnol.** 2006; 7(6): 531-534.

*Non-Linear Dynamics for Clinicians: Chaos Theory, Fractals, and Complexity at the Bedside*, Goldberger, **Lancet** 1996; 347: 1312–1314.

*Megadose Vitamins in Bladder Cancer: A Double-Blind Clinical Trial*, Lamm, Riggs, Shriver et al., **J. Urol.** 1994; 151 (1): 21-26

*Health Implications of Mediterranean Diets in Light of Contemporary Knowledge: Meat, Wine, Fats, and Oils*, Kushi, Lenart & Willett, **Am. J. Clin. Nutr.** 1995; 61 (6Suppl): 1416S-1427S.

*Adherence to the Mediterranean Diet Attenuates Inflammation and Coagulation Process in Healthy Adults: The ATTICA Study*, Chrysohoou, Panagiotakos, Pitsavos, et al., **J. Am. Coll. Cardiol.** 2004; 44 (1): 152-158.

*A Supplemental High-Fat Low-Carbohydrate Diet for the Treatment of Glioblastoma*, Martuscello, Vedam-Mai, McCarthy, et al. **Clin Cancer Res.** 2015 Dec 2. [Epub ahead of print]

*Targeting Energy Metabolism in Brain Cancer Through Calorie Restriction and the Ketogenic Diet*, Seyfried, Kiebish, Marsh & Mukherjee, **J. Can. Res. Ther.** 2009; 5: 7-15.

*The Calorically Restricted Ketogenic Diet, An Effective Alternative Therapy for Malignant Brain Cancer*, Zhou, Mukherjee, Kiebish, Markis, Mantis & Seyfried, **Nutrition & Metabolism** 2007, 4: 5. doi:10.1186/1743-7075-4-5.

*Roles of Caloric Restriction, Ketogenic Diet and Intermittent Fasting during Initiation, Progression and Metastasis of Cancer in Animal Models: A Systematic Review and Meta-Analysis*, Lv, Zhu, Wang, Wang, & Guan, **PLOS ONE** 2014; |DOI:10.1371/journal.pone.0115147.

*Fibrinogen: A Novel Predictor of Responsiveness in Metastatic Melanoma Patients Treated with Bio-Chemotherapy: IMI (Italian Melanoma Inter-group) Trial*, Guida, Ravaioli, Sileni, et al., **J. Transl. Med.** 2003; 1 (1): 13.

*Analysis of Botanicals and Dietary Supplements for Antioxidant Capacity: A Review*, Prior, Cao, Prior & Cao, **J. AOAC Int.** 2000; 83 (4): 950-956.

*Berberine Inhibits Acute Radiation Intestinal Syndrome in Human with Abdomen Radiotherapy*, Li, Wang, Hu, et al., **Med. Oncol.** 2010; 27 (3): 919-925.

*Inhibitory Effects of Berberine on the Activation and Cell Cycle Progression of Human Peripheral Lymphocytes*, **Cell. Mol. Immunol.** Xu, Liu & He, 2005; 2 (4): 295-300.

*Berberine and Berberine-Containing Plants As Antineoplastic Agents*, Tang, Feng, Wang, et al., **J. Ethnopharmacol.** 2009; 128: 5-17.

*Seronea repens (Permixon, Saw Palmetto) Inhibits the 5-Alpha-Reductase Activity of Human Prostate Cancer Cell Lines Without Interfering with PSA Expression*, Habib, Ross, Ho, et al., **Int. J. Cancer** 2005; 114 (2): 190-194.

*Efficacy of Homeopathic Therapy in Cancer Treatment*, Milazzo, Russell & Ernst, **Eur. J. Cancer**, 2006; 42 : 282-289.

*Ultra-Diluted Remedies on Breast Cancer Cells*, Frenkel, Mishra, Sen, et al., **Int. J. Oncol.** 2010; 36 (2): 395-403. PMID: 20043074

*Ruta 6C Selectively Induces Cell Death in Brain Cancer Cells But Proliferation in Normal Blood Lymphocytes: A Novel Treatment For Human Brain Cancer*, Pathak, Multani, Banerji & Banerji, **Int. J. Oncol.** 2003; 23 (4): 975-982. PMID: 12963976.

*Association Between Coffee Drinking and K-ras Mutations in Exocrine Pancreatic Cancer*, Porta, Malats, Guarner, et al., **J. Epidemiol. Comm. Health** 1999; 53: 702-709

*Series of Case Reports: Clinical Evaluation of a Complex Homeopathic Injection Therapy in the Management of Pain in Patients After Breast Cancer Treatment*, Orellana, Ruiz de Viñaspre & Kaszkin-Bettag, **Altern. Ther. Health Med.** 2010; 16 (1): 54-59.

*Pancreatic Proteolytic Enzyme Therapy Compared With Gemcitabine-Based Chemotherapy for the Treatment of Pancreatic Cancer*, Chabot, Tsai, Fine, et al., **J. Clin. Oncol.** 2009 Aug 17. PMID 19687327.

*Berberine and Berberine-Containing Plants As Antineoplastic Agents*, Tang, Feng, Wang, et al., **J. Ethnopharmacol.** 2009; 128: 5-17.

*Increased Rates of Chromosome Breakage in BRCA1 Carriers Are Normalized by Oral Selenium Supplementation*, Kowalska, Narod, Huzarski, et al., **Cancer Epidemiol. Biomark. & Prev.** 2005; 14 (5): 1302-1306.

*Impact of Stress and Mast Cells on Brain Metastases*, Theoharides, Rozniecki , Sahagian, et al., **J. Neuroimmunol.** 2008; 205 (1-2): 1-7.

*Forgiveness Can Improve Immune Function*, Owen, **Soc. Behav. Med.** 32nd Annual Meeting and Scientific Sessions: Abstract 4010. Presented April 30, 2011.

*The Mental-Emotional-Spiritual Components of Cancer Care*, McKinney, CAND Vital Link, 2014; Fall-Winter: 33-45.

*ProstaCaid Induces G2/M Cell Cycle Arrest and Apoptosis in Human and Mouse Androgen-Dependent and –Independent Prostate Cancer Cells*, Yan & Katz, **Integr. Cancer Ther.** 2010; 9: 186-196.

*A Tissue Biomarker Panel Predicting Systemic Progression after PSA Recurrence Post-Definitive Prostate Cancer Therapy*, Nakagawa, Kollmeyer, Morlan, et.al., **PLoS ONE** 2008; 3 (5): e2318. Epub 2008 May 28.

*Perioperative Arginine-Supplemented Nutrition in Malnourished Patients with Head and Neck Cancer Improves Long-Term Survival*, Buijs, van Leeuwen, et al, **Amer. J. Clin. Nutr.** 2010; [Epub ahead of print] September 29, 2010, doi:10.3945/ajcn.2010.29532

*Retrolective Cohort Study of an Additive Therapy with an Oral Enzyme Preparation in Patients with Multiple Myeloma*, Sakalova, Bock, Dedik, et al., **Cancer Chemother. Pharmacol.** 2001; 47 (Suppl.): S38-S44.

*Dietary Vitamin K Intake in Relation to Cancer Incidence and Mortality: Results from the Heidelberg Cohort of the European Prospective Investigation into Cancer and Nutrition (EPIC-Heidelberg)*, Nimptsch, Rohrmann, Kaaks & Linseisen, **Am. J. Clin. Nutr.** 2010; 91 (5): 1348-1358. Comment in: **Am. J. Clin. Nutr.** 2010; 92 (6): 1533-1534; author reply 1534-1535.

*Distinct Roles of Different Forms of Vitamin E in DHA-Induced Apoptosis in Triple-Negative Breast Cancer Cells*, Xiong, Yu, Tiwary, et al., **Mol. Nutr. Food Res.** 2012; 56 (6): 923-934.

*Selenium for Preventing Cancer*, Dennert, Zwahlen, Brinkman, et al., **Cochrane Database of Systematic Reviews** 2011, 5: CD005195. DOI: 10.1002/14651858.CD005195.pub2

*A Low Carbohydrate, High Protein Diet Slows Tumour Growth and Prevents Cancer Initiation*, Ho, Leung, Hsu, et al. **Cancer Res.** 2011; 71: 4484-4493.

*BRCA1 is an Essential Regulator of Heart Function and Survival Following Myocardial Infarction*, Shukla, Singh, Quan, et al. **Nat. Commun.** 2011; DOI:10.1038/ncomms1601.

*Zinc Gluconate in the Treatment of Dysgeusia—A Randomized Clinical Trial*, Heckmann, Hujoel, Habiger , et al., **J. Dent. Res.** 2005; 84 (1): 35-38.

*Betaine In Human Nutrition*, Craig, **Am. J. Clin. Nutr.** 2004; 80: 539–549.

*Beyond Weight Loss: A Review of the Therapeutic Uses of Very-Low-Carbohydrate (Ketogenic) Diets*, Paoli1, Rubini1, Volek2 & Grimaldi, **Euro. J. Clin.Nutr.** 2013; 67: 789–796.

*Diet Rapidly and Reproducibly Alters the Human Gut Microbiome*, David, Maurice, Carmody, et al., **Nature** 2013; [Epub before print] doi:10.1038/nature12820.

*Effects of Limiting Energy Availability Via Diet and Physical Activity on Mammalian Target of Rapamycin-Related Signaling in Rat Mammary Carcinomas*, Jiang, Zhu & Thompson, **Carcinogenesis**. 2012; 34 (2): 378-387.

*Epigenetic Targets of Bioactive Dietary Components for Cancer Prevention and Therapy*, Meeran, Ahmed, & Tollesbol, **Clin. Epigenetics**. 2010; 1 (3-4): 101–116.

*Fasting vs. Dietary Restriction in Cellular Protection and Cancer Treatment: From Model Organisms to Patients*, Lee & Longo, **Oncogene** 201; 30(30): 3305-3316.

*Fasting and Differential Chemotherapy Protection in Patients*, Raffaghelli, Safdie, Bianchi,...& Longo, **Cell Cycle** 2010; 9 (22): 4474-4476.

*Starvation-Dependent Differential Stress Resistance Protects Normal But Not Cancer Cells Against High-Dose Chemotherapy*, 2. Raffaghelli, Lee,...Longo, **Proc. Natl. Acad. Sci. U S A.** 2008; 105 (24): 8215-8220.

*Starvation, Detoxification, and Multidrug Resistance in Cancer Therapy*, Lee, Raffaghello & Longo, **Drug Resist Updat.** 2012; 15 (1-2): 114-122.

*Fruit and Vegetable Consumption and All-Cause, Cancer and CVD Mortality: Analysis of Health Survey for England Data*, Oyebode, Gordon-Dseagu, Walker, & Mindell **J. Epidemiol. Comm. Health** 2014; 68 (9): 856-862.

*Accruing Evidence About Benefits of Adherence to the Mediterranean Diet on Health: An Updated Systematic Review and Meta-Analysis*, Sofi, Abbate, Gensini & Casini **Amer. J. Clin. Nutr.** 2010; 92 (5): 1189-1196.

#### GINGER

*Ginger for Chemotherapy-Related Nausea in Cancer Patients: A URCC CCOP Randomized, Double-Blind, Placebo-Controlled Clinical Trial of 644 Cancer Patients*, Ryan, Heckler, Dakhil et al., **J. Clin. Oncol.** 2009; 27: 15s, (suppl; abstr 9511 - 2009 ASCO Annual Meeting).

*Phase II Trial of Encapsulated Ginger as a Treatment for Chemotherapy-Induced Nausea and Vomiting*, Zick, Ruffin, Lee et al., **Support Care Cancer** 2009; 17 (5): 563-572.

*Protein and Ginger for the Treatment of Chemotherapy-Induced Delayed Nausea*, Levine, Gillis, Koch et al., **J. Altern. Complement. Med.** 2008; 14 (5): 545-551.

*A Phase II/III Randomized, Placebo-Controlled, Double-Blind Clinical Trial of Ginger (*Zingiber officinale*) for Nausea Caused by Chemotherapy for Cancer: A Currently Accruing URCC CCOP Cancer Control Study*, Hickok, Roscoe, Morrow & Ryan, **Support Cancer Ther.** 2007; 4 (4): 247-250.

*Anti-Emetic Effect of Ginger Powder Versus Placebo as an Add-On Therapy in Children and Young Adults Receiving High Emetogenic Chemotherapy*, Pillai, Sharma, Gupta & Bakhshi, **Pediatr. Blood Cancer** 2011; 56 (2): 234-238.

*Antiemetic Effect of Ginger in Gynecologic Oncology Patients Receiving Cisplatin*. Manusirivithaya, Sripramote, Tangjitung et al., **Int. J. Gynecol. Cancer** 2004; 14 (6): 1063-1069.

#### GRAPESEED EXTRACT & RESVERATROL

*Oligomeric Proanthocyanidin Complexes: History, Structure & Phytopharmaceutical Applications*, A. M. Fine, **Alt. Med Rev.** 2000; Vol. 5, No. 2: 144-151.

*Cellular Protection with Proanthocyanidins Derived from Grape Seeds*, Bagchi, Bagchi & Stohs, et al, **Ann. N. Y. Acad. Sci.** 2002; 957: 260-270.

*Oligomeric Proanthocyanidins (OPCs) – Monograph*, **Alt. Med. Rev.** 2003; Vol. 8, No.4: 442-450.

*Chemoprevention of Colorectal Cancer by Grapeseed Proanthocyanidin is Accompanied by a Decrease in Proliferation and Increase in Apoptosis*, Nomoto, Iigo, Hamada, et al. **Nutr. & Cancer**. 2004; Vol. 49, No. 1: 81-89.

*Alcohol and Polyphenolic Grape Extract Inhibit Platelet Adhesion in Flowing Blood*, de Lange, Scholman, Kraaijenhagen, et al., **Eur. J. Clin. Invest.** 2004; 4 (12): 818-824.

*Red Wine and Red Wine Polyphenolic Compounds But Not Alcohol Inhibit ADP-Induced Platelet Aggregation*, de Lange, van Golden, Scholman, et al., **Eur. J. Intern. Med.** 2003; 14 (6): 361-366.

*Grape Seed and Skin Extracts Inhibit Platelet Function and Release of Reactive Oxygen Intermediates*, Vitseva, Varghese, Chakrabarti, et al., **J. Cardiovasc. Pharmacol.** 2005; 46 (4): 445-451.

*Proanthocyanidin from Grape Seeds Enhances Anti-Tumour Effect of Doxorubicin Both in vitro & in vivo*, Zhang, Bai, Wu, et al, **Pharmazie**, 2005; 60: 533-538.

*Grape Seed Proanthocyanidin Extract Induced Mitochondria-Associated Apoptosis in Human Acute Myeloid Leukaemia 14.3D10 Cells*, Hong & Qin, **Chin. Med. J.** 2006; 119 (5): 417-421.

*Grapeseed Extract Induces Apoptotic Death of Human Prostate Carcinoma DU145 Cells Via Caspases Activation Accompanied by Dissipation of Mitochondrial Membrane Potential and Cytochrome C Release*, Agarwal, Singh & Agarwal, **Carcinogenesis** 2002; 23 (11): 1869-1876.

*Suppression of Estrogen Biosynthesis by Procyanidin Dimers in Red Wine and Grape Seeds*, Eng, Ye, Williams, et al., **Cancer Res.** 2003; 63 (23): 8516-8522.

*Grapeseed Extract is an Aromatase Inhibitor and a Suppressor of Aromatase Expression*, Kijima, Phung, Hur, et al., **Cancer Res.** 2006; 66 (11): 5960-5967.

*Grapeseed Extract Inhibits Advanced Human Prostate Cancer Growth and Angiogenesis and Upregulates Insulin-Like Growth Factor Binding Protein 3*, Singh, Tyagi, Dhanalakshmi, et al., **Int. J. Cancer** 2004; 108 (5): 733-740.

*Grape Seed Extract Induces Anoikis and Caspase-Mediated Apoptosis in Human Prostate Carcinoma LNCaP Cells: Possible Role of Ataxia Telangiectasis Mutated-p53 Activation*, Kaur, Agarwal & Agarwal, **Mol. Cancer Ther.** 2006; 5 (5): 1265-1274.

*Grape Seed Proanthocyanidin Extract Induced Mitochondria-Associated Apoptosis in Human Acute Myeloid Leukaemia 14.3D10 cells*, Hu & Qin, **Chin. Med. J.** 2006; 119 (5): 417-421.

*Proanthocyanidins from Grape Seeds Inhibit Expression of Matrix Metalloproteinases in Human Prostate Carcinoma Cells, Which is Associated with the Inhibition of Activation of MAPK and NF kappa B*, Vayalil, **Carcinogenesis** 2004; 25 (6): 987-985.

*Anti-Angiogenic Efficacy of Grape Seed Extract in Endothelial Cells*, Agarwal, Singh, Dhanalakshmi & Agarwal, **Oncol. Rep.** 2004; 11 (3): 681-685.

*Grape Seed Extract Inhibits Advanced Human Prostate Tumour Growth and Angiogenesis and Upregulates Insulin-Like Growth Factor Binding Protein-3*, Singh, Tyagi, Dhanalakshmi, et al., **Int. J. Cancer** 2004; 108 (5): 733-740.

*Anti-Cancer Activity of Grape and Grape Skin Extracts Alone and Combined with Green Tea Infusions*, Morré & Morré, **Cancer Lett.** 2006; 238 (2): 202-209.

*Grape Seed Extract Induces Apoptotic Death of Human Prostate Carcinoma DU145 Cells Via Caspases Activation Accompanied by Dissipation of Mitochondrial Membrane Potential and Cytochrome C Release*, Agarwal, Singh & Agarwal, **Carcinogenesis** 2002; 23 (11): 1869-1876.

*Inhibition of NF-kappaB Pathway in Grape Seed Extract-Induced Apoptotic Death of Human Prostate Carcinoma DU145 Cells*, Dhanalakshmi, Agarwal & Agarwal, **Int. J. Oncol.** 2003; 23 (3): 721-727.

*Grape Seed Extract Inhibits EGF-Induced and Constitutively Active Mitogenic Signalling But Activated JNK in Human Prostate Carcinoma DU145 Cells: Possible Role in Antiproliferation and Apoptosis*, Tyagi, Agarwal & Agarwal, **Oncogene** 2003; 22 (9): 1302-1316.

*Matrix Metalloproteinases in Cancer Metastasis: Molecular Targets for Prostate Cancer Prevention by Green Tea Polyphenols and Grape Seed Proanthocyanidins*, Katiyar, **Endocr. Metabol. Immune Disord. Drug Targets**, 2006; 6 (1): 17-24.

*Grape Seed Extract Inhibits in vitro and in vivo Growth of Human Colorectal Carcinoma Cells*, Kaur, Singh, Gu, et al., **Clin. Cancer Res.** 2006; 12 (20 Pt 1): 6194-6202.

*Proanthocyanidin from Grape Seeds Inactivates the PI3-kinase/PKB Pathway and Induces Apoptosis in a Colon Cancer Cell Line*, Engelbrecht, Mattheyse, Ellis, et al., **Cancer Lett.** 2007; 258 (1): 144-153.

*Experimental Model for Treating Pulmonary Metastatic Melanoma Using Grape-Seed Extract, Red Wine and Ethanol*, Martínez Conesa, Vicente Ortega, et al., **Clin. Transl. Oncol.** 2005; 7 (3): 115-121.

*Grapeseed Extract Inhibits Angiogenesis Via Suppression of the Vascular Endothelial Growth Factor Receptor Signaling Pathway*, Wen, Lu, Zhang & Chen, **Cancer Prev. Res.** 2008; 1 (7): 554-561

*Grapeseed Extract Inhibits VEGF Expression Via Reducing HIF-1 alpha Protein Expression*, Lu, Zhang, Chen & Wen, **Carcinogenesis** 2009; 30 (4): 636-644.

*Free Radicals and Grape Seed Proanthocyanidin Extract: Importance in Human Health and Disease Prevention*, Bagchi, Bagchi, Stohs, et al., **Toxicol.** 2000; 148 (2-3): 187-197.

*Chemoprevention of Colorectal Cancer by Grape Seed Proanthocyanidin is Accompanied by a Decrease in Proliferation and Increase in Apoptosis*, Nomoto, Hiroshi, Iigo, et al., **Nutr. & Cancer** 2004; 49 (1): 81-89.

*Synergistic Anti-Cancer Effects of Grapeseed Extract and Conventional Cytotoxic Agent Doxorubicin Against Human Breast Carcinoma Cells*, Sharma, Tyagi, Singh, et al., **Breast Cancer Res. Treat.** 2004; 85 (1): 1-12.

*Chemopreventative Effects of Grape Seed Proanthocyanidin Extract on Chang Liver Cells*, Joshi, Kuszynski, Bagchi & Bagchi, **Toxicol.** 2000; 155: 83-90.

*Dermal Wound Healing Properties of Redox-Active Grape Seed Proanthocyanidins*, Khanna, Venojarvi, Roy, et al., **Free Rad. Biol. Med.** 2002; 33: 1089.

*Gallic Acid, an Active Constituent of Grapeseed Extract, Exhibits Anti-proliferative, Pro-Apoptotic and Anti-Tumourigenic Effects Against Prostate Carcinoma Xenograft Growth in Nude Mice*, Kaur, Velmurugan, Rajamanickam, et al., **Pharm. Res.** 2009; June 20 [Epub ahead of print] PMID: 19543955.

*Molecular Mechanisms Behind the Chemopreventive Effects of Anthocyanidins*, Hou, Fujii, Terahara & Yoshimoto, **Biomed. Biotechnol.** 2004; 2004 (5): 321-325.

*Signal Transduction Pathways: Targets for Chemoprevention of Skin Cancer*, Bode, **Lancet Oncol.** 2000; 1: 181-188.

*The Cytotoxic Effects of a Novel Grape Seed Proanthocyanidin Extract on Cultured Human Cancer Cells*, Joshi, Ye, Liu, et al., **Sci. Proc. 89<sup>th</sup> Ann. Meet. Amer. Assoc. Cancer Res.** 1998, Vol. 39.

*Grape Seed Extract Inhibits Advanced Human Prostate Tumour Growth and Angiogenesis and Upregulates Insulin-Like Growth Factor Binding Protein-3*, Singh, Tyagi, Dhanalakshmi, Agarwal, & Agarwal, C. **Int. J. Cancer** 2004; 108: 733-740.

*Anti-Thrombotic Effect of Proanthocyanidin, a Purified Ingredient of Grape Seed*, Sano, Oda, Yamashita, et al., **Thromb. Res.** 2005; 115: 115-121.

*Induction of Apoptosis in Human Leukemia Cells by Grape Seed Extract Occurs Via Activation of c-Jun NH2-Terminal Kinase*, Gao, Budhraja, Cheng , et al., **Clin. Cancer Res.** 2009; 15 (1): 140-149.

*Effect of Concord Grape Juice on Chemotherapy-Induced Nausea and Vomiting: Results of a Pilot Study*, Ingersoll, Wasilewski, Haller, et al., **Oncol. Nurs. Forum** 2010; 37 (2): 213-221.

*Synergic Effect of Grape Seed Extract with Amphotericin B against Disseminated Candidiasis Due to Candida albicans*, Han, **Phytomedicine**, 2007; 14:733–738. <http://dx.doi.org/10.1016/j.phymed.2007.08.004>

*Antibacterial and Antioxidant Activities of Grape (*Vitis vinifera*) Seed Extracts*, Jayaprakasha, Selvi, & Sakariah, **Food Res. Intern.** 2003; 36:117–122.

*Relation Between Intake of Flavonoids and Risk for Coronary Heart Disease in Male Health Professionals*, Rimm, Katan, Ascherio, et al., **Ann.Intern. Med.** 1996; 125: 384–389.

*Antiulcer Activity of Grape Seed Extract and Procyanidins*, Saito, Hosoyama, Ariga, et al., **J. Agri. Food Chem.** 1998; 46: 1460–1464.

*Grapeseed Proanthocyanidin Extract Induced Mitochondria-Associated Apoptosis in Human Acute Myeloid Leukemia 14.3D10 Cells*, Hu & Qin, **Chin. Med. J. (Engl.)** 2006; 119 (5): 417-421.

*Generation of Reactive Oxygen Species by Grapeseed Extract Causes Irreparable DNA Damage Leading to G2/M Arrest and Apoptosis Selectively in Head and Neck Squamous Cell Carcinoma Cells*, Shrotriya, Deep, Gu, et al., **Carcinogenesis** 2012 doi: 10.1093/carcin/bgs019

*Pycnogenol as an Adjunct in the Management of Childhood Asthma*, Lau, Riesen, Truong, et al., **J. Asthma** 2004; 41 (8): 825-832.

*Pharmacokinetic and Safety Profile of Trans-Resveratrol in a Rising Multiple-Dose Study in Healthy Volunteers*, Almeida, Vaz-da-Silva, Falcão, et al., **Mol Nutr Food Res.** 2009; 53 Suppl 1: S7-15.

*Role of Resveratrol in Prevention and Therapy of Cancer: Preclinical and Clinical Studies*, Aggarwal, Bhardwaj, Aggarwal, et al., **Anticancer Res.** 2004; 24 (5A): 2783-2840.

*Resveratrol-induced Apoptosis in Human Breast Cancer Cells is Mediated Primarily Through the Caspase-3-dependent Pathway*, Alkhafaf, El-Mowafy, Renno , et al., **Arch. Med. Res.** 2008; 39 (2): 162-168.

*Resveratrol Inhibits Proliferation, Induces Apoptosis, and Overcomes Chemo-Resistance Through Down-Regulation of STAT3 and Nuclear factor-kappaB-regulated Anti-apoptotic and Cell Survival Gene Products in Human Multiple Myeloma Cells*, Bhardwaj, Sethi, Vadhan-Raj, et al., **Blood** 2007; 109 (6): 2293-2302.

*Resveratrol Induces the Suppression of Tumour-Derived CD4+CD25+ Regulatory T Cells*, Yang, Paik, Cho, et al., **Int. Immunopharmacol.** 2008; 8 (4): 542-547.

*Resveratrol Induces Apoptosis and Differentiation in Acute Pro-Myelocytic Leukemia (NB4) Cells*, Cao, Wang, Liu, et al., **J. Asian Nat. Prod. Res.** 2005; 7 (4): 633-641.

*Resveratrol: A Candidate Nutritional Substance for Prostate Cancer Prevention*, Stewart, Artime & O'Brian, **J. Nutr.** 2003; 133 (7 Suppl): 2440S-2443S.

*Resveratrol Inhibits Aggregation of Platelets from High-Risk Cardiac Patients with Aspirin Resistance*, Stef, Csiszar, Lereia, et al., **J. Cardiovasc. Pharmacol.** 2006; 48 (2): 1-5.

*Anti-Angiogenic Activity of Resveratrol, a Natural Compound from Medicinal Plants*, Cao, Fu, Wang, et al., **J. Asian Nat. Prod. Res.** 2005; 7 (3): 205-224.

*Resveratrol Acts as an Estrogen Receptor (ER) Agonist in Breast Cancer Cells Stably Transfected with ER alpha*, Levenson, Gehm, Pearce, et al., **Int. J. Cancer** 2003; 104: 587-597.

*The Cancer Preventative Agent Resveratrol is Converted to the Anti-cancer Agent Piceattanol by the Cytochrome P450 Enzyme CYP1B1*, Potter, Patterson, Wanogho, et al., **Br. J. Cancer** 2002; 86: 774-778.

*Involvement of p21WAF1/Cip1, pRB, Bax and NF-kappaB in Induction of Growth Arrest and Apoptosis by Resveratrol in Human Lung Carcinoma A549 cells*, Kim, Lee, Choi, et al., **Int. J. Oncol.** 2003; 23 (4): 1143-1149.

*Cancer Chemopreventive Activity of Resveratrol*, Bhat & Pezzuto, **Ann. N. Y. Acad. Sci.** 2002; 957: 210–229.

*Resveratrol and N-Acetyl-Cysteine Block the Cancer-Initiating Step in MCF-10F Cells*, Zahid, Saeed, Beseler, et al., **Free Radic. Biol.** 2010; Epub Oct 7. Pubmed/20934508

*N-Acetyl-Cysteine, Reactive Oxygen Species and Beyond*, Sun, **Cancer Biol. Ther.** 2010; 9 (2): 109–110.

*Mechanisms of Resveratrol-Induced Platelet Apoptosis*, Lin, Hsiao, Shih, et al., **Cardiovasc. Res.** 2009; 83 (3): 575–585.

*Multiple Molecular Targets of Resveratrol: Anti-Carcinogenic Mechanisms*, Athar, Back, Kopelovich, et al., **Arch. Biochem. Biophys.** 2009; 486 (2): 95–102.

#### GREEN TEA EGCG

*Green Tea Catechin Controls Apoptosis in Colon Cancer Cells by Attenuation of H<sub>2</sub>O<sub>2</sub>-Stimulated COX-2 Expression via the AMPK Signaling Pathway at Low-Dose H<sub>2</sub>O<sub>2</sub>*, Park, Lee, Hwang, et al., **Ann. N.Y. Acad. Sci.** 2009; 1171: 538-544. [re: NAC blocks EGCG effects]

*Green Tea Monograph*, McKenna, Hughes & Jones, **Alt. Ther.** May 2000; Vol. 6, No. 3: 61-84.

*Green Tea Extract and (-)-Epigallocatechin-3-Gallate, the Major Tea Catechin, Exert Oxidant but Lack Antioxidant Activities*, Elbling, Weiss, Teufelhofer, et al., **FASEB J.** 2005; 19 (7): 807-809.

*Prospective Cohort Study of Green Tea Consumption and Colorectal Cancer Risk in Women*, Yang, Shu, Li. Et al., **Cancer Epidemiol. Biomarkers Prev.** 2007; 16 (6): 1219-1223.

*Green Tea (*Camellia sinensis*) Extract Does Not Alter Cytochrome P450 3A4 or 2D6 Activity in Healthy Volunteers*, Donovan, Chavin & Devane **Drug. Metab. Dispos.** 2004; 32: 906-908.

*Efficacies of Tea Components on Doxorubicin-Induced Anti-Tumour Activity and Reversal of Multi-Drug Resistance*, Sadzuka, Sugiyama & Sonobe, **Toxicol. Letters** 2000; 114: 155-162.

*Green Tea Inhibits VEGF Induction in Human Breast Cancer Cells*, Sartippour, Shao, Heber, et al, **J. Nutr.** 2002; 132: 2307-2311.

*The Effects of Green Tea Consumption on Incidence of Breast Cancer and Recurrence of Breast Cancer: A Systematic Review and Meta-analysis*, Seely, Mills, Wu P, et al., **Integr. Cancer Ther.** 2005; 4 (2): 144-155.

*Green Tea Catechins Inhibit VEGF-induced Angiogenesis in vitro Through Suppression of VE-Cadherin Phosphorylation & Inactivation of Akt Molecule*, Tang, Nguyen & Meydani, **Int. J. Cancer** 2003; 106: 871-878.

*Epigallocatechin-3-Gallate Inhibits Epidermal Growth Factor Receptor Signalling Pathway. Evidence for Direct Inhibition of ERK1/2 and AKT Kinases*, Sah, Balasubramanian, Eckert & Rorke, **J. Biol. Chem.** 2004; 279 (13): 12755 – 12762.

*Green Tea Appears to Protect Against Breast Cancer*, Wu, **Int. J. Cancer** 2003; 106: 574-579.

*Green Tea Component Destroys Leukemia Cells*, Kay, **Blood** Mar.2, 2004 On-line edition.

*Green Tea Catechins Containing a Galloyl Group in the 3' Position Inhibit Tissue Factor-Induced Thrombin Generation*, Stampfuss, Schror & Weber, **Thromb. Haemost.** 2005; 93 (6): 1200-1201.

*Green Tea Epigallocatechin-3-Gallate Inhibits Platelet Signalling Pathways Triggered by Both Proteolytic and Non-proteolytic Agonists*, Deana, Turetta, Donella-Deana, et al., **Thromb Haemost.** 2003; 89 (5): 866-874.

*Tea Polyphenols, Their Biological Effects and Potential Molecular Targets*, Chen, Milacic, Chen, et al., **Histol. Histopathol.** 2008; 23 (4): 487-496.

*Antioxidant Activity of Tea Polyphenols in vivo: Evidence From Animal Studies*, Frei & Higdon, **J. Nutr.** 2003; 133 (10): 3275S-3284S.

*Clinical Effects of Oral Green Tea Extracts in Four Patients with Low Grade B-Cell Malignancies*, Shanafelt, Lee, Call, et al., **Leuk. Res.** 2006; 30: 707-712.

*Green Tea Polyphenols and Cancer Chemoprevention: Multiple Mechanisms and Endpoints for Phase II Trials*, Moyers & Kumar, **Nutr. Rev.** 2004; Vol. 62 No. 5: 204-211.

*Pigments in Green Tea Leaves (*Camellia sinensis*) Suppress Transformation of the Aryl Hydrocarbon Receptor Induced by Dioxin*, Fukada, Sakane, Yabushita, et al., **J. Agric. Food Chem.** 2004; 52 (9): 2499-2506.

*Clinical Effects of Oral Green Tea Extracts in Four Patients with Low Grade B-Cell Malignancies*, Shanafelt, Lee, Call, et al., **Leuk. Res.** 2006; 30 (6): 707-712.

*Anti-Oxidants from Green Tea and Pomegranate for Chemoprevention of Prostate Cancer*, Adhami and Mukhtar, **Biotechnol.** 2007; 37 (1): 52-57.

*Inhibition of Aromatase Activity by Green Tea Extract Catechins and Their Endocrinological Effects of Oral Administration in Rats*, Satoh, Sakamoto, Ogata, et al., **Food Chem. Toxicol.** 2002; 40 (7): 925-933.

*Structure-Activity Relationships for Inhibition of Human 5-Alpha-Reductases by Polyphenols*, Hiipkka, Zhang, Dai, et al., **Biochem. Pharmacol.** 2002; 63 (6): 1165-1176.

*Selective Inhibition of Steroid 5-Alpha-Reductase Isozymes by Tea Epicatechin-3-gallate and Epigallocatechin-3-gallate*, Liao & Hipakka, **Biochem. Biophys. Res. Commun.** 1995; 214 (3): 833-838.

*The Antifolate Activity of Tea Catechins*, Navarro-peran, Cabezas-Herrera, Garcia-Canovas, et al., **Cancer Res.** 2005; 65 (6): 2059-2064.

*Effects of Aqueous Green Tea Extract on Activities of DNA Turn-Over Enzymes in Cancerous and Non-Cancerous Human Gastric and Colon Tissues*, Ergruder, Namusui, Sozener, et al., **Altern. Ther. Health Med.** 2008; 14 (3): 30-33.

*Interactions Affecting the Bioavailability of Dietary Polyphenols in vivo*, Scholz & Williamson, **Int. J. Vitam. Nutr. Res.** 2007; 77 (3): 224-235.

*Green Tea Extracts for the Prevention of Metachronous Colorectal Adenomas: A Pilot Study*, Shimizu, Fukutomi, et al., **Cancer Epidemiol. Biomarkers Prev.** 2008; 17 (11): 3020-3025.

*Essential Role of Caspases in Epigallocatechin-3-Gallate-Mediated Inhibition of Nuclear Factor kappa B and Induction of Apoptosis*, Gupta, et al., **Oncogene** 2004; 23 (14): 2507-2522.

*Epigallocatechin-3-Gallate is a Potent Natural Inhibitor of Fatty Acid Synthase in Intact Cells and Selectively Induces Apoptosis in Prostate Cancer Cells*, Brusselmans, De Schrijver, Heyns, et al., **Int. J. Cancer** 2003; 106 (6): 856-862.

*Prostate Carcinoma and Green Tea: PSA-Triggered Basement Membrane Degradation and MMP-2 Activation are Inhibited by (-) Epigallocatechin-3-Gallate*, Pezzato, Sartor, Dell'Aica, et al., **Int. J. Cancer** 2004; 112 (5): 787-792.

*EGCG Inhibits Activation of HER3 and Expression of Cyclooxygenase-2 in Human Colon Cancer Cells*, Shimizu, Deguchi , Joe, et al., **J. Exp. Ther. Oncol.** 2005; 5 (1): 69-78.

*Epigallocatechin-3-Gallate Inhibits Activation of HER-2/neu and Downstream Signaling Pathways in Human Head and Neck and Breast Carcinoma Cells*, Masuda, Suzui, Lim & Weinstein, **Clin. Cancer Res.** 2003; 9 (9): 3486-3491.

*Role of p53 and NF-kappaB in Epigallocatechin-3-Gallate-Induced Apoptosis of LNCaP Cells*, Hastak, Gupta, Ahmad, et al., **Oncogene** 2003; 22 (31): 4851-4859.

*Green Tea Constituent (-)-Epigallocatechin-3-Gallate Inhibits Hep G2 Cell Proliferation and Induces Apoptosis Through p53-Dependent and Fas-Mediated Pathways*, Kuo & Lin, **J. Biomed. Sci.** 2003; 10 (2): 219-227.

*Combined Effect of Green Tea and Ganoderma lucidum on Invasive Behaviour of Breast Cancer Cells*, Thyagarajan, Zhu & Sliva, **Int. J. Oncol.** 2007; 30 (4): 963-969.

*The Tea Polyphenol, (-)-Epigallocatechin Gallate Effects on Growth, Apoptosis, and Telomerase Activity in Cervical Cell Lines*, Yokoyama, Noguchi, Nakao, et al., **Gynecol. Oncol.** 2004; 92 (1): 197-204.

*EGCG Down-Regulates Telomerase in Human Breast Carcinoma MCF-7 Cells, Leading to Suppression of Cell Viability and Induction of Apoptosis*, Mittal, Pate, Wylie, et al., **Int. J. Oncol.** 2004; 24 (3): 703-710.

*Matrix Metalloproteinases in Cancer Metastasis: Molecular Targets for Prostate Cancer Prevention by Green Tea Polyphenols and Grape Seed Proanthocyanidins*, Katiyar, **Endocr. Metabol. Immune Disord. Drug Targets**, 2006; 6 (1): 17-24.

*Anti-Cancer Activity of Grape and Grape Skin Extracts Alone and Combined with Green Tea Infusions*, Morré & Morré, **Cancer Lett.** 2006; 238 (2): 202-209.

*Green Tea Polyphenol Causes Differential Oxidative Environments in Tumour Versus Normal Epithelial Cells*, Yamamoto, Hsu, Lewis, et al., **J. Pharmacol. Exp. Ther.** 2003; 307 (1): 230-236.

*EGCG Inhibits Growth, Invasion, Angiogenesis and Metastasis of Pancreatic Cancer*, Shankar, Ganapathy, Hingorani & Srivastava, **Front. Biosci.** 2008; 13: 440-452.

*(-)-Epigallocatechin Gallate Inhibits Membrane-Type 1 Matrix Metalloproteinase, MT1-MMP, and Tumour Angiogenesis*, Yamakawa, Asai, Uchida, et al., **Cancer Lett.** 2004; 210 (1): 47-55.

*Dietary Intakes of Mushrooms and Green Tea Combine to Reduce the Risk of Breast Cancer in Chinese Women*, Zhng, Huang, Xie & Holman, **Int. J. Cancer** 2009; 1246: 1404-1408.

*Phase II Randomized, Placebo-Controlled Trial of Green Tea Extract in Patients with High-Risk Oral Premalignant Lesions*, Tsao, Liu, Martin, et al. **Cancer Prev Res** 2009; 2 (11): 931-941.

*Phase II Trial of Daily, Oral Green Tea Extract in Patients with Asymptomatic, Rai Stage 0-II Chronic Lymphocytic Leukemia (CLL)*, Shanafelt, Call, Zent, et al., **J. Clin. Oncol.** 2010; 28 (Suppl.): S7. Abstract 6522 ASCO 2010.

*Green Tea Catechin Controls Apoptosis in Colon Cancer Cells by Attenuation of H2O2-Stimulated Cox-2 Expression via the AMPK Signaling Pathway at Low-Dose H2O2*, Park, Lee, Hwang, et al., **Ann. N. Y. Acad. Sci.** 2009; 1171: 538-544.

*Antithrombotic Activities of Green Tea Catechins and (-)-Epigallocatechin Gallate*, Kang, Lim, Yuk, et al., **Thromb. Res.** 1999; 96 (3): 229-237.

*Interaction of Green Tea Catechins with Breast Cancer Endocrine Treatment: A Systematic Review*, Yiannakopoulou, **Pharmacology** 2014; 94: 245-248. DOI: 10.1159/000369170

## INDOLE-3-CARBINOL / DIM

*Indole-3-Carbinol – Monograph, Alt. Med. Rev.* 2005; Vol. 10 No. 4: 337-342.

*Molecular Targets and Anticancer Potential of Indole-3-Carbinol and Its Derivatives*, Aggarwal & Ichikawa, **Cell Cycle** 2005; 4 (9): 1201-1215.

*Changes in Levels of Urinary Estrogen Metabolite After Oral Indole-3-Carbinol Treatment in Humans*, Michnovicz, Adlercreutz & Bradlow, **J. Natl. Cancer Inst.** 1997; 89 (10): 718-723.

*Indole-3-Carbinol and Tamoxifen Cooperate to Arrest the Cell Cycle of MCF-7 Human Breast Cancer Cells*, Cover, Hsieh, Cram, et al., **Cancer Res.** 1999; 59 (6):1244-1251.

*Indole-3-Carbinol and Prostate Cancer*, Sarkar, **J. Nutr.** 2004; 134 (12 Suppl): 3493S-3498S.

*Indole-3-Carbinol as a Chemopreventive and Anti-Cancer Agent*, Weng, Tsai, Kulp & Chen, **Cancer Lett.** 2008; 262 (2): 153-163.

*Multiple Molecular Targets of Indole-3-Carbinol, A Chemopreventative Anti-Estrogen in Breast Cancer*, Ashtok, Chen, Garikapati, et. al., **Eur. J. Cancer Prev.** 2002; Suppl. 2: 86-93.

*Placebo-Controlled Trial of Indole-3-Carbinol in the Treatment of CIN*, Bell, Crowley-Nowick, Bradlow, et al., **Gynecol. Oncol.**, 2000 Aug.; 78(2): 123-129.

*BRCA1 and BRCA2 as Molecular Targets for Phytochemicals Indole-3-Carbinol and Genistein in Breast and Prostate Cancer Cells*. Fan, Meng, Auborn, et al., **Br. J. Cancer** 2006 Feb 13; 94(3): 407-426.

*Indole-3-Carbinol and 3'-3'-Diindolylmethane Antiproliferative Signaling Pathways Control Cell-Cycle Gene Transcription in Human Breast Cancer Cells by Regulating Promoter-Sp1 Transcription Factor Interactions*, Firestone & Bjeldanes, **J. Nutr.** 2003; 133: 2448S-2455S.

*Indole-3-Carbinol and Prostate Cancer*, Sarkhar & Li, **J. Nutr.** 2004; 134 (12Suppl.): 3493S-3498S.

*Indole-3-Carbinol (I3C) Induces Apoptosis in Tumourigenic But Not in Nontumourigenic Breast Epithelial Cells*, Rahman, Aranha & Sarkar, **Nutr. Cancer** 2003; 45 (1): 101-112.

*Indole-3-Carbinol Activates the ATM Signaling Pathway Independent of DNA Damage to Stabilize p53 and Induce G1 Arrest of Human Mammary Epithelial Cells*. Brew, Aronchik, Sheen, et al., **Int. J. Cancer** 2006 Feb 15; 118(4): 857-868.

*Gene Expression Profiling Revealed Survivin as a Target of 3,3'-Diindolylmethane-Induced Cell Growth Inhibition and Apoptosis in Breast Cancer Cells*. Rahman, Li, Wang, et al., **Cancer Res.** 2006 May 1; 66(9): 4952-4960.

*Indole-3-Carbinol (I3C) Inhibits Cyclin-dependent Kinase-2 Function in Human Breast Cancer Cells by Regulating the Size Distribution, Associated Cyclin E Forms, and Subcellular Localization of the CDK2 Protein Complex*. Garcia, Brar, Nguyen, et al., **J. Biol. Chem.** 2005 Mar. 11; Vol. 280, No. 10: 8756-8764.

*Synthetic Dimer of Indole-3-Carbinol: Second Generation Diet Derived Anti-Cancer Agent in Hormone Sensitive Prostate Cancer*. Garikapaty, Ashok, Tadi, et al., **Prostate** 2006 Apr 1; 66(5): 453-462.

*Indole-3-Carbinol (I3C) Induces Apoptosis in Tumourigenic But Not in Non-Tumourigenic Breast Epithelial Cells*, Rahman, Aranha, & Sarkar, **Nutr. Cancer** 2003; 45 (1): 101-112.

*Translocation of Bax to Mitochondria Induces Apoptotic Cell Death in Indole-3-Carbinol (I3C) Treated Breast Cancer Cells*, Rahman, Aranha, Glazyrin, et al, **Oncogene** 2000; 19 (50): 5764-5771.

*Indole-3-Carbinol Enhances Ultraviolet-B-induced Apoptosis by Sensitizing Human Melanoma Cells*, Kim, Jeong, Moon, et al., **Cell. Mol. Life Sci.** 2006; 63 (22): 2661-2668.

*3,3'-Diindolylmethane is a Novel Mitochondrial H(+)-ATP Synthase Inhibitor That Can Induce p21(Cip1/Waf1) Expression by Induction of Oxidative Stress in Human Breast Cancer Cells*, Gong, Sohn, Xue, et al., **Cancer Res.** 2006; 66 (9): 4880-4887.

*Apoptosis-Inducing Effect of Erlotinib is Potentiated by 3,3'-Diindolylmethane in vitro and in vivo Using an Orthoptic Model of Pancreatic Cancer*, Ali, Banerjee, Ahmad, et al., **Mol. Cancer Ther.** 2008; 7 (6): 1708-1719.

*Indole-3-Carbinol Inhibition of Androgen Receptor Expression and Down-regulation of Androgen Responsiveness in Human Prostate Cancer Cells*, Hsu, Zhang, Dev, et al., **Carcinogenesis** 2005;

*Indole-3-Carbinol (I3C) Induced Cell Growth Inhibition, G1 Cell Cycle Arrest and Apoptosis in Prostate Cancer Cells*, Chinni, Li, Upadhyay, et al., **Oncogene** 2001;

*Akt Inactivation is a Key Event in Indole-3-Carbinol-Induced Apoptosis in PC-3 Cells*, Chinni & Sarkhar, **Clin. Cancer Res.** 2002; 8 (4): 1228-1236.

*Anti-Carcinogenic and Anti-Metastatic Properties of Indole-3-Carbinol in Prostate Cancer*, Garikpaty, et al., **Oncol. Rep.** 2005; 13 (1): 89-93.

*Indole-3-Carbinol Induces a G1 Cell Cycle Arrest and Inhibits Prostate-Specific Antigen Production in Human LNCaP Prostate Carcinoma Cells*, Zhang, Hsu, Kinseth, et al., **Cancer** 2003; 98 (11): 2511-2520.

*Selective Growth Regulatory and Pro-apoptotic Effects of DIM is Mediated by AKT and NF-kappaB Pathways in Prostate Cancer Cells*, Li, Chinni & Sarkhar, **Front. Biosci.** 2005; 10: 236-243.

*Indole-3-Carbinol Prevents PTEN Loss in Cervical Cancer in vivo*, Qi, Anderson, Chen, et al., **Mol. Med.** 2005; 11 (1-12): 59-63.

*BRCA1 and BRCA2 as Molecular Targets for Phytochemicals Indole-3-Carbinol and Genistein in Breast and Prostate Cancer Cells*, Fan, Meng, Auburn, et al., **Br. J. Cancer** 2006; 94 (3): 407-426.

*Molecular Targets and Anticancer Potential of Indole-3-Carbinol and its Derivatives*, Aggarwal & Ichikawa, **Cell Cycle** 2005; 4 (9): 1201-1215.

*Modulation of the Constitutive Activated STAT3 Transcription Factor in Pancreatic Cancer Prevention: Effects of Indole-3-Carbinol (I3C) and Genistein*, Lian, Word, Taylor, et al., **Anticancer Res.** 2004; 24 (1): 133-137.

*Sulforaphane Absorption and Excretion Following Ingestion of a Semi-Purified Broccoli Powder Rich in Glucoraphanin and Broccoli Sprouts in Healthy Men*, Cramer, & Jeffery, **Nutr. Cancer** 2011; 63 (2): 196 - 201.

*Induction of Growth Arrest and Apoptosis in Human Breast Cancer Cells by 3,3-Diindolylmethane is Associated with Induction and Nuclear Localization of p27kip*, Wang, Yu, Rahman, et al., **Mol. Cancer Ther.** 2008; 7: 341-349.

*Differential Effects of Sulforaphane on Histone Deacetylases, Cell Cycle Arrest and Apoptosis in Normal Prostate Cells versus Hyperplastic and Cancerous Prostate Cells*, Clarke, Hsu, Yu, et al., **Mol. Nutr. Food Res.** 2010; Published online ahead of print, doi: 10.1002/mnfr.201000547

*Translocation of Bax To Mitochondria Induces Apoptotic Cell Death In Indole-3-Carbinol (I3C) Treated Breast Cancer Cells*, Rahman, Aranha, Glazyrin, et al., **Oncogene** 2000; 19 (50): 5764-5771.

## L-GLUTAMINE

*Enteral Glutamine: The “Trojan Horse” of Naturopathic Oncology* Mark Gignac, ND, FABNO  
ONCANP Feb 26, 2016.

*Hypoxia-Resistant Profile Implies Vulnerability of Cancer Stem Cells to Physiological Agents, Which Suggests New Therapeutics*, Cipolleschi, Marzi, Santini, et al., **Cell Cycle** 2014; 13 (2): 268-278.

*Clinical Use of Glutamine Supplementation*, Wernerman, **J. Nutr.** 2008; 138 (10): 2040S-2044S.

*The Effect of Glutamine Supplementation on Hematopoietic Stem Cell Transplant Outcome in Children: A Case-Control Study*, Kuskonmaz, Yalcin, Kucukbayrak, et al., **Pediatr. Transplant.** 2008; 12 (1): 47-51.

*Glutamine Supplementation in Cancer Patients Receiving Bone Marrow Transplantation and High-Dose Chemotherapy*, Ziegler, **J. Nutr.** 2001; 131 (9 Supplement): 2578S-2584S; discussion 2590S.

*Nutrition Support for Bone Marrow Transplant Patients*, Murray & Pindoria, **Cochrane Database Syst. Rev.** 2008; (4): CD002920.

*Effects of Oral Glutamine Supplementation on Children with Solid Tumours Receiving Chemotherapy*, Okur, Ezgu, Tumer, et al., **Pediatr. Hematol. Oncol.** 2006; 23 (4): 277-285.

*Exogenous Glutamine: The Clinical Evidence*, Bongers, Griffiths & McArdle, **Crit. Care Med.** 2007; 35 (9 Supplement): 545S-552S.

*Bolus Oral Glutamine Protects Rats Against CPT-11-Induced Diarrhea and Differentially Activates Cytoprotective Mechanisms in Host Intestine But Not Tumour*, Xue, Sawyer, Field, et al., **J. Nutr.** 2008; 138 (4): 740-746.

*Prevention of Chemotherapy and Radiation Toxicity with Glutamine*, Savarese, Savy, Vahdat, et al., **Cancer Treat. Rev.** 2003; 29 (6): 501-513.

*Oral Glutamine for the Prevention of Chemotherapy-Induced Peripheral Neuropathy*, Amara, **Ann. Pharmacother.** 2008; 42 (10): 1481-1485.

*Oral Glutamine Ameliorates Chemotherapy-Induced Changes of Intestinal Permeability and Does Not Interfere with the Antitumour Effect of Chemotherapy in Patients with Breast Cancer: A Prospective Randomized Trial*, Li, Yu, Liu, et al., **Tumouri**, 2006; 92 (5): 396-401.

*Metabolic Shifts Toward Glutamine Regulate Tumour Growth, Invasion and Bioenergetics in Ovarian Cancer*, Yang, Moss, Mangala, et al., **Molec. Syst. Biol.** 2014; 10 (728): 1-123.

*L-Glutamine Decreases The Severity Of Mucositis Induced By Chemoradiotherapy In Patients With Locally Advanced Head And Neck Cancer: A Double-Blind, Randomized, Placebo-Controlled Trial*, Tsujimoto, Yamamoto, Wasa, et al., **Oncology Reports** 2015; 33: 33-39.

## LOW-DOSE NALTREXONE

*Enhancement of Natural Cytotoxicity by Beta-Endorphin*, Matthew, Froelich, Sibbitt, et al., **J. Immunol.** 1983; 130:1658-1662.

*Naltrexone Prolongs the Survival Time of Mice Treated with Neuroblastoma*, Zagon & McLaughlin, **Life Sci.** 1981; 28: 1095-1102.

*Naltrexone Modulates Tumour Response in Mice with Neuroblastoma*, Zagon & McLaughlin, **Science** 1983; 221: 671-673.

*Inhibition of Human Colon Cancer by Intermittent Opioid Receptor Blockade with Naltrexone*, Hytrek, McLaughlin, Lang & Zagon, **Cancer Letters** 1996; 101 (2): 159-164.

*Opioid Growth Factor ([Met5]Enkephalin) Prevents the Incidence and Retards the Growth of Human Colon Cancer*, Zagon, Hytrek, Lang, et al., **Amer. J. Physiol.** 1996; 271 (3 Pt 2): R780-R786.

*Opioid Antagonists Inhibit the Growth of Metastatic Murine Neuroblastoma*, Zagon & McLaughlin, **Cancer Letters** 1983; 21: 89-94.

*Duration of Opiate Receptor Blockade Determines Tumourigenic Response in Mice with Neuroblastoma: A Role for Endogenous Opioid Systems in Cancer*, Zagon & McLaughlin, **Life Sci.** 1984; 35: 409-416.

*Opioid Antagonist Modulation of Murine Neuroblastoma: A Profile of Cell Proliferation and Opioid Peptides and Receptors*, Zagon & McLaughlin, **Brain Res.** 1989; 480: 16-28.

*Opioid Growth Factor (OGF) [Metenkephalin] Inhibits Human Pancreatic Cancer Transplanted into Nude Mice*, Zagon, Hytrek, Smith & McLaughlin, **Cancer Letters** 1997; 112 (2): 167-175.

*Neuro-immunotherapy of Untreatable Metastatic Solid Tumours with Subcutaneous Low-dose Interleukin-2, Melatonin and Naltrexone: Modulation of Interleukin-2-induced Anti-tumour Immunity by Blocking the Opioid System*, Lissoni, Malugani, Malysheva, et al., **Neuroendocrinol. Lett.** 2002; 23 (4): 341-344.

*A New Neuro-immuno-therapeutic Strategy of Subcutaneous Low-Dose Interleukin-2 Plus the Long-acting Opioid Antagonist Naltrexone in Metastatic Cancer Patients Progressing on Interleukin-2 Alone*, Lissoni, Malugani, Bordin, et al., **Neuroendocrinol. Lett.** 2002; 23 (3): 255-258.

*Opioid Growth Factor Regulates the Cell Cycle of Human Neoplasias*, Zagon, Roesener, Verderame, et al., **Int. J. Oncol.** 2000; 17 (5): 1053-1061.

*Reversal of Signs and Symptoms of a B-Cell Lymphoma in a Patient Using Only Low-dose Naltrexone*, **Integr. Cancer Ther.** 2007; 6 (3): 293-296.

*The Long-term Survival of a Patient with Pancreatic Cancer with Metastases to the Liver After Treatment with the Intravenous Alpha-Lipoic Acid/Low-Dose Naltrexone Protocol*, Berkson, Rubin & Berkson, **Integr. Cancer Ther.** 2006; 5 (1): 83-89.

*Revisiting the ALA/N (Alpha Lipoic Acid/Low Dose Naltrexone) Protocol for People with Metastatic and Non-Metastatic Pancreatic Cancer; A Report of 3 New Cases*, Berkson, Rubin & Berkson, **Integr. Cancer Ther.** 2009; (4): 416-422.

*Neuroimmunotherapy of Untreatable Metastatic Solid Tumours with Subcutaneous Low-Dose Interleukin-2, Melatonin and Naltrexone: Modulation of Interleukin-2-Induced Antitumour Immunity by Blocking the Opioid System*, Lissoni, Malugani, Malysheva et al., **Neuro. Endocrinol. Lett.** 2002; (4): 341-344.

*Effect of Peri-Operative Opioids on Cancer Recurrence: A Hypothesis*; Singleton & Moss, **Future Oncol.** 2010; 6 (8): 1237-1242.

*Increased Post-Operative Opiod Consumptio is Associated with Greater Incidence of Non-Small Cell Lung Cancer Recurrence – A Retrospective Study*, Maher, et al., **American. Pain Society** 2014; Poster # 442: 33<sup>rd</sup> Annual Scientific Meeting. Presented May2, 2014.

*Attenuation of the Tumour-Promoting Effect of Surgery by Spinal Blockade in Rats*, Ben-Eliyahu, Bar-Yosef, et al., **Anesthesiology** 2001; 94: 1066-1073.

*The Effect of Paravertebral Block During Surgery on the Recurrence of Breast Cancer*, Oppfeldt & Carlsson, **Amer. Soc. Anaesthesiol.** 2013; Annual Mtg. Abstract # 4253, presented Oct. 15, 2013.

*Combined Spinal and General Anesthesia Attenuates Liver Metastasis by Preserving TH1/TH2 Cytokine Balance*, Wada, Seki, Takahashi, et al., **Anesthesiology** 2007; 106: 499–506.

*Morphine Stimulates Angiogenesis by Activating Proangiogenic and Survival-promoting Signaling and Promotes Breast Tumour Growth*, Gupta, Kshirsagar, Chang, et al., **Cancer Res.** 2002; 62: 4491–4498.

*Morphine Stimulates VEGF-like Signaling in Mouse Retinal Endothelial Cells*, Chen, Farooqui & Gupta, **Curr. Neurovasc. Res.** 2006; 3: 171–180.

*Naloxone Acts as an Antagonist of Estrogen Receptor in MCF7 Cancer Cells*, Farooqui, Stephenson, Geng Zhen, et al., **Mol. Cancer Therap.** 2006; 5: 611–620.

*Methylnaltrexone Inhibits Opiate and VEGF-induced Angiogenesis: Role of Receptor Transactivation*, Singleton, Lingen, Fekete, et al., **Microvasc. Res.** 2006; 72: 3–11.

*Methylnaltrexone Inhibits EGF- and IGF-Induced Human Bronchioalveolar Carcinoma Proliferation and Migration*, Lennon, Mambetsariev, Garcia, et al., **Mol. Cancer Ther.** 2009; 8: C78–C78.

*The ( $\mu$ )  $\mu$ -Opioid Receptor Regulates Lewis Lung Carcinoma Tumour Growth and Metastasis*, Mathew, Lennon, Siegler, et al., **Mol. Cancer Ther.** 2009; 8: C79–79C.

*Opium Use and Mortality in Golestan Cohort Study: Prospective Cohort Study of 50,000 Adults in Iran*, Khademi, Malekzadeh, Pourshams, et al., **BMJ.** 2012 Apr 17;344:e2502. doi: 10.1136/bmj.e2502.

*Long-Term Remission of Adenoid Cystic Tongue Carcinoma with Low Dose Naltrexone and Vitamin D3 – A Case Report*, Khan, **Oral Health Dental Manag.** 2014; 13 (3): 721-724.

*Naltrexone At Low Doses Upregulates A Unique Gene Expression Not Seen With Normal Doses: Implications For Its Use In Cancer Therapy*, Liu, Scott, Dennis, et al., **Int. J. Oncol.** 2016; 49 (2): 793-802.

## MELATONIN

*The Therapeutic Application of Melatonin in Supportive Care and Palliative Medicine*, Mahmoud, Sarhill & Mazurczak, **Am. J. Hosp. Palliat. Care** 2005; 22: 295-309.

*Aromatase Inhibitor-Induced Joint Pain: Melatonin's Role*, Burk, **Med. Hypoth.** 2008; doi: 10.1016/j.mehy.2008.07.040.

*Melatonin – Monograph*, **Alt. Med. Rev.** 2005; Vol. 10, No. 4: 326-336.

*Melatonin Provokes Cell Death in Human B-Lymphoma Cells by Mitochondria-Dependent Apoptotic Pathway Activation*, Trubiani, Recchioni, Moroni, et al., **J. Pineal Res.** 2005; 39 (4): 425-431.

*Melatonin Induces Apoptosis in Human Neuroblastoma Cancer Cells*, Garcia-Santos, Antolin, Herrara, et al., **J. Pineal Res.** 2006; 41 (2): 130-135.

*Increased Survival Time in Brain Glioblastoma by a Radio-Neuro-Endocrine Strategy with Radiotherapy Plus Melatonin Compared to Radiotherapy Alone*, Lissoni, Meregalli, Nosetto, et al., **Oncology** 1996; 53: 43-46.

*Five-Years Survival in Metastatic Non-Small Cell Lung Cancer Patients Treated with Chemotherapy Alone or Chemotherapy with Melatonin: A Randomized Trial*, Lissoni, et al., **J. Pineal Res.** 2003; 35 (1): 12-15.

*Circadian Function in Patients with Advanced Non-Small-Cell Lung Cancer*, Levin, Daehler, Grutsch, et al., **Br. J. Cancer** 2005; 93 (11): 1202-1208.

*Light at Night Co-distributes with Incident Breast But Not Lung Cancer in the Female Population of Israel*, Kloog, Haim, Stevens, et al., **Chronobiol. Int.** 2008; 25 (1): 65-81.

*Global Co-distribution of Light at Night (LAN) and Cancers of Prostate, Colon, and Lung in Men*, Kloog, Haim, Stevens & Portnov, **Chronobiol. Int.** 2009; 26 (1): 108-125.

*Randomized Study with the Pineal Hormone Melatonin versus Supportive Care Alone in Advanced Non-Small-Cell Lung Cancer Resistant to a First-Line Chemotherapy Containing Cisplatin*, Lissoni, Barni, Ardizzoia, et al., **Oncology** 1992; 49 (5): 336-339.

*Neuro-Immunotherapy of Untreatable Metastatic Solid Tumours with Subcutaneous Low-Dose Interleukin-2, Melatonin and Naltrexone: Modulation of Interleukin-2-Induced Anti-Tumour Immunity by Blocking the Opioid System*, Lissoni, Malugani, Malysheva, et al., **Neuro. Endocrinol. Lett.** 2002; 23 (4): 341-344.

*Melatonin in Human Breast Cancer Tissue: Association with Nuclear Grade and Estrogen Receptor Status*, Maestroni & Conti, **Lab. Inv.** 1996; 75 (4): 557-561.

*Immune and Endocrine Mechanisms of Advanced Cancer-Related Hypercortisolemia*, Lissoni, Brivio, Fumagalli, et al., **In Vivo** 2007; 21 (4): 647-650.

*Melatonin Increase as Predictor for Tumour Objective Response to Chemotherapy in Advanced Cancer Patients*, Lissoni, Tancini, Barni, et al., **Tumouri** 1998; 74 (3): 339-345.

*Chronotherapy for Cancer*, Eriguchi, Levi, Hisa, et al., **Biomed. Pharmacother.** 2003; 57 Suppl 1: 92s-95s.

*Making Circadian Cancer Therapy Practical*, Block, Block, Fox, et al., **Integr. Cancer Ther.** 2009; 8(4): 371-386.

*Melatonin in Clinical Oncology*, Bartsch, Bartsch & Karasek, **Neuro. Endocrinol. Lett.** 2002; 23 Suppl 1: 30-

*Melatonin: Fifty Years of Scientific Journey from the Discovery in Bovine Pineal Gland to Delineation of Functions in Human*, Chowdhury, Sengupta & Maitra, **Indian J Biochem Biophys.** 2008; 45 (5): 289-304.

*Biomodulation of Cancer Chemotherapy for Metastatic Colorectal Cancer: A Randomized Study of Weekly Low-Dose Irinotecan Alone versus Irinotecan Plus the Oncostatic Pineal Hormone Melatonin in Metastatic Colorectal Cancer Patients Progressing on 5-Fluorouracil-Containing Combinations*, Cerea, Vagh, Ardizzoia, et al., **Anticancer Res.** 2003; 23 (2C): 1951-1954.

*The Immune-Pineal Axis: Stress as a Modulator of Pineal Gland Function*, Couto-Moraes, Palermo-Neto & Markus, **Ann N Y Acad Sci.** 2009; 1153: 193-202.

*A Review of the Evidence Supporting Melatonin's Role as an Antioxidant*, Reiter, Melchiorri, Sewerynek, et al., **J Pineal Res.** 1995; 18 (1): 1-11.

*Health Disorders of Shift Workers*, Knutsson, **Occup Med (Lond)**. 2003; 53 (2): 103-108.

*Night-Shift Work and Risk of Colorectal Cancer in the Nurses' Health Study*, Schernhammer, Laden, Speizer, et al., **J. Natl. Cancer Inst.** 2003; 95 (11): 825-828.

*Molecular Mechanisms of Melatonin Anticancer Effects*, Hill, Frasch, Xiang, et al., **Integr. Cancer Ther.** 2009; 8 (4): 337-346.

*Circadian Stage-Dependent Inhibition of Human Breast Cancer Metabolism and Growth by the Nocturnal Melatonin Signal: Consequences of its Disruption by Light at Night in Rats and Women*, Blask, Dauchy, Brainard & Hanifin, **Integr. Cancer Ther.** 2009; 8 (4): 347-353.

*An Overview of Melatonin and Breast Cancer*, Kaczor, **Nat. Med. J.** 2010; 2 (2): 1-4.

*Melatonin in the Treatment of Cancer: A Systematic Review of Randomized Controlled Trials and Meta-Analysis*, Mills, Wu, Seely & Guyatt, **J. Pineal Res.** 2005; 39 (4): 360-366.

*Clinical Results with the Pineal Hormone Melatonin in Advanced Cancer Resistant to Standard Antitumour Therapies*, Lissoni, Barni, Meregalli, et al., **Oncology** 1991; 48: 448-450.

*A Randomized Study of the Pineal Hormone Melatonin Versus Supportive Care Alone in Patients with Brain Metastases Due to Solid Neoplasms*, Lissoni, Barni, Ardizzoia, et al., **Cancer** 1994; 73: 69-701.

*Aromatase Inhibitor-Induced Joint Pain: Melatonin's Role*, Burk **Med. Hypoth.** 2008; Sept. [Epub ahead of print]

*Extended Exposure to Dietary Melatonin Reduces Tumour Number and Size in Aged Male Mice*, Sharman, Sharman & Bondy, **Exp. Gerontol.** 2010 Sep 14. [Epub ahead of print] PMID: 20837128

*Diurnal Cortisol Rhythm as a Predictor of Breast Cancer Survival*, Sephton, Sapolsky, Kraemer & Spiegel, **J. Natl. Cancer Inst.** 2000; 92 (12): 994-1000.

*Melatonin Modulates Aromatase Activity in MCF-7 Human Breast Cancer Cells*, Cos, Martínez-Campa, Mediavilla & Sánchez-Barceló, **J. Pineal Res.** 2005; 38 (2): 136-142.

*Modulation of Cancer Endocrine Therapy by Melatonin: A Phase II Study of Tamoxifen Plus Melatonin in Metastatic Breast Cancer Patients Progressing Under Tamoxifen Alone*, Lissoni, Barni, Meregalli, et al., **Br. J. Cancer** 1995; 71 (4): 854-856.

*Pro-Oxidant Effect of Melatonin in Tumour Leukocytes: Relation with its Cytotoxic and Pro-Apoptotic Effects*, Bejarano, Espino, Barriga, et al., **Basic Clin. Pharmacol. Toxicol.** 2011; 108 (1): 14-20.

*Melatonin Cytotoxicity in Human Leukemia Cells: Relation with its Pro-Oxidant Effect*, Buyukavci, Ozdemir, Buck, et al., **Fundam. Clin. Pharmacol.** 2006; 20 (1): 73-79.

*Melatonin: From Basic Research to Cancer Treatment Clinics*, Vijayalaxmi, Reiter & Herman, **J. Clin. Oncol.** 2002; 20 (10): 2575-2601.

*A Phase II Study of Chemo-Neuro-Immunotherapy with Platinum, Subcutaneous Low-Dose Interleukin-2 and the Pineal Neuro-Hormone Melatonin (P.I.M. schedule) as a Second-Line Therapy in Metastatic Melanoma Patients Progressing on Dacarbazine Plus Interferon-Alpha*, Lissoni, Vaghi & Ardizzoia, **In Vivo** 2002; 16 (2): 93-96.

*Adjuvant Therapy With the Pineal Hormone Melatonin in Patients with Lymph Node Relapse Due To Malignant Melanoma*, Lissoni, Brivio, Brivio, et al., **J. Pineal Res.** 1996; 21 (4): 239-242.

*Melatonin Therapy of Advanced Human Malignant Melanoma*, Gonzalez, Sanchez, Ferguson, et al., **Melanoma Res.** 1991; 1 (4): 237-243.

*Reduction of Cisplatin-Induced Anemia by the Pineal Indole 5-MethoxyTryptamine in Metastatic Lung Cancer Patients*, Lissoni, Malugani, Bukovec, et al., **Neuro. Endocrinol. Lett.** 2003; 24 (1-2): 83-85.

*Selective Effect of Melatonin on the Proliferation of Lymphoid Cells*, Persengiev & Kyurkchiev, **Int. J. Biochem.** 1993;25 (3): 441-444.

*Melatonin: Reducing the Toxicity and Increasing the Efficacy of Drugs*, Reiter, Tan, Sainz , et al., **J. Pharm. Pharmacol.** 2002; 54 (10): 1299-1321.

*Biochemotherapy with Standard Chemotherapies Plus the Pineal Hormone Melatonin in the Treatment of Advanced Solid Neoplasms*, Lissoni, **Pathol. Biol.** 2007; 55 (3-4): 201-204.

*The Efficacy and Safety of Melatonin in Concurrent Chemotherapy or Radiotherapy for Solid Tumours: a Meta-Analysis of Randomized Controlled Trials*, Wang, Jin, Ai, et al., **Cancer Chemother. Pharmacol.** 2012; 69 (5): 1213-1220. published online Jan 24, DOI 10.1007/s00280-012-1828-8

*Melatonin as Adjuvant Cancer Care With and Without Chemotherapy: A Systematic Review and Meta-Analysis of Randomized Trials*, Seely, Wu, Fritz, et al., **Integr. Cancer Ther.** 2011; published online 21 October 2011 DOI: 10.1177/1534735411425484

*Melatonin Reduces Lead Levels in Blood, Brain and Bone and Increases Lead Excretion in Rats Subjected to Subacute Lead Treatment*, Hernández-Plata, Quiroz-Compeán, Ramírez-García, et al., **Toxicol. Lett.** 2015; 233 (2): 78-83.

#### MILK THISTLE

*Advances in the Use of Milk Thistle*, Post-White, Ladas & Kelly, **Integr. Cancer Ther.** 2007; 6 (2): 104-109.

*Toward the Definition of the Mechanism of Action of Silmarin: Activities Related to Cellular Protection from Toxic Damage Induced by Chemotherapy*, Comelli, Mengs, Schneider, et al., **Integr. Cancer Ther.** 2007; 6 (2): 120-129.

*Milk Thistle (Silybum marianum) is Associated with Reductions in Liver Function Tests (LFTs) in Children Undergoing Therapy for Acute Lymphoblastic Leukemia (ALL)*, Ladas, Cheng, Hughes, et al., **Int. Conf. Soc. Integr. Oncol.** 2006; abstract D045.

*Clinical Applications of Silybum marianum in Oncology*, Greenlee, Abascal, Yarnell, et al, **Integr. Cancer Ther.** 2007; 6 (2): 158-165.

*Antiproliferative Effect of Silybin on Gynaecological Malignancies: Synergism with Cisplatin and Doxorubicin*, Scambia, DeVincenzo, Ranelletti, et al., **Eur. J. Cancer** 1996; 32 A (5): 877-882.

*Silybin and its Bioavailable Phospholipid Complex (IdB 1016) Potentiate in vitro and in vivo the Activity of Cisplatin*, Giacomelli, Gallo, Apollonio, et al, **Life Sci.** 2002; 70 (12): 1447-1459.

*Effect of Silibinin on the Growth and Progression of Primary Lung Tumours in Mice*, Singh, Deep, Chittezhath, et al., **J. Natl. Cancer Inst.** 2006; 98 (12): 846-855.

*Milk thistle and Indinavir: A Randomized Controlled Pharmacokinetics Study and Meta-Analysis*, Mills, Wilson, Clarke, et al., **Eur. J. Clin. Pharmacol.** 2005; 61(1): 1-7.

*Effect of Milk Thistle (Silybum marianum) on the Pharmacokinetics of Irinotecan*, van Erp, Baker, Zhao, et al., **Clin. Cancer Res.** 2005; 11 (21): 7800-7806.

*Milk Thistle: Safe and Effective Around Chemotherapy?*, Kerry Bone, **Acupuncture Today** December, 2010, Vol. 11, Issue 12.

*Chemotherapeutic Activity of Silymarin Combined with Doxorubicin or Paclitaxel in Sensitive and Multidrug-Resistant Colon Cancer Cells*, Colombo, Lupi, Falcetta, et al., **Cancer Chemother. Pharmacol.** 2010 Apr 30. [Epub ahead of print]

*Silymarine During Maintenance Therapy of Acute Promyelocytic Leukemia*, Invernizzi, Bernuzzi, Ciani, et al., **Haematologica** 1993;78 (5): 340-341.

*A Randomized, Controlled, Double-Blind, Pilot Study of Milk Thistle for the Treatment of Hepatotoxicity in Childhood Acute Lymphoblastic Leukemia (ALL)*, Ladas, Kroll, Oberlies, et al., **Cancer** 2010; 116 (2): 506-513.

*Modulation of Human Cytochrome P450 3A4 (CYP3A4) and P-glycoprotein (P-gp) in Caco-2 Cell Monolayers by Selected Commercial-Source Milk Thistle and Goldenseal Products*, Budzinski, Trudeau, Drouin, et al., **Can. J. Physiol. Pharmacol.** 2007; 85 (9): 966-978. doi:10.1139/Y07-091

*In Vivo Assessment of Botanical Supplementation on Human Cytochrome P450 Phenotypes: Citrus aurantium, Echinacea purpurea, Milk Thistle, and Saw Palmetto*, Gurley, Gardner, Hubbard, et al., **Clin. Pharmacol. Ther.** 2004; 76 (5): 428-440. Erratum in: **Clin. Pharmacol. Ther.** 2005; 77 (5): 456.

*Effect of Milk Thistle (*Silybum marianum*) and Black Cohosh (*Cimicifuga racemosa*) Supplementation on Digoxin Pharmacokinetics in Humans*, Fuhr, Beckmann-Knopp, Jetter, et al., **Planta Med.** 2007; 73 (14): 1429-1435.

*Study on the Influence of Silymarin Pretreatment on Metabolism and Disposition of Metronidazole*, Rajnarayana, Reddy, Vidyasagar & Krishna **Arzneim-Forsch** 2004; 54:109-113.

*Effect of Continuous Silymarin Administration on Oral Talinolol Pharmacokinetics in Healthy Volunteers*, Han, Guo, Chen, et al., **Xenobiotica** 2009; 39, (9): 694-699.

*Effect of Silymarin on the Pharmacokinetics of Losartan and Its Active Metabolite E-3174 in Healthy Chinese Volunteers*, Han, Guo, Chen, et al., **Eur. J.Clin.Pharmacol.** 2009; 65 (6): 585-591.

*Effect of Silymarin Supplement on the Pharmacokinetics of Ornnidazole in Healthy Volunteers*, Repalle, Yamsani, Gannu, et al., **Acta Pharma.Sci.** 2009; 51 (1): 15-20.

*Silibinin Sensitizes Human Prostate Carcinoma DU145 Cells to Cisplatin- and Carboplatin-Induced Growth Inhibition and Apoptotic Death*, Dhanalakshmi, Agarwal, Glode & Agarwal, **Int. J. Cancer** 2003; 106 (5): 699-705.

*Anti-Proliferative Effect of Silybin on Gynaecological Malignancies: Synergism with Cisplatin and Doxorubicin*, Scambia, De Vincenzo, Ranelletti, et al., **Eur. J. Cancer Part A** 1996; 32: 877-882.

*Silibinin Restores Paclitaxel Sensitivity to Paclitaxel-Resistant Human Ovarian Carcinoma Cells*, **Anticancer Res.** 2008; 28 (2A): 1119-1127.

*Oral Silibinin Inhibits Lung Tumour Growth in Athymic Nude Mice and Forms a Novel Chemocombination with Doxorubicin Targeting Nuclear Factor kappa B-Mediated Inducible Chemoresistance*, Singh, Mallikarjuna, Sharma, et al., **Clin. Cancer Res.** 2004; 10 (24): 8641-8647.

*Antimetastatic Efficacy of Silibinin: Molecular Mechanisms and Therapeutic Potential Against Cancer*, Deep & Agarwal, **Cancer Metast. Rev.** 2010; 29 (3): 447-463.

## MISTLETOE

*Differential Effects of Viscum album Extract Iscador Qu on Cell Cycle Progression and Apoptosis in Cancer Cells*, Harmsma, Gromme, Ummelin, et. al., **Int. J. Oncol.** 2004; 25: 1521 – 1529.

*Impact of Complementary Mistletoe Extract Treatment on Quality of Life in Breast, Ovarian and Non-Small Cell Lung Cancer Patients. A Prospective, Randomized Controlled Clinical Trial*, Piao, Wang, Xie, et al. **Anticancer Res.** 2004; 34: 303-309.

*Use of Iscador, an Extract of European Mistletoe (Viscum album) in Cancer Treatment: Prospective Non-Randomized and Randomized Matched-Pair Studies Nested Within a Cohort Study*, Grossarth-Maticek, Kiene, Baumgartner & Ziegler **Alt. Ther.** 2001; Vol. 7 No. 3: 57-78.

*Treatment of Advanced Pancreatic Cancer with Mistletoe: Results of a Pilot Trial* Friesse, et al. 1996; **Anticancer Res.** 16 : 915-920.

*Mistletoe Extract May Be Alternative Bladder Cancer Therapy*, Elsaesser-Beile, et al. July 2005; **J. Urol.** 174: 176-179.

*Final Results of the EORTC 18871 / DKG 80-1 Randomised Phase III Trial: rIFN-alpha2b vs. rIGN-gamma vs. Iscador M vs. Observation After Surgery in Melanoma Patients with Either High-risk Primary or Regional Lymph Node Metastasis*, Kleeberg, Suciu, Brocker, et al., **Eur. J. Cancer** 2004; 40: 390-402.

*Anti-Proliferative Effect of Iscador Against Urinary Bladder Carcinoma*, Urech, et al., **Anti-Cancer Res.** 2006; 26: 3049-3056.

*Safety and Efficacy of the Long-term Treatment of Primary Intermediate to High-Risk Malignant Melanoma (UICC/AJCC stage II and III) with a Standardized Fermented European Mistletoe Extract: Results from a Multicenter, Comparative, Epidemiological Cohort Study in Germany and Switzerland*, Augustin, Bock, Hanisch, et. al., **Arzeimittelforschung**, 2005; 55 (1):38-49.

*Iscador Qu Spezial Inhibits Tube Formation*, Elluru, et al, **Drug Res.**, 2006; 56: 461.

*Palliative In-Patient Cancer Treatment in an Anthroposophic Hospital: II. Quality of Life During and After Stationary Treatment, and Subjective Treatment Benefits*, Heusser, Braun, Burtschy et al., **Forsch Komplementarmed**, 2006; 13: parts I & II.

*Iscador in Breast Cancer (I)*, Leroi, **Helvet Chir Acta** 1977; 44.

*Iscador in Breast Cancer (II)*, Hellan, et. al., **Krebs und Alternativ-Medizin II**, 1990, Springer.

*Iscador in Breast Cancer (III)*, Grossarth-Maticek, et. al., **Altern. Ther. Health Med.**, 2001; 7.

*Iscador in Breast Cancer (IV)*, Grossarth-Maticek, et. al., **Altern. Ther. Health Med.**, 2001; 7.

*Iscador in Breast Cancer (V)*, Bock et. al., **Drug Res.** 2004; 58.

*Iscador in Cancer of Different Locations*, Grossarth-Maticek, et. al., **Altern. Ther. Health Med.**, 2001; 7: 3.

*Efficacy and Safety of Long-term Complementary Treatment with Standardized European Mistletoe Extract (Viscum album. L.) in Addition to the Conventional Adjuvant Oncological Therapy in Patients with Primary Non-Metastatic Breast Cancer – Results of a Multicentre, Comparative, Epidemiological Cohort Study*, Bock, Friedel, Hanisch et. al., **Arneim-Forsch/ Drug Res.** 2004; 54 No. 8: 456 – 466.

*Anticancer Activity of a Lectin-Rich Mistletoe Extract Injected Intratumourally into Human Pancreatic Cancer Xenografts*, Rostock, Huber, Greiner, et al., **Anticancer Res** 2005; 25 (3B): 1969-1975.

*Reducing Malignant Ascites Accumulation by Repeated Intraperitoneal Administrations of a Viscum album Extract*, Bar-Sela, Goldberg, Beck, et al., **Anticancer Res.** 2006; 26 (1B): 709-713.

*Quality of Life is Improved in Breast Cancer Patients by Standardized Mistletoe Extract PS76A2 During Chemotherapy and Follow-Up: A Randomised, Placebo-Controlled, Double-Blind, Multicentre Clinical Trial*, Semiglazov, Stepula, Dudov, et al., **Anticancer Res.** 2006; 26 (2B): 1519-1529.

*Nitric-Oxide Involvement in the Anti-Tumour Effect of Mistletoe (Viscum album L.) Extract Iscador on Human Macrophages*, Mossalayi, Alkharrat & Malvy, **Arzneimittelforschung** 2006; 56 (6A): 457-460.

*Immunological Effector Mechanisms of a Standardized Mistletoe Extract On the Function of Human Monocytes and Lymphocytes in vitro, ex vivo and in vivo*, Heinzerling, von Baehr, Liebenthal, et al., **J. Clin. Immunol.** 2006; 26 (4): 347-359.

*Induction of Maturation and Activation of Human Dendritic Cells: A Mechanism Underlying the Beneficial Effect of Viscum album as a Complimentary Therapy in Cancer*, Elluru, et al., **BMC Cancer** 2008; 8: 161.

*Anticancer Activity of a Lectin-Rich Mistletoe Extract Injected Intratumourally into Human Pancreatic Cancer Xenografts*, Rostock, Huber, Greiner, et al., **Anticancer Res.** 2005; 25 (3B): 1969-1975.

*Prospective Controlled Cohort Studies on Long-Term Therapy of Breast Cancer Patients with a Mistletoe Preparation (Iscador(r))*, Grossarth-Maticek & Ziegler, **Fortsch Komplementarmed** 2006; 13 (5): 285-292.  
*Immune Modulation Using Mistletoe (Viscum album L.) Extracts Iscador*, Büsing, **Arzneimittelforschung** 2006; 56 (6A): 508-515.

*Anti-Proliferative Effects of Mistletoe (Viscum album L.) Extract in Urinary Bladder Carcinoma Cell Lines*, Urech, Büssing, Thalmann, et al., **Anticancer Res.** 2006; 26 (4B): 3049-3055.

*Mistletoe for Cancer? A Systematic Review of Randomised Clinical Trials*, Ernst, Schmidt & Steuer-Vogt, **Int. J. Cancer** 2003; 107 (2): 262-267.

*Complementary Cancer Therapy: A Systematic Review of Prospective Clinical Trials on Anthroposophic Mistletoe Extracts*, Kienle & Kiene, **Eur. J. Med. Res.** 2007; 12 (3): 103-119

*Mistletoe Therapy in Oncology*, Horneber, Bueschel, Huber R, et al., **Cochrane Database Syst. Rev.** 2008; (2): CD003297.

*Survival of Cancer Patients Treated with Mistletoe Extract (Iscador): A Systematic Literature Review*, Ostermann, Raak & Bussing, **BMC Cancer** 2009; 9 (1): 451.

*Systematic Evaluation of the Clinical Effects of Supportive Mistletoe Treatment within Chemo-and/or Radiotherapy Protocols and long-Term Mistletoe Application in Nonmetastatic Colorectal Carcinoma: Multicenter, Controlled, Observational Cohort Study*, Friedel, Matthes, Bock & Zanker, **J. Soc. Integr. Oncol.** 2009; 7 (4): 137-145.  
*Viscum album L. Extracts in Breast and Gynaecological Cancers: A Systematic Review of Clinical and Preclinical Research*, Kienle, Glockmann, Schink & Kiene, **J. Exp. Clin. Cancer Res.** 2009; 28: 79.

*Viscum Album Extracts Iscador® P and Iscador® M Counteract the Growth Factor Induced Effects in Human Follicular B – NHL Cells and Breast Cancer Cells*, Hugo, Schwitalla, Niggemann, et al., **Medicina** 2007; 67 (Suppl. II): 90-96.

*Quality of Life, Immunomodulation and Safety of Adjuvant Mistletoe Treatment in Patients with Gastric Carcinoma - A Randomized, Controlled Pilot Study*, Kim, Yook, Eisenbraun, et al., **BMC Compl. Alt. Med.** 2012; 12: 172.

*Viscum album [L.] Extract Therapy in Patients with Locally Advanced or Metastatic Pancreatic Cancer: A Randomised Clinical Trial On Overall Survival*, Troger, Galun, Reif, et al., **Eur. J. Cancer** 2013; S0959-8049(13)00550-9. doi: 10.1016/j.ejca.2013.06.043.

*Molecular Mistletoe Therapy: Friend or Foe in Established Anti-Tumour Protocols? A Multicenter, Controlled, Retrospective Pharmaco-Epidemiological Study in Pancreas Cancer*, Matthes, Friedel, Bock & Zänker, **Curr Mol Med.** 2010; 10 (4): 430-439.

*A Specific Mistletoe Preparation (Iscador-Qu) in Colorectal Cancer (CRC) Patients: More Than Just Supportive Care?*, Zaenker, Matthes, Bock, et al., **J. Cancer Sci. Ther.** 2012; 49: 264 - 270.

*Targeting Inflammation In Cancer-Related Fatigue: A Rationale for Mistletoe Therapy As Supportive Care in Colorectal Cancer Patients*, Bock, Hanisch, Matthes & Janker, **Inflamm Allergy Drug Targets**, 2014 Apr. 27; epub ahead of print. PMID: 24766319.

*Mistletoe Therapy in Patients with Metastatic Pancreatic Cancer: The Survival-Prolonging Effects of Now Confirmed for the First Time in a Prospective Randomized Phase III Study*, Tröger, Galun, Reif, et al., **Eur. J. Cancer** 2013; 49 (18): 3788-3797.

*The Viscum album Extract Iscador P Does Not Cause An Autocrine Interleukin-6 Loop In B-Non-Hodgkin's Lymphoma Cell Lines*, Hugo, Dittmar, Treutler, et al., **Onkologie** 2005; 28 (8-9): 415-420.

*Efficacy And Risk Estimation Of Subcutaneous Mistletoe Treatment (Viscum album L. Pini) In Patients With Non-Hodgkin's Lymphoma, A Retrospective Controlled Case Study*, Kuehn, Scheer, Alban, Becker, et al., “**Die Mistel in der Tumour-therapie 2: Aktueller Stand der Forschung und klinische Anwendung**”, 2009; pp. 353-373. ISBN 978-3-933351-82-1

*Observational Study on Treatment of Lymphocytic Non Hodgkin's Lymphoma (CLL) with Viscum album Products Helixor P or A: Clinical Course and Safety*, Gutscha, Rieger, & Schloßdörfer, **Phytomedicine** 2011; 18. DOI: 10.1016/j.phymed.2011.09.025

#### MITOCHONDRIA & DICHLOROACETATE DCA

*Mitochondria and Cancer*, Jurasunas, **Townsend Letter** 2006; # 277/78: 83-86, 146-148.

*Mitochondria and Cancer*, Wallace, **Nature Rev.- Cancer** 2012; 12: 685-697.

*The Role of Mitochondria in Glioma Pathophysiology*, Orbys, Launay, Deighton, et al., **Mol. Neurobiol.** 2010; 42 (1): 64-75.

*Cancer Cell Mitochondria Confer Apoptosis Resistance and Promote Metastasis*, Kulawiec, Owens & Singh, **Cancer Biol. Ther.** 2009; 8 (14): 1378-1385.

*The Causes of Cancer Revisited: ``Mitochondrial Malignancy`` and ROS-Induced Oncogenic Transformation - Why Mitochondria are Targets for Cancer Therapy*, Ralph, Rodriguez-Enriquez, Neuzil, et al., **Mol. Aspects Med.** 2010; 31 (2): 145-170.

*ROS-Generating Mitochondrial DNA Mutations Can Regulate Tumour Cell Metastasis*, Ishikawa, Takenaga, Akimoto, et al., **Science** 2008; 320 (5876): 661-664.

*Somatic Mutations in Mitochondrial Genome and Their Potential Roles in the Progression of Human Gastric Cancer*, Hung, Wu, Yin, et al., **Biochem. Biophys. Acta** 2010; 1800 (3): 264-270.

*Positive Contributions of Pathogenic Mutations in the Mitochondrial Genome to the Promotion of Cancer by Prevention of Apoptosis*, Shigara, Yamagata, Kanamori, et al., **Cancer Res.** 2005; 65 (5): 1655-1663.

*Mitochondrial Dysfunction is a Common Phenotype in Aging and Cancer*, Singh, **Ann. NY Acad. Sci.** 2004; 1019: 260-264.

*Oxidative Stress, Mitochondrial DNA Mutation, and Apoptosis in Aging*, Lee & Wei, **Exp. Biol. Med.** 2006; 232 (5): 592-606.

*Mitochondria-Targeted Antioxidants in the Treatment of Disease*, Smith, Adlam, Blaikie, et al., **Ann. NY Acad. Sci.** 2008; 1147: 105-111.

*A Mitochondria-K<sup>+</sup> Channel Axis is Suppressed in Cancer and its Normalization Promotes Apoptosis & Inhibits Cancer Growth*, Bonnet, Archer, Allalunis-Turner, et al., **Cancer Cell** 2007; 11 (1): 37-51.

*The Biological Significance of Cancer: Mitochondria as a Cause of Cancer and the Inhibition of Glycolysis with Citrate as a Cancer Treatment*, Halabe Bucay, **Med Hypotheses** 2007; 69(4): 826-828.

*Cheap, Safe Drug Kills Most Cancers*, Coghlan, **New Scientist** January 2007.

*Clinical Pharmacology and Toxicology of Dichloroacetate*, Stacpoole, Henderson, Yan & James, **Envir. Health Perspect.** 1998; 106 (Suppl. 4): 989-994.

*Metabolic Interactions of Dichloroacetate and Insulin in Experimental Diabetic Ketoacidosis*, Backshear, Holloway & Alberti, **Chem. Res. Toxicol.** 2000;13 (4): 2312-236.

*Trial of Dichloroacetate in MELAS: Toxicity Overshadows the Assessment of Potential Benefit*, Schaefer, **Neurology** 2006; 66 (3): 302-303.

*Dichloroacetate Causes Toxic Neuropathy in MELAS: A Randomized Controlled Clinical Trial*, Kaufmann, Engelstad, Wei, et al., **Neurology** 2006; 66 (3): 324-330.

*Dichloroacetate Causes Reversible Demyelination In Vitro: Potential Mechanism for Its Neuropathic Effect*, Felitsyn, Stacpoole & Notterpek, **J. Neurochem.** 2007; 100 (2): 429-436.

*Treatment of Symptomatic Diabetic Polyneuropathy with the Antioxidant α-Lipoic Acid. A 7-Month Multicenter Randomized Controlled Trial (ALA-DIN III Study)*, Ziegler, Hanefeld, Ruhnau, et al., **Diabetes Care** 1999; 22: 1296-1301.

*Pangamic Acid (“Vitamin B15”)*, Victor Herbert, **Amer. J. Clin. Nutr.** 1979; 32: 1534-1540.

*Prevention of Incipient Diabetic Nephropathy by High-Dose Thiamine and Benfotiamine*, Babaei-Jadidi, Karachalias, Ahmed, et al., **Diabetes** 2003; 52: 2110-2120.

*Effects of Dichloroacetate and Ubiquinone Infusions on Glycolysis Activity and Thermal Sensitivity During Sepsis*, L'Her & Sebert, **J. Lab. Clin. Med.** 2004; 143 (6): 352-357

*Metabolic Modulation of Glioblastoma with Dichloroacetate*, Michelakis, et al., **Sci. Transl. Med.** 2 2010; 31ra34: DOI: 10.1126/scitranslmed.3000677.

*Use of Oral Dicholoracetate for Palliation of Leg Pain Arising from Metastatic Poorly Differentiated Carcinoma: A Case Report*, Khan, **J.Palliat. Med.** 2011; 14 (5):

*Sodium Dichloroacetate (DCA) Reduces Apoptosis in Colorectal Tumour Hypoxia*, Shahrzad, Lacombe, Adamcic, et al., **Cancer Lett.** 2010; 297 (1):75-83.

*Restoration of Cellular Energetic Balance with L-Carnitine in the Neuro-bioenergetic Approach for Cancer Prevention and Treatment*, Hoang, Shaw, Pham & Levine, **Med. Hypotheses** 2007; 69 (2): 262-272.

*Increased Carnitine-Dependent Fatty Acid Uptake into Mitochondria of Human Colon Cancer Cells Induces Apoptosis*, Wenzel, Nickel & Daniel, **J. Nutr.** 2005; 135 (6): 1510-1514.

*Carnitine Supplementation Alleviates Cancer-Related Fatigue*, Cruciani, et al., **J. Pain Sympt. Man.** 2006; 32: 551-559.

*Voltage-Dependent Anion Channel (VDAC) as Mitochondrial Governor – Thinking Outside the Box*, Lemasters & Holmuhamedov, **Biochem.Biophys. Acta** 2006; 1762 (2): 181-190.

*Lactate: Mirror and Motor of Tumour Malignancy*, Walenta & Mueller-Klieser ,**Semin Radiat Oncol.** 2004; 14 (3): 267-74.

*High Lactate Levels Predict Likelihood of Metastases, Tumour Recurrence, and Restricted Patient Survival in Human Cervical Cancers*, Walenta, Wetterling, Lehrke, et al., **Cancer Res.** 2000; 60 (4): 916-921.

*Tumour-Derived Lactic Acid Modulates Dendritic Cell Activation and Antigen Expression*, Gottfried, Kunz-Schughart, Ebner, et al., **Blood.** 2006; 107 (5): 2013-2021.

*Lactate Dehydrogenase 5 Expression in Operable Colorectal Cancer: Strong Association with Survival and Activated Vascular Endothelial Growth Factor Pathway—A Report of the Tumour Angiogenesis Research Group*, Koukourakis, Giatromanolaki, Sivridis, et al., **J Clin Oncol.** 2006; 24 (26): 4301-4308. Epub 2006 Aug 8.

*Pyruvate Kinase M2 Is a PHD3-Stimulated Coactivator for Hypoxia-Inducible Factor 1*, Luo, Hu, Chang, et al., **Cell** 2011; 145 (5): 732-744.

*Lactate Dehydrogenase 5 (LDH5) Relates to Up-Regulated Hypoxia Inducible Factor Pathway and Metastasis in Colorectal Cancer*, Koukourakis, Giatromanolaki, Simopoulos, et al., **Clin Exp Metastasis** 2005; 22( 1): 25-30.

*Studies with Glycolysis-Deficient Cells Suggest That Production of Lactic Acid is Not the Only Cause of Tumour Acidity*, Newell, Franchi, Pouysségur & Tannock, **Proc Natl Acad Sci U S A.** 1993; 90 (3): 1127-1131.

*Early and Late Apoptosis Events in Human Transformed and Non-Transformed Colonocytes are Independent of Intracellular Acidification*, Wenzel & Daniel, **Cell Physiol Biochem.** 2004;14 (1-2): 65-76.

*Mitochondria and Cancer: Warburg Addressed*, Wallace, **Cold Spring Harb. Symp. Quant. Biol.** 2005; 70: 363-374.

*Choosing Between Glycolysis and Oxidative Phosphorylation: A Tumour's Dilemma?*, Jose, Bellance & Rossignol, **Biochimica et Biophysica Acta (BBA) - Bioenergetics** 2011; 1807 (6): 552-561.

*Cofactors of Mitochondrial Enzymes Attenuate Copper-Induced Death in vitro and in vivo*, Sheline, Choi, Kim-Han, et al., **Ann Neurol.** 2002; 52 (2): 195-204.

*Effect of Thiamine Phosphates on the Activity of Regulatory Enzymes of the Pyruvate Dehydrogenase Complex*, Parkhomenko, Chernysh, Cjurilova, et. al., **Ukr. Biokhim. Zh.** 1987; 59 (5): 49-54.

*Co-Enzyme Q10 Improves Lactic Acidosis, Stroke-like Episodes and Epilepsy in a Patient with MELAS (Mitochondrial Myopathy, Encephalopathy, Lactic Acidosis and Stroke-like Episodes)*, Berbel-Gacia, Barbera-Farre, Etessam, et al., **Clin. Neuropharmacol.** 2004; 27 (4): 187-191.

*Mitochondria Rescue (Possibly) Heals Cancer?* McKinney, **Naturopathic Doctor News & Review** - May 2008; 4 (5): 10-11.

*Activation of Mitochondria and Release of Mitochondrial Apoptogenic Factors by Betulinic Acid*, Fulda, Scaffidi, Susin, et al., **J. Biol. Chem.** 1998; 18: 273 (51): 33942-33948.

*Pharmacological Effects On Mitochondrial Function*, Cohen, **Develop. Disab. Res. Rev.** 2010; 16: 189-199.

*On-Target Inhibition of Tumour Fermentative Glycolysis as Visualized by Hyperpolarized Pyruvate*, Seth, Grant, Tang, et al., **Neoplasia** 2011; 13 (1): 60-71.

*The Control of the Metabolic Switch in Cancers by Oncogenes and Tumour Suppressor Genes*, Levine, Puzio-Kuter, **Science** 2010; 330 (6009): 1340-1344.

*Rescue of Death Receptor and Mitochondrial Apoptosis Signalling in Resistant Human NSCLC in vivo*, Okouovo, Herzer, Ucur, et al., **Int. J. Cancer** 2004; 108 (4): 580-587

*Mitochondria in Cancer: Not Just Innocent Bystanders*, Frezza & Gottlieb, **Sem. Cancer Biol.** 2009; 19: 4-11.

*Opportunities in Discovery and Delivery of Anticancer Drugs Targeting Mitochondria and Cancer Cell Metabolism*, Pathania, Millard & Neamati, **Adv. Drug Deliv. Rev.** 2009; 61 (14): 1250-1275.

*The Hallmarks of Cancer (Review)*, Hanahan & Weinberg, **Cell**; 100: 57-70.

*The Hallmarks of Cancer- The Next Generation*, Hanahan & Weinberg, **Cell** 2011; 144: 646-674.

*On the Metabolic Origin of Cancer: Substances That Target Tumour Metabolism*, Israel & Schwartz, **Biomed. Res.** 2011; 22 (2): 130-164.

*The Anti-Neoplastic Effects of Alpha-Lipoic Acid: Clinical Benefits in System Tumours Besides Lung Carcinomas*, Kapoor, **Korean J Thorac Cardiovasc Surg.** 2013; 46 (2): 162–163. [re: ALA+HCA]

*Mitochondrial Oxidative Stress Drives Tumour Progression and Metastasis: Should We Use Antioxidants as a Key Component of Cancer Treatment and Prevention?*, Sotgia, Martinez-Outschoorn , & Lisanti, **BMC Med.** 2011; 9:62. doi: 10.1186/1741-7015-9-62.

*A Novel Form (IV) of Dichloroacetate Therapy for Patients with Advanced Cancer: A Report of 3 Cases*, Khan, Marier, Marsden & Andrews, *Altern. Ther.* 2014; 20 (Suppl. 2): 21-28.

*Sensitization of Metformin-Cytotoxicity by Dichloroacetate Via Reprogramming Glucose Metabolism in Cancer Cells*, Choi, **Cancer Lett.** 2014; 346 (2): 300-308. doi: 10.1016/j.canlet.2014.01.015. Epub 2014 Jan 27

*NAD+ Metabolism, A Therapeutic Target for Age-Related Metabolic Disease*, Mouchiroud, Houtkooper & Auwerx, **Crit. Rev. Biochem. Mol. Biol.** 2013 ; 48( 4): doi:10.3109/10409238.2013.789479.

*Antagonistic Role of Natural Compounds in mTOR-Mediated Metabolic Reprogramming*, Cerella et al., **Cancer Lett.** 2014; <http://dx.doi.org/10.1016/j.canlet.2014.02.008>

*The Hallmarks of Cancer- The Next Generation*, Hanahan & Weinberg, **Cell** 2011; 144: 646-674.

*Otto Warburg's Contributions To Current Concepts Of Cancer Metabolism*, Koppenol, Bounds & Dang, **Cancer** 2011; 11: 325-3337.

*Metabolic Treatment of Cancer: Intermediate Results of a Prospective Case Series*, Schwartz, Buhler, Icard, et al., **Anticancer Res.** 2014; 34 (2): 973-980.

*The Addition of Chloroquine and Metformine to Metabloc Induces a Rapid Drop of Tumour Markers in Advanced Carcinoma*, Schwartz, Buhler & Steyaert, **Cancer Ther** 2014;10: 20-27.

*New Cancer Paradigm and New Treatment: The Example of METABLOC*, Schwartz, et al. **Conf. Papers Med.** 2013: 1-5.

*Mitochondrial Metabolism in Cancer Metastasis*, Sotgia, Whitaker-Menzes, Martinez-Outschoorn, et al., **Cell Cycle** 2012; 11 (7): 1445-1454.

*Adding a Combination of Hydroxycitrate and Lipoic Acid (METABLOC) to Chemotherapy Improves Effectiveness Against Tumour Development: Experimental Results and Case Report*, Guais, Baronzio, Sanders, et al, **Invest. New Drugs** 2012; 30 (1): 200-211.

*Early Clinical and Toxicological Results of a Combination of Natural Glycolysis Inhibitors (METABLOC<sup>TM</sup>) On Cancer Patients*, Baronzio, Crespi1, Guais, et al., **Biomed. Res.** 2012; 23: 219-222.

*Screening of Well-Established Drugs Targeting Cancer Metabolism: Reproducibility of the Efficacy of a Highly Effective Drug Combination in Mice*, Abolhassani, Guais, Sanders,et al., **Invest. New Drugs** 2012; 30 (4): 1331-1342.

*Tumour Regression with a Combination of Drugs Interfering with the Tumour Metabolism: Efficacy of Hydroxycitrate, Lipoic Acid and Capsaicin*, Schwartz, Guais, Israel, et al., **Invest. New Drugs** 2012;

*Metabolic Modulation of Glioblastoma with Dichloroacetate*, Michelakis, Sutendra, Dromparis, et al., **Science Transl. Med.** 2010; 13: 31-34.

*Case Report of Long Term Complete Remission of Metastatic Renal Squamous Cell Carcinoma After Palliative Radiotherapy and Adjuvant Dichloroacetate*, Khan, **Adv. Cancer Res.Treat.** 2012; vol. 2012; ID 441895.

*The Metabolic Advantage of Tumour Cells*, Israel & Schwartz, **Mol. Cancer** 2011; 10, (70).

*A Combination of Alpha-Lipoic Acid and Calcium Hydroxycitrate is Efficient Against Mouse Cancer Models: Preliminary Results*, Schwartz, Abolhassani, Guais, et al., **Oncol. Rep.** 2010; 23: 1407-1416.

*Is Akt the “Warburg Kinase”? Akt-Energy Metabolism Interactions and Oncogenesis*, Robey & Hay, **Sem. Cancer Biol.**, 2009; 19, (1):, 25–31.

*Pyruvate Into Lactate and Back: From the Warburg Effect to Symbiotic Energy Fuel Exchange in Cancer Cells*, Feron, **Radiother. & Oncol.** 2009; 92 (3): 329–333.

*Normal Human Melanocytes Exposed to Chronic Insulin and Glucose Supplementation Undergo Oncogenic Changes*, Morvan, Steyaert, Schwartz, et al., **Amer. J. Physiol.. Endocrinol. & Metabol.** 2012; 302 (11): E1407–E1418.

*PP2A Activity is Controlled by Methylation and Regulates Oncoprotein Expression in Melanoma Cells: A Mechanism Which Participates in Growth Inhibition Induced by Chloroethylnitrosourea Treatment*, Guénin, Schwartz,. Morvan, et al., **Int. J. Oncol.** 2008; 32 (1): 49–57.

*Roles of p53, MYC and HIF-1 in Regulating Glycolysis—The Seventh Hallmark of Cancer*, Yeung, Pan & Lee, **Cell. Mol. Life Sciences** 2008; 65 (24): 3981–3999.

*Curcumin Induces the Mitochondrial Permeability Transition Pore Mediated by Membrane Protein Thiol Oxidation*, Morina, Barthélémyc, Zinia, et al., **FEBS Letters** 2001; 495, (1-2): 131-136.

*Cytoplasmic Mediation of Malignancy*, Israel & Schaeffer, **In Vitro Cell Dev. Biol.** 1988;24 (5): 487-490.

*Mitochondrial Dynamics – Mitochondrial Fission and Fusion in Human Diseases*, Longo, **N. Eng. J. Med.** 2013; 369 (13): 2236-2251.

*Bioflavonoid Regulation of ATPase and Hexokinase Activity in Erlich Ascites Cell Mitochondria*, Graziani, **Biochim. Biophysica Acta** 1977; 460 (2): 364-373.

#### MODIFIED CITRUS PECTIN

*The Potential Role of Modified Citrus Pectin in the Prevention of Cancer Metastasis*, Eliaz, **Clin. Pract. Altern. Med.** 2001; 2 (3): 177-179.

*Galectin-3 as a Potential Target in Tumours Arising from Malignant Epithelia*, Johnson, Glinskii, et al., **Neoplasia** 2007; 9 (8): 662-670.

*Modified Citrus Pectin Slows PSA Doubling Time: A Pilot Clinical Trial*, Strum, et al., **Int. Conf. on Diet & Prev. Cancer** 1999.

*Modulation of the Lung Colonization of B16-F1 Melanoma Cells by Citrus Pectin*, Platt & Raz, **J. Natl. Cancer Inst.** 1992; 84 (6): 438-442.

*Citrus Pectin: Characterization and Inhibitory Effect on Fibroblast Growth Factor-Receptor Interaction*, Liu, Ahmad, Luo, et. al., **J. Agric. Food Chem.** 2001, 49 (6): 3051-3057.

*Inhibition of Spontaneous Metastasis in a Rat Prostate Cancer Model by Oral Administration of Modified Citrus Pectin*, Pienta, Naik, Akhtar, et. al, **J. Natl. Cancer Inst.** 1995; 87 (5): 348-353.

*Inhibition of Human Cancer Cell Growth and Metastasis in Nude Mice by Oral Intake of Modified Citrus Pectin*, Nangia-Makker, Pratima, Hogan, et al., **J. Natl. Cancer Inst.** 2002; 94 (24): 1854-1862.

*Galectin-3 Induces Endothelial Cell Morphogenesis and Angiogenesis*, Nangia-Makker, Honjo, Sarvis, et. al., **Am. J. Pathol.** 2000, 156 (3): 899-909.

*Galectin-9 Suppresses Tumour Metastasis by Blocking Adhesion to Endothelium and Extracellular Matrices*, Nobumoto, Nagahara, Oomizu, et al., **Glycobiol.** 2008;18 (9): 735-744.

*Recognition of Galactan Components of Pectin by Galectin-3*, Gunning, Bongaerts & Morris, **Fed. Amer. Soc. Exp. Biol. J.** 2008; 10.1096: fj. O8-106617.

*PectaSol-C Modified Citrus Pectin Induces Apoptosis and Inhibition of Proliferation in Human and Mouse Androgen-Dependent and -Independent Prostate Cancer Cells*, Yan & Katz, **Integr. Cancer Ther.** 2010; 9: 197-203.

*Modified Citrus Pectin Enhances the Effect of Novel Dietary Supplement Formulas Inhibition of Invasiveness of Breast and Prostate Cancer Cells by Down-Regulation of Urokinase Plasminogen Activator (uPA) Secretion*, Wojnowski, Jaing, Jedinak & Sliva, **Experimental Biology** 2010, Anaheim, CA, April, 2010. (**FASEB J.** 24: 207.4)

*Clinical Benefit in Patients with Advanced Solid Tumours Treated with Modified Citrus Pectin: A Prospective Pilot Study*, Azemar, Hildenbrand, Haering, et al., **Clin. Med. Oncol.** 2007; 1: 173-180.

*Modified Citrus Pectin (MCP) Increases the Prostate-Specific Antigen Doubling Time in Men with Prostate Cancer: A Phase II Pilot Study*, Guess, Scholz, Strum, et al., **Prostate Cancer Prostatic Dis.** 2003;6(4):301-304.

*Effects of Daily Oral Administration of Quercitin Chalcone and Modified Citrus Pectin on Implanted Colon-25 Tumour Growth in Balb-c Mice*, Hayashi, Gillen & Lott, **Altern. Med. Rev.** 2000; 5 (6): 546-552.

*Changes in Cell Growth, Cyclin/Kinase, Endogenous Phosphoproteins and nm23 Gene Expression in Human Prostatic JCA-1 Cells Treated with Modified Citrus Pectin*, Hsieh & Wu, **Biochem. Mol. Biol. Int.** 1995; 37 (5): 833-841.

*Effects of Natural Complex Carbohydrate (Citrus Pectin) on Murine Melanoma Cell Properties Related to Galectin-3 Functions*, Inohara & Raz, **Glycoconj. J.** 1994; 11 (6): 527-532.

*Inhibition of Human Cancer Cell Growth and Metastasis in Nude Mice by Oral Intake of Modified Citrus Pectin*, Nangia-Makker, Hogan, Honjo, et al., **J. Natl. Cancer Inst.** 2002; 94 (24): 1854-1862.

*Inhibition of in vitro Tumour Cell-Endothelial Adhesion by Modified Citrus Pectin: A pH Modified Natural Complex Carbohydrate*, Naik, Pilat & Donat, **Proc. Am. Assoc. Cancer Res.** 1995; 36: A377.

*Modified Citrus Pectin Anti-Metastatic Properties: One Bullet, Multiple Targets*, Vladislav, Glinsky & Avraham, **Carb. Res.** 2009; 344 (14): 1788-1791

## MUSHROOMS

*Anti-Aromatase Activity of Phytochemicals in White Button Mushrooms (*Agaricus bisporus*)*, Chen, Oh, Phung, et al., **Cancer Res.** 2006; 66 (24): 12026-12034.

*White Button Mushroom Phytochemicals Inhibit Aromatase Activity and Breast Cancer Cell Proliferation*, Grube, Eng, Kao, et al., **J. Nutr.** 2001; 131 (12): 3288-3293.

*Ganodermic Acid T from Ganoderma lucidum Mycelia induces Mitochondria Mediated Apoptosis in Lung Cancer Cells*, Tang, Liu, Zhao, et al., **Life Sci.** 2006; 80 (3): 205-211.

*Novel Antioxidant Peptides from Fermented Mushroom Ganoderma lucidum*, Sun, He & Xie, **J. Agric. Food Chem.** 2004; 52 (21): 6646-6652.

*Enhanced induction of mitochondrial damage and apoptosis in human leukemia HL-60 cells by Ganoderma lucidum and Duchesnea chrysanthra extracts*, Kim, Kim, Son & Kim, **Cancer Lett.** 2007; 246 (1-2): 210-217.

*Coriolus versicolor (Yunzhi) Extract Attenuates Growth of Human Leukemia Xenografts and Induces Apoptosis Through the Mitochondrial Pathway*, Zhang, Soboloff, Zhu & Berger, **Mol. Pharmacol.** 2006; 16 (3): 609-616.

*Ganoderma lucidum Inhibits Proliferation of Human Breast Cancer Cells by Down-regulation of Estrogen Receptor and NF-kappaB Signalling*, Jiang, Slivova & Sliva, **Int. J. Oncol.** 2006; 29 (3): 695-703.

*Androgen Receptor-Dependent and -Independent Mechanisms Mediate Ganoderma lucidum Activities in LNCaP Prostate Cancer Cells*, Zaidman, Wasser, Nevo & Mahajna, **Int. J. Oncol.** 2007; 31 (4): 959-967.

*Effects of Water-Soluble Ganoderma lucidum Polysaccharides on the Immune Functions of Patients with Advanced Lung Cancer*, Gao, Tang, Dai, et al., **J. Med. Food** 2005; 8 (2): 159-168.

*Effects of Ganopoly (A Ganoderma lucidum Polysaccharide Extract) on the Immune Functions in Advanced-stage Cancer Patients*, Gao, Zhou, Jiang, et al., **Immunol. Invest.** 2003; 32 (3): 201-215.

*Combined Effect of Green Tea and Ganoderma lucidum on Invasive Behaviour of Breast Cancer Cells*, Thyagarajan, Zhu & Sliva, **Int. J. Oncol.** 2007; 30 (4): 963-969.

*Telomerase-Associated Apoptotic Events by Mushroom Ganoderma lucidum on Pre-malignant Human Urothelial Cells*, Yuen, Gohel & Au, **Nutr. Cancer** 2008; 60 (1): 109-119.

*Dietary Intakes of Mushrooms and Green Tea Combine to Reduce the Risk of Breast Cancer in Chinese Women*, Zhng, Huang, Xie & Holman, **Int. J. Cancer** 2009; 1246: 1404-1408.

*Ganoderma lucidum (Reishi) in Cancer Treatment*, Sliva, **Integr. Cancer Ther.** 2003; 2 (4): 358-364.

*The Use of Mushroom Glucans and Proteoglycans in Cancer Treatment*, Kidd, **Altern. Med. Rev.** 2000; 5(1):4-27.

*Anticancer Effects of Ganoderma lucidum: A Review of Scientific Evidence*, Yuen & Gohel **Nutr. Cancer** 2005; 53 (1): 11-17

*Natural Killer Cell Activity and Quality of Life Were Improved by Consumption of a Mushroom Extract, Agaricus blazei Murill Kyowa, in Gynecological Cancer Patients Undergoing Chemotherapy*, Ahn, Kim, Chae, et al., **Int. J. Gynecol. Cancer** 2004; 14 (4): 589-594.

*Secretion of TNF-alpha, IL-8 and Nitric Oxide by Macrophages Activated with Agaricus blazei Murill Fractions in vitro*, Sorimachi, Akimoto, Ikehara, et al., **Cell Struct. Funct.** 2001; 26 (2): 103-108.

*Characterization and Immuno-modulating Activities of Polysaccharide from Lentinus edodes*, Zheng, Jie, Hanchuan & Moucheng, **Int. Immunopharmacol.** 2005; 5 (5): 811-820.

*Effects of Ganopoly (a Ganoderma lucidum Polysaccharide Extract) on the Immune Functions in Advanced-stage Cancer Patients*, Gao, Zhou, Jiang, et al., **Immunol. Invest.** 2003; 32 (3): 201-215.

*Protective Effects of Ganoderma lucidum Polysaccharides Peptide on Injury of Macrophages Induced by Reactive Oxygen Species*, You & Lin, **Acta Pharmacol. Sin.** 2002; 23 (9): 787-791.

*The Use of Mushroom Glucans and Proteoglycans in Cancer Treatment*, Kidd, **Altern. Med. Rev.** 2000; 5 (1): 4-27.

*Anticancer Effects and Mechanisms of Polysaccharide-K (PSK): Implications of Cancer Immunotherapy*, Fisher & Yang, **Anticancer Res.** 2002; 22 (3): 1737-1754.

*A Review of Research on the Protein-bound Polysaccharide (Polysaccharopeptide, PSP) from the Mushroom Coriolus versicolor (Basidiomycetes: Polyporaceae)*, Ng, **Gen. Pharmacol.** 1998; 30 (1): 1-4.

*Efficacy of Yun Zhi (Coriolus versicolor) on Survival in cancer Patients: Systematic Review and Meta-Analysis*, Eliza, Fai & Chung, **Rec. Pat. Inflamm. Aller. Drug Disc.** 2012; 6:78-87.

*Augmentation of Various Immune Reactivities of Tumour-Bearing Hosts with an Extract of Cordyceps sinensis*, Yamaguchi, Yoshida, Ren et al., **Biotherapy** 1990; 2 (3): 199-205.

*Evidence That Naturopathic Therapy Including Cordyceps sinensis Prolongs Survival of Patients with Hepato-cellular Carcinoma*, Matsuura, Murakami, sasto, et al., **Integr. Cancer Ther.** 2012; Apr. 26 [Epub before print].

*Ganoderma lucidum Inhibits Proliferation of Human Breast Cancer Cells by Down-Regulation of Estrogen Receptor and Nf-kappaB Signalling*, Jiang, Slivova & Sliva, **Int. J. Oncol.** 2006; 29: 695-703.

*Ganoderic Acids Suppress Growth and Invasive Behaviour of Breast Cancer Cells by Modulating AP-1 and NF-kappaB Signalling*, Jiang, Grieb, Thyagarajan & Sliva, **Int. J. Mol. Med.** 2008; 21: 577-584.

*Ganoderma lucidum Inhibits Proliferation and Induces Apoptosis in Human Prostate Cells PC-3*, Jiang, Slivova, Valachovicova, et al., **Int. J. Oncol.** 2004; 24: 1093-1099.

*Ganoderma lucidum (Reishi Mushroom) for Cancer Treatment (Review)*, Jin, Beguerie, Sze & Chan, **Cochrane Collaboration** 2012 ;6: 1-38.

*Supplements for Immune Enhancement in Hematological Malignancies*, Sze ,Chan, **Hematology** 2009; 313-319.

### OMEGA 3 OILS

*Modulation of Angiogenesis by Omega-3 Polyunsaturated Fatty Acids is Mediated by Cyclooxygenases*, Szymczak, Murray & Petrovic, **Blood** 2008; 111 (7): 3514-3521.

*N-3 Fatty Acids, Cancer and Cachexia: A Systematic Review of the Literature*, Colomer, Moreno-Nogufeira, Garcia-Luna, et al., **Br. J. Nutr.** 2007; 975: 823-831.

*Dietary Omega-3 Fatty Acids, Cyclooxygenase-2 Genetic Variation, and Aggressive Prostate Cancer Risk*, Fradet, Cheng, Casey & Witte, **Clin Cancer Res.** 2009; 15 (7): 2559-2566.

*Prevention and Treatment of Pancreatic Cancer by Curcumin in Combination with Omega-3 Fatty Acids*, Swamy, Citineni, et al, **Nutr. Cancer** 2008; 60 Suppl. 1: 81-89.

*Omega 3 Fatty Acids: Biological Activity and Effects on Human Health*, La Guardia, Giannanco, Di Majo, et al., **Panminerva Med.** 2005; 47 (4): 245-257.

*Effect of Eicosapentaenoic Acid, Protein and Amino Acids on Protein Synthesis and Degradation in Skeletal Muscle of Cachectic Mice*, Smith, Greenberg & Tisdale, **Br. J. Cancer** 2004; 91 (2): 408-412.

*Role of Omega-3 Fatty Acid Supplementation in Inflammation and Malignancy*, Jho, Cole, Lee & Espat, **Integr. Cancer Ther.** 2004; (2): 98-111.

*Cytotoxic Drugs Efficacy Correlates with Adipose Tissue Docosahexaenoic Acid Level in Locally Advanced Breast Carcinoma*, Bougnoux, Germain, Chajes, et al., **Br. J. Cancer** 1999; 79 (11-12): 1765-1769.

*Complementary Actions of Docosahexaenoic Acid and Genistein on COX-2, PGE2 and Invasiveness in MDA-MB-231 Breast Cancer Cells*, Horia E, Watkins BA. **Carcinogenesis** 2007; 28 (4): 809-815.

*n-3 PUFAs Modulate T-cell Activation via Protein Kinase C-alpha and -epsilon and the NF-kappaB Signaling Pathway*, Denys , Hichami & Khan, **J. Lipid Res.** 2005; 46 (4): 752-758.

*n-3 Fatty Acids, Inflammation, and Immunity: Relevance to Post-surgical and Critically Ill Patients*, Calder, **Lipids** 2004; 39 (12): 1147-1161.

*Impact of Post-operative Omega-3 Fatty Acid-Supplemented Parenteral Nutrition on Clinical Outcomes and Immuno-modulations in Colorectal Cancer Patients*, Liang, Wang, Ye, et al., **World J. Gastroenterol.** 2008; 14 (15): 2434-2439.

*High Omega-3 Fat Intake Improves Insulin Sensitivity and Reduces CRP and IL6, But Does Not Affect Other Endocrine Axes in Healthy Older Adults*, Tsitouras, Gucciardo, Salbe, et al., **Horm. Metab. Res.** 2008; 40 (3): 199-205.

*Nutritional Intervention with Omega-3 Fatty Acids in a Case of Malignant Fibrous Histiocytoma of the Lungs*, Pardini, Wilson, Schiff, Bajo & Pierce, **Nutr. Cancer** 2005; 52 (2): 121-129.

*Dietary Omega-3 Fatty Acids, Cyclo-oxygenase-2 Genetic Variation, and Aggressive Prostate Cancer Risk*, Fradet, Cheng, Casey & Witte, **Clin. Cancer Res.** 2009; 15 (7): 2559-2566.

*The Potential for Treatment with Dietary Long-chain Polyunsaturated n-3 Fatty Acids During Chemotherapy*, Biondo, Brindley, Sawyer & Field, **J. Nutr. Biochem.** 2008; 1912: 787-796.

*Chemoprotective and Renal Protective Effects for Docosahexaenoic Acid (DHA): Implications of CRP and Lipid Peroxides*, Elmesery, et al., **Cell Div.** 2009; 4 (1): 6.

*Omega-3 Fatty Acids Can Improve Radioresponse Modifying Tumour Interstitial Pressure, Blood Rheology and Membrane Permeability*, Baronzio, Freitas, Griffini et al., **Anticancer Res.** 1994; 14 (3A): 1145-1154

*Neuroblastoma Cell Death in Response to Docosahexaenoic acid: Sensitization to Chemotherapy and Arsenic-Induced Oxidative Stress*, Lindskog, Gleissman, Ponthan et al., **Int. J. Cancer** 2006; 118 (10): 2584-2593.

*Differential Sensitization of Cancer Cells to Doxorubicin by DHA: A Role for Lipoperoxidation*, Maheo, Vibet, Steghens et al., **Free Radic. Biol. Med.** 2005; 39 (6): 742-751.

*Cytotoxic Drugs Efficacy Correlates with Adipose Tissue Docosahexaenoic Acid Level in Locally Advanced Breast Carcinoma*, Bougnoux, Germain, Chajes et al., **Br. J. Cancer** 1999; 79 (11-12): 1765-1769.

*Sensitization by Docosahexaenoic Acid (DHA) of Breast Cancer Cells to Anthracyclines Through Loss of Glutathione Peroxidase (GPx1) Response*, Vibet, Goupille, Bougnoux, et al., **Free Radic. Biol. Med.** 2008; 44 (7): 1483-1491.

*Phase II Study of High-Dose Fish Oil Capsules for Patients with Cancer-Related Cachexia*, Burns, Halabi, Clamon, et al., **Cancer** 2004; 101: 370-378.

*The Effect of Dietary Omega-3 Polyunsaturated Fatty Acids on T-lymphocyte Subsets of Patients with Solid Tumours*, Gogos, Ginopoulos, Zoumbos, et al., **Cancer Detect. & Prev.** 1995; 19 (5): 415-417.

*Effect of a Protein and Energy Dense N-3 Fatty Acid Enriched Oral Supplement on Loss of Weight and Lean Tissue in Cancer Cachexia: A Randomised Double Blind Trial*, Fearon, Von Meyenfeldt, Moses, et al., **Gut** 2003; 52 (10): 1479-1486.

*Improving Outcome of Chemotherapy of Metastatic Breast Cancer by Docosahexaenoic Acid: A Phase II Trial*, Bougnoux, Hajjaji, Ferrasson, et al., **Brit. J. Cancer** 2009; 101, 1978 – 1985.

*Polyunsaturated fatty Acids Potentiate Cytotoxicity of Cisplatin in A549 Cells*, Zajdel, Wilcozok, Latocha, et al., **Acta Polon. Pharm. Drug Res.** 2014; 71 (6): 1060-1065.

*Modulation of Inflammation and Cytokine Production by Dietary (n-3) Fatty Acids*, Blok, Katan & van der Meer, **J. Nutr.** 1996; 126 (6): 1515-1533.

*Effect of Dietary Fish Oil on Development and Selected Functions of Murine Inflammatory Macrophages*, Hubbard, Somers & Erikson, **J. Leukoc. Biol.** 1991; 49: 592.

*Enteral (Oral or Tube Administration) Nutritional Support and Eicosapentaenoic Acid in Patients with Cancer: A Systematic Review*, Elia, Van Bokhorst-de van der Schueren, Garvey, et al., **Int. J. Oncol.** 2006; 28 (1): 5-23.

*Antitumour Activity of Fish Oils Against Human Lung Cancer is Associated with Altered Formation of PGE<sub>2</sub> and PGE<sub>3</sub> and Regulation of Akt Phosphorylation*, Yang, Chan, Cartwright, et al., **5th AACR Int. Conf. Frontiers Cancer Prev. Res.** 2006.

*Dietary Omega-3 Polyunsaturated Fatty Acids Plus Vitamin E Restore Immunodeficiency and Prolong Survival for Severely Ill Patients with Generalized Malignancy: A Randomized Control Trial*, Gogos, Ginopoulos, Salsa, et al., **Cancer** 1998; 82 (2): 395-402.

*Dietary n-3 Polyunsaturated Fatty Acids Enhance Metastatic Dissemination of Murine T Lymphoma Cells*, Mannini, Kerstin, Calorini, et al., **Br. J. Nutr.** 2009; 102 (7): 958-961.

*Marine Fatty Acid Intake Is Associated with Breast Cancer Prognosis*, Patterson, Pierce, et al, **J. Nutr.** 2010 Dec 22; [Epub ahead of print].

*Mechanism of Attenuation of Skeletal Muscle Protein Catabolism in Cancer Cachexia by Eicosapentaenoic Acid*, Whitehouse, Smith, Drake & Tisdale, **Cancer Res.** 2001; 61 (9): 3604-3609.

*Supplementation with Fish Oil Increases First-Line Chemotherapy Efficacy in Patients with Advanced NonSmall Cell Lung Cancer*, Murphy, Mourtzakis, Chu, et al., **Cancer** 2011 Feb 15. doi: 10.1002/cncr.25933. [Epub ahead of print]

*Fish Oil Prevents Breast Cancer Cell Metastasis to Bone*, Mandal, Ghosh-Choudhury, Yoneda, et al., **Biochem. Biophys. Res. Comm.** 2010; 402: 602–607.

*Phase I Clinical Study of Fish Oil Fatty Acid Capsules for Patients with Cancer Cachexia: Cancer and Leukemia Group B Study 9473*, Burns, Halabi, Clamon, et. al., **Clin. Cancer Res.** 1999; 5: 3842–3947.

*Omega-3 Fatty Acids are Protective Against Paclitaxel-Induced Peripheral Neuropathy: A Randomized Double-Blind Placebo Controlled Trial*, Ghoreishi, Esfahani, Djazayeri, et al., **BMC Cancer**. 2012; 12: 355.

## PHYTOESTROGENS & SOY

*Phytoestrogens and Antioxidants – Bits of Experimental Evidence*, Mariani, **Medscape General Medicine** 01/24/2005

*Phytoestrogens in Botanical Dietary Supplements: Implications for Cancer*, Piersen, **Integr. Cancer Ther.**, 2003; 2 (2): 120-138.

*Dietary Phytoestrogen Intake – Lignans, Isoflavones – and Breast Cancer Risk (Canada)*, Cotterchio, Boucher, Kreiger, et al., **Cancer Causes & Control** 2008; 193: 259-272.

*Effects of Commercially Available Soy Products on PSA in Androgen-Deprivation-Naïve and Castration-Resistant Prostate Cancer*, Joshi, Agostino, Gingrich, et al., **South Med. J.** 2011; 104(11): 736-740.

*Inhibitory Effect of Isoflavones on Prostate Cancer Cells and PTEN Gene*, Cao, Jin & Zhou, **Biomed. Environ. Sci.** 2006; 19 (1): 35-41.

*Induction of Apoptosis in Low to Moderate Grade Human Prostate Carcinoma by Red Clover-Derived Dietary Isoflavones*, Jarred, Keikha, Dowling, et al., **Cancer Epidemiol. Biomarkers Prev.** 2002; 11 (12): 1689-1696.

*Multi-Targeted Therapy of Cancer by Genistein*, Banerjee, Li, Wang & Sarkar, **Cancer Lett.** 2008; 269 (2): 226-242.

*Xenoestrogens Modulate Vascular Endothelial Growth Factor Secretion in Breast Cancer Cells Through an Estrogen Receptor-dependent Mechanism*, Buteau-Lozano, Velasco, Cristofari, et al., **J. Endocrinol.** 2008; 196 (2): 399-412.

*Soy Food Intake and Breast Cancer Survival*, Shu, Zheng, Cai, et al., **JAMA** 2009; 302: 2437-2443.

*Potentiation of the Effect of Erlotinib by Genistein in Pancreatic Cancer: The Role of Akt and Nuclear Factor-kappaB*, E-Rayes, Ali, Ali, et al., **Cancer Res.** 2006; 66 (21): 10553-10559.

*Effect of Soybean on Breast Cancer According to Receptor Status: A Case-Control Study in Japan*, Suzuki, Matsuo, Tsunoda, et al., **Int. J. Cancer** 2008; 123 (7): 1674-1680.

*Soy Isoflavones, Estrogen Therapy, and Breast Cancer Risk: Analysis and Commentary*, Messina & Wood, **Nutr. J.** 2008; 7: 17.

*Soy Isoflavones in Conjunction with Radiation Therapy in Patients with Prostate Cancer*. Ahmad, Forman, Sarkar, et al. **Nutr. Cancer** 2010; 627: 996-1000.

*Genestein Inhibits p38 Map Kinase Activation, Matrix Metalloproteinase Type 2, and Cell Invasion in Human Prostate Epithelial Cells*, Huang, Chen, Xu, et al., **Cancer Res.** 2005; 65 (8): 3470-3478.

*Genestein Induces Cell Growth Inhibition in Prostate Cancer Through the Suppression of Telomerase Activity*, Ouchi, Ishiguro, Ikeda, et al., **Int. J. Urol.** 2005; 12 (1): 73-80.

*Genestein Inhibits Vitamin D Hydroxylases CYP24 and CYP27B1 Expression in Prostate Cells*, Farhan, et al., **J. Steroid Biochem. Mol. Biol.** 2003; 84 (4): 423-429.

*Implications of Phytoestrogen Intake for Breast Cancer*, Duffy, Perez & Partridge, **CA Cancer J. Clin.** 2007; 57 (5): 260-277.

*Genestein Potentiates the Growth Inhibitory Effects of 1,25-dihydroxyvitamin D(3) in DU145 Human Prostate Cancer Cells: Role of the Direct Inhibition of CYP24 Enzyme Activity*, Swami, et al., **Mol. Cell Endocrinol.** 2005; 241 (1-2): 49 – 61.

*Soy-Derived Isoflavones Inhibit the Growth of Adult T-cell Leukemia Cells in vitro and in vivo*, Yamasaki, Fujita, Ishiyama, et al., **Cancer Sci.** 2007; 98 (11): 1740-1746.

*Soy for Breast Cancer Survivors: A Critical Review of the Literature*. Messina, Loprinzi. **J. Nutr.** 2001; 131: 3095S-3108S.

*Addressing the Soy and Breast Cancer Relationship: Review, Commentary, and Workshop Proceedings*, Messina M, McCaskill-Stevens W, Lampe JW. **J. Natl. Cancer Inst.** 2006; 98 (18): 1275-1284.

*Point-Counterpoint: Soy Intake for Breast Cancer Patients*, Block, Constantinou, Hilakivi-Clarke et al., **Integr. Cancer Ther.** 2002; 1 (1): 90-100.

*Various Doses of Soy Isoflavones Do Not Modify Mammographic Density in Postmenopausal Women*, Masarinec, Verheus, Steinberg et al., **J. Nutr.** 2009; 139 (5): 981-986.

*Dietary Intake of Isoflavones and Breast Cancer Risk by Estrogen and Progesterone Receptor Status*, Zhang, Yang & Holman, **Breast Cancer Res. Treat.** 2009; Epub Feb. 28, 2009; DOI 10.1007/s10549-009-0354-9.

*Dietary Soy Intake and Breast Cancer Risk*, Enderlin, Coleman, Stewart & Hakkak, **Oncol. Nurs. Forum** 2009; 36 (5): 531-539.

*Soy Food Intake After Diagnosis of Breast Cancer and Survival: An In-Depth Analysis of Combined Evidence from Cohort Studies of US and Chinese Women*, Neschuta, Caan, Chen, et al., **Amer. J. Clin. Nutr.** 2012; 96: 123-132.

*Positive Effects of Soy Isoflavone Food on Survival of Breast Cancer Patients in China*, Zhang, Kang, Li & Zhang, **Asian Pac. J. Cancer Prev.: Apjcp.** 2012; 132: 479 - 482.

*Effects of Diverse Dietary Phytoestrogens on Cell Growth, Cell Cycle and Apoptosis in Estrogen-Receptor Positive Breast Cancer*, Sakamoto, Horiguchi, Oguma & Kayama, **J. Nutr. Biochem.** 2009; Oct 2. [Epub ahead of print] PMID: 19800779.

*Flaxseed and its Lignans Inhibit Estradiol-induced Growth, Angiogenesis, and Secretion of Vascular Endothelial Growth Factor in Human Breast Cancer Xenografts in vivo*, Bergman, Jungeström, Thompson & Dabrosin, **Clin. Cancer Res.** 2007; 13 (3): 1061-1067.

*Dietary Lignan Intakes in Relation to Survival Among Women with Breast Cancer: The Western New York Exposures and Breast Cancer (WEB) Study*, McCann, Thompson, Nie, et al., **Breast Cancer Res. Treat.** 2010; 122 (1): 229-235.

*Biological Effects of Dietary Flaxseed in Patients with Breast Cancer*, Thompson et al. **Breast Cancer Res. Treat.** 2000; 64 (1): 50, A157

*Effects of a Flaxseed Mixture and Plant Oils Rich in Alpha-linolenic Acid on the Adenoma Formation in Multiple Intestinal Neoplasia (Min) Mice*, Oikarinen, Pajari, Salminen et al., **Br. J. Nutr.** 2005; 94 (4): 510-518.

*Dietary Flaxseed Inhibits Human Breast Cancer Growth and Metastasis and Down-Regulates Expression of Insulin-Like Growth Factor and Epidermal Growth Factor Receptor*, Chen, et al., **Nutr.Cancer** 2002;43:187-192.

#### POMEGRANATE & ELLAGIC ACID

*Pomegranate Extract Inhibits Androgen-Independent Prostate Cancer Growth Through a Nuclear Factor Kappa-B Dependent Mechanism*, Rettig, et al., **Mol. Cancer Ther.** 2008; 7 (9): 2662-2671.

*In vitro Anti-Proliferative, Apoptotic and Antioxidant Activities of Punicalagin, Ellagic Acid and a Total Pomegranate Tannin Extract are Enhanced in Combination with other Polyphenols as Found in Pomegranate Juice*, Seeram, Adams, Henning, et al., **J. Nutr. Biochem.** 2005; 16 (6): 360-367.

*Pomegranate Polyphenols Down-regulate Expression of Androgen-synthesizing Genes in Human Prostate Cancer Cells Over-expressing the Androgen Receptor*, Young, Hong, Seeram & Heber, **J. Nutr. Biochem.** 2008; 19 (12): 848-855.

*Ellagic Acid Induces Apoptosis Through Inhibition of Nuclear Factor Kappa B in Pancreatic Cancer Cells*, Edderkaoui, Odinokova, Ohno, et al., **World J. Gastroenterol.** 2008; 14 (23): 3672-3680.

*Combined Inhibition of PDGF and VEGF Receptors by Ellagic Acid, a Dietary-derived Phenolic Compound*, Labrecque, Lamy, Chapus, et al., **Carcinogenesis** 2005; 26 (4): 821-826.

*In vitro Anti-proliferative Activities of Ellagic Acid*, Losso, Bansode, Trappey, et al., **J. Nutr. Biochem.** 2004; 15 (11): 672-678.

*Support Ellagic Acid Therapy in Patients with Hormone Refractory Prostate Cancer (HRPC) on Standard Chemotherapy Using Vinorelbine and Estramustine Phosphate*, Falsaperla, Morgia, Tartarone, et al., **Eur. Urol.** 2005; 47 (4): 449-454.

*Berry Phytochemicals, Genomic Stability and Cancer: Evidence for Chemoprotection at Several Stages in the Carcinogenic Process*, Duthie, **Mol. Nutr. Food Res.** 2007; 51 (6): 665-674.

*Phase II Study of Pomegranate Juice for Men with Rising Prostate-Specific Antigen Following Surgery or Radiation for Prostate Cancer*, Pantuck, Leppert, Zomorodian, et al., **Clin. Cancer Res.** 2006; 12 (13): 4018-4026.

## PREVENTION

*Molecular Targets of Phytochemicals for Cancer Prevention*, Lee, Bode & Dong, **Rev. Cancer** 2011; 11 (3): 211-218.

*Prostate Cancer Prevention by Nutritional Means to Alleviate Metabolic Syndrome*, Barnard, **Amer. J. Clin. Nutr.** 2007; 863, s. 889-893.

*Chemoprevention of Human Prostate Cancer by Oral Administration of Green Tea Catechins in Volunteers with High-grade Prostate Intraepithelial Neoplasia, A Preliminary Report from a One-year Proof-of-Principle Study*, Betuzzi, Brausi, Rizzi & Castagnetti, **Cancer Res.** 2006; 66 (2): 1234-1240.

*Resveratrol: a Candidate Nutritional Substance for Prostate Cancer Prevention*, Stewart, Artime & O'Brian, **J. Nutr.** 2003; 133 (7 Suppl.): 2440S-2443S.

*Cancer Prevention – the Easy Choices*, McKinney, **Alive - Canadian Journal of Health & Nutrition**, April 2005; 270: 48-53.

*How to Prevent and Treat Cancer with Natural Medicine*, Murray, Birdsall, Pizzorno & Reilly, **Riverhead Books**, 2002.

*Antioxidant Vitamin and Mineral Supplementation May Help Prevent Prostate Cancer* Meyer, et al., **Int. J. Cancer**, 2005; 116: 182-186.

*Herbicides and Non-Hodgkins Lymphoma: New Evidence from a Study of Saskatchewan Farmers*, Blair, **J. Int. Cancer Inst.** 1990; 85: 544-545.

*Childhood Brain Tumours, Residential Insecticide Exposure, and Pesticide Metabolism Genes*, Searles Nielsen, McKean-Cowdin, Federico, et al., **Envir. Health Perspect.** 118:144–149 (2010).

*EcoCancers: Do Environmental Factors Underlie a Breast Cancer Epidemic?* Raloff, **Sci. News** 1993;144:10-13.

*Paraben Esters: Review of Recent Studies of Endocrine Toxicity, Absorption, Esterase and Human Exposure, and Discussion of Potential Human Health Risks*, Darbe & Harvey, **J. Appl. Toxicol.** 2008; 285: 561-578.

*Coffee Consumption and the Risk of Oral, Pharngeal and Esophageal Cancers in Japan: The Miyagi Cohort Study*, Naganuma, Kuriyama, Kakizaki, et al., **Am. J. Epidemiol.** 2008; 16812: 1425-1432.

*Red Meat Intake, Doneness, Polymorphisms in Genes that Encode Carcinogen-metabolizing Enzymes, and Colorectal Cancer Risk*, Cotterchio, Boucher, Manno, et al., **Cancer Epidemiol. Biomarkers & Prev.** 2008; 1711: 3098-3107.

*Associations of Serum Concentrations of Organochlorine Pesticides with Breast Cancer and Prostate Cancer in U.S. Adults*, Xu, Dailey, Talbott, et al., **Environ. Health Perfect.** 2010; 118 (1): 60-66.

## QUERCITIN

*Antioxidants and Cancer III – Quercitin*, Lamson & Brignall, **Alt. Med. Rev.** 2000; Vol. 5 No. 6: 196-208.

*Suppression of Insulin-like Growth Factor Signalling Pathway and Collagen Expression in Keloid-derived Fibroblasts by Quercitin: It's Therapeutic Potential Use in the Treatment and/or Prevention of Keloids*, Phan, See, Tran, et al., **Br. J. Dermatol.** 2003; 148 (3): 544-552.

*Differential Responses of Skin Cancer Chemoprotective Agents Silibinin, Quercitin and Epigallocatechin 3-Gallate on Mitogenic Signalling and Cell Cycle Regulators in Human Epidermoid carcinoma A431 Cells*, Bhatia, Agarwal & Agarwal, **Nutr. & Cancer.** 2001; 39 (2): 292-299.

*Role of Mitochondria in Quercitin-Enhanced Chemotherapeutic Response in Human Non-Small Cell Lung Carcinoma H-520 Cells*, Kuhar, Sen & Singh, **Anticancer Res.** 2006; 26 (2A): 1297-1303.

*Apoptosis of Murine Melanoma B16-BL6 Cells Induced by Quercitin Targeting Mitochondria, Inhibiting Expression of PKC-alpha and Translocating PKC-delta*, Zhang, Chen, Xia & Xu, **Cancer Chemother. Pharmacol.** 2005; 55 (3): 251-262.

*Inhibition of Lung Cancer Cell Growth by Quercitin Glucoronides via G2/M Arrest and Induction of Apoptosis*, Yang, Hsia, Kuo, et al., **Drug Metab. Dispos.** 2006, 34 (2): 296-304.

*Induction of Cell-cycle Arrest and Apoptosis in Human Breast cancer Cells by Quercitin*, Choi, Kim, Lee, et al., **Int. J. Oncol.** 2001; 19 (4): 837-844.

*Quercetin Decreases Intracellular GSH Content and Potentiates the Apoptotic Action of the Antileukemic Drug Arsenic Trioxide in Human Leukemia Cell Lines*, Ramos & Aller, **Biochem Pharmacol.** 2008;75 (10):1912-1923.

*Enhanced Bioavailability of Tamoxifen after Oral Administration of Tamoxifen with Quercitin in Rats*, Shin, Choi & Li, **Int. J. Pharm.** 2006; 313 (1-2): 144-149.

*Inhibition of P-Glycoprotein by Flavonoid Derivatives (Quercitin and Morin) in Adriamycin-Resistant Human Myelogenous Leukemia (K562/ADM) Cells*, Ohtani, Koyabu, Juichi, et al., **Cancer Lett.** 2002; 177 (1): 89-93.

*Effects of Quercitin on the Cell Growth and the Intracellular Accumulation and Retention of Adriamycin*, Asaum, Matsuzaki, Kawasak, et al., **Anticancer Res.** 200; 20 (4): 2477-2483.

*Quercitin Potentiates the Effect of Adriamycin in a Multi-Drug-Resistant MCF-7 Human Breast Cancer Cell Line: P-Glycoprotein as a Possible Target*, Scambia, Ranelletti, Panici, et al., **Cancer Chemother. Pharmacol.** 1994; 34 (6): 459-464.

*Suppression of Multi-Drug Resistance Via Inhibition of Heat Shock Factor by Quercitin in MDR Cells*, Kim, Yeo, Lim, et al., **Exp. Mol. Med.** 1998; 30 (2): 87-92.

*Synergistic Antiproliferative Activity of Quercitin and Cisplatin on Ovarian Cancer Cell Growth*, Scambia, Ranelletti, Benedetti, et al., **Anticancer Drugs** 1990; 1 (1): 45-48.

*Drug Resistance Against Gemcitabine and Topotecan Mediated by Constitutive HSP-70 Over-expression in vitro: Implication of Quercitin as a Sensitiser in Chemotherapy*, Sluitz, Karlseder, Temfer, et al., **Br. J. Cancer** 1996; 74 (2): 172-177.

*Low-concentrations of Quercitin and Ellagic Acid Synergistically Influence Proliferation, Cytotoxicity and Apoptosis in MOLT-4 Human Leukemia Cells*, Mertens-Talcott, Talcott & Percival, **J. Nutr.** 2003; 133 (8): 2669-2674.

*Spontaneous Mitochondrial Membrane Potential Change During Apoptotic Induction by Quercitin in K562 and K562/adr Cells*, Kothan, Dechsupa, Leger, et al., **Can. J. Physiol. Pharmacol.** 2004, 82 (12): 1084-1090.

*Food-Derived Polyphenols Inhibit Pancreatic Cancer Growth Through Mitochondrial Cytochrome C Release and Apoptosis*, Suolinna, Buschbaum & Racker, **Cancer Res.** 1975; 35 (7): 1865-1872.

*Quercitin Induces Necrosis and Apoptosis in SCC-9 Oral Cancer Cells*, Haghia & Walle, **Nutr. Cancer** 2005; 53 (2):220-231.

*Selective Aromatase Inhibition for Patients with Androgen-independent Prostate Carcinoma*, Smith, Kaufman, George, et al., **Cancer** 2002; 95 (9): 1864-1868.

*Absorption and Disposition Kinetics of the Dietary Antioxidant Quercitin in Man*, Hollman, vd Gaag, Mengelers, et al., **Free Rad Biol Med** 1996; 21 (5): 703-707.

*Quercetin Potentiates the Effect of Adriamycin in a Multidrug-Resistant MCF-7 Human Breast-Cancer Cell Line: P-glycoprotein as a Possible Target*, Scambia, Ranelletti, Panici, et al. **Cancer Chemother. Pharmacol.** 1994; 34 (6): 459-464.

*Flavonoids: A Class of Modulators with Bifunctional Interactions at Vicinal ATP- and Steroid-Binding Sites on Mouse P-glycoprotein*, Conseil, Baubichon-Cortay, Dayan, et al., **Proc. Nat. Acad. Sci.** 1998; 95 (17): 9831-9836.

*The Synergistic Reversal Effect of Multidrug Resistance by Quercetin and Hyperthermia in Doxorubicin-Resistant Human Myelogenous Leukemia Cells*, Shen, Zhang, Wu & Zhu, **Int. J. Hyperthermia** 2008 ;24 (2): 151-159.

*Quercetin-Induced Ubiquination and Down-Regulation of Her2/neu*, Jeong, An, Kwon, et al., **J. Cell Biochem.** 2008; 105: 585-595.

*Exploiting Tyrosinase Expression and Activity in Melanocytic Tumours: Quercitin and the Central Role of p53*, Vargas, Sittajody, Thangasamy, et al., **Integr. Cancer Ther.** 2011; 10 (4): 328-340.

*Quercetin Exerts Anti-Melanoma Activities and Inhibits STAT3 Signaling*, Cao, Tse, Kwan, et al., **Biochem. Pharmacol.** 2014; 87 (3): 424-434.

*Effects of Fresh Yellow Onion Consumption on CEA, CA125 and Hepatic Enzymes in Breast Cancer Patients: A Double-Blind Randomized Controlled Clinical Trial*, Jafarpour-Sadegh, Montazeri, Adili, et al., **Asian Pac. J. Cancer Prev.** 2015; 16 (17): 7517-7522.

## RADIATION

*Timing is Everything in Combined Antiangiogenic / Radiation Therapy*, Jain, **Cancer Cell** 2004; 6: 553-563.

*Effects of Zinc Supplementation on Clinical Outcomes in Patients Receiving Radiotherapy for Head and Neck Cancers: A Double-Blinded Randomized Study*, Lin, Que, Lin, et al., **Int. J. Radiat. Oncol. Biol. Phys.** 2008; 702: 368-373.

*Curcumin – A New Radiosensitizer of Squamous Cell Carcinoma Cells*, Khafif, et al., **Otolaryngol. Head Neck Surg.**, 2005; 132: 317-321.

*The Chemopreventive Agent Curcumin is a Potent Radiosensitizer of Human Cervical Tumour Cells via Increased Reactive Oxygen Species Production and Overactivation of the Mitogen-Activated Protein Kinase Pathway*, Javvadi, Segan, Tuttle & Koumenis, **Mol Pharmacol.** 2008 May; 73 (5): 1491-501.

*Curcumin Induces Chemo/Radio-Sensitization in Ovarian Cells and Curcumin Nanoparticles Inhibit Ovarian Cancer Cell Growth*, Yallapu, Maher, Sundram, et al., **J. Ovar. Res.** 2010; 3: 11.

*ARCON (Accelerated Radiotherapy with Carbogen and Nicotinamide): A Novel Biology-Based Approach in Radiotherapy* Kanders, Bussink & van der Kogel, **Lancet Oncol.** 2002; 3 (12): 728-737.

*Accelerated Radiotherapy with Carbogen and Nicotinamide (ARCON) for Laryngeal Cancer*, Kaanders, Pop, Marres, et al., **Radiother. Oncol.** 1998; 48 (2): 115-122.

*The Potentiation of Radiation Damage by Nicotinamide in the SCCVII Tumour in vivo*, Horsman, Wood,, Chaplin, et al., **J. Radiother Oncol.** 1990; 18 (1): 49-57.

*Radiosensitization by Nicotinamide in vivo: A Greater Enhancement of Tumour Damage Compared to That of Normal Tissue*, Horsman, Chaplin & Brown, **Rad. Res.** 1987; 109: 479-489.

*Mechanism of Action of the Selective Tumour Radio-Sensitizer Nicotinamide*, Horsman, Brown, et al, **Int. J. Rad. Onc. Biophys.** 1988; 15: 685-690.

*Nicotinamide and Other Benzamide Analogs as Agents for Overcoming Hypoxic Cell Radiation Resistance in Tumours. A Review*, Horsman, **Acta Oncol.** 1995; 34 (5): 571-587.

*Do Antioxidants Interfere with Radiation Therapy for Cancer?* Moss, **Integr. Cancer Ther.** 2007; 6 (3): 281-292.

*Should Patients Undergoing Chemotherapy and Radiotherapy Be Prescribed Antioxidants?*, Moss, **Integr. Cancer Ther.** 2006; 5 (1): 63-82.7

*Antioxidants and Radiation Therapy*, **J. Nutr.** Borek, 2004; 134: S3207-S-3209.

*Acute Adverse Effects of Radiation Therapy and Local Recurrence in Relation to Dietary and Plasma Beta Carotene and Alpha Tocopherol in Head and Neck Cancer Patients*, Meyer, Bairati, Jobin, et al., **Nutr. Cancer** 2007; 59 (1): 29-35.

*Dietary Counselling Benefits Patients Undergoing Radiotherapy*, Ravasco. et al., **J. Clin. Oncol.** 2005; 23: 1348-1349, 1431-1438.

*Effect of Concomitant Naturopathic Therapies on Clinical Tumour Response to External Beam Radiation Therapy for Prostate Cancer (Abstract)*, Birdsall, Alschuler, Martin, et al., **Soc. Integr. Oncol.** Nov. 2006, Boston, Mass.

*Effect of Complementary Alternative Medical (CAM) Therapy on Tumour Response in Prostate Cancer Patients Treated with Radiation Therapy*, Cain, Flynn, Kelly, et al., **J. Clin. Oncol.** 2007; 25: 15585.

*Potential for Combined Modality Therapy of Cyclooxygenase Inhibitors and Radiation*, Saha & Choy, **Prog Exp Tumour Res.** 2003; 37: 193-209.

*Long-Term Use of Cellular Phones and Brain Tumours: Increased Risk Associated with Use for >=10 Years*, Hardell, Carlberg, Soderqvist, et al., **Occup. Envir. Med.** 2007; 64 (9): 626-632.

*Oral Vitamin A Therapy for a Patient with a Severely Symptomatic Post-Radiation Anal Ulceration*, Levitsky, Hong, Jani & Ehrenpreis, **Dis Colon Rectum** 2003; 46 (5): 679- 682.

*Phase I Study of Concurrent Radiotherapy with TS-1 and Vitamin A (TAR Therapy) for Head and Neck Cancer*, Nakashima, Kuramoti, Yamamoto, et al., **Gan To Kagaku Ryoho** 2005; 32 (6): 803-807.

*Sensitization of Cervical Cancer Cell Lines to Low-Dose Radiation by Retinoic Acid Does Not Require Functional p53*, Tillmanns, Kamelle, Guruswamy, et al., **Gynecol Oncol** 2005; 97 (1): 142-150.

*Supplemental Vitamin A Prevents the Acute Radiation-Induced Defect in Wound Healing*, Levenson, Gruber, Rettura, et al., **Ann Surg** 1984; 200 (4): 494-512.

*Protective Effects of Berberine on Radiation-Induced Lung Injury via Intercellular Adhesion Molecular-1 and Transforming Growth Factor-beta-1 in Patients with Lung Cancer*, Liu, Yu, Zhang, et al., **Eur. J. Cancer** 2008; 44 (16): 2425-2432.

*Protective Effect of Vitamin A on Acute Radiation Injury in the Small Intestine*, Beyzadeoğlu, Balkan, Demiriz, et al., **Radiat. Med.** 1997; 15 (1): 1-5.

*Randomized Trial of Antioxidant Vitamins to Prevent Acute Adverse Effects of Radiation Therapy in Head and Neck Cancer Patients*, Bairati, Meyer, Gélinas, et al., **J. Clin. Oncol.** 2005; 23 (24): 5805-5813.

*Arachidonic Acid Metabolites Mediate the Radiation-Induced Increase in Glomerular Albumin Permeability*, Sharma, McCarthy, Sharma, et al., **Exp. Biol. Med.** 2006; 231: 99-106.

*Enhanced Radiosensitivity of Rat Autochthonous Mammary Tumours by Dietary Docosahexaenoic Acid*, Colas, Paon, Denis, et al., **Int. J. Cancer** 2004; 109 (3): 449-454.

*[Omega-3 Fatty Acid-containing Diet (Racol) Reduces Toxicity of Chemo-radiation Therapy for Patients with Esophageal Cancer]*, Minami, Miyata, Doki, et al., **Gan To Kagaku Ryoho** 2008; 35 (3): 437-440.

*Aloe vera for Preventing Radiation-Induced Skin Reactions: A Systematic Literature Review*, Richardson, Smith, McIntyre, et al., **Clin. Oncol (R. Coll. Radiol.)**. 2005; 17 (6): 478-484.

*Prevention of Chemotherapy and Radiation Toxicity with Glutamine*, Savarese, Savy, Vahdat, et al., **Cancer Treat. Rev.** 2003; 29 (6): 501-513.

*Successful and Sustained Treatment of Chronic Radiation Proctitis with Antioxidant Vitamins E and C*, Kennedy, Brunninga, Mutlu, et. al., **Am. J.Gastroenterol.** 2001; 96 (4): 1080-1084.

*D-Alpha-Tocopherol Succinate(Vitamin E) Enhances Radiation-Induced Chromosomal Damage Levels In Human Cancer Cells, But Reduces It In Normal Cells*, Kumar, Jha, Cole, et al., **J. Amer. Coll Nutr.** 2002; 21 (4): 339-343.

*Randomized Phase II Trial of High-Dose Melatonin and Radiation Therapy for RPA Class 2 Patients with Brain Metastases (RTOG 0119)*, Berk, Berkey, Rich et al., **Int. J. Radiat. Oncol. Biol. Phys.** 2007 Jul 1;68(3):852-7. Epub 2007 Apr 6.

*Oral Glutamine to Alleviate Radiation-Induced Oral Mucositis: A Pilot Randomized Trial*, Huang, Leung, Wang, et al., **Int. J. Radiat. Oncol. Biol. Phys.** 2000; 46 (3): 535-539.

*Prevention of Chemotherapy and Radiation Toxicity with Glutamine*, Savarese, Savy, Vahdat, et al., **Cancer Treat. Rev.** 2003; 29 (6): 501-513.

*Interferon-Gamma Links Ultraviolet Radiation to Melanomagenesis in Mice*, Zaidi, Davis, Noonan, et al., **Nature** 2010, DOI: 10.1038/nature09666.

*Soy Isoflavones in Conjunction with Radiation Therapy in Patients with Prostate Cancer*. Ahmad, Forman, Sarkar, et al. **Nutr. Cancer** 2010; 627: 996-1000.

*The Effect of Naturopathic and Nutritional Supplement Treatment on Tumour Response, Control, and Recurrence in Prostate Cancer Patients Treated with Radiation Therapy*, Braun, Gupta, Birdsall, et al., **J. Altern. Compl. Med.** 2012 (In Press)

*Case Report of Long Term Complete Remission of Metastatic Renal Squamous Cell Carcinoma after Palliative Radiotherapy and Adjuvant Dichloroacetate*, Akbar Khan, **Adv. Cancer: Res. & Treat.** 2012; Article ID 441895, 7 pages . DOI: 10.5171/2012.441895

*Phase II Study of Ginkgo Biloba in Irradiated Brain Tumour Patients: Effect on Cognitive Function, Quality of Life, and Mood*, Attia, Rapp, Case, et al., **J. Neurooncol.** 2012; 1092: 357 - 363.

*Phase III Randomized Trial of Calendula officinalis Compared with Trolamine for the Prevention of Acute Dermatitis During Irradiation for Breast Cancer*, Pommier, Gomez, Sunyach, et al., **J. Clin. Oncol.** 2004; 22 (8): 1447-1453.

*Role of IGF-1 Receptor in Radiation Response*, Valenciano, Henríquez-Hernández, Moreno, et al., **Transl. Oncol.** 2012; 5: 1-9.

*Targeting the Insulin Growth Factor Receptor 1*, Arnaldez & Helman, **Hematol. Oncol. Clin. North Am.** 2012; 26 (3): 527-542. doi:10.1016/j.hoc.2012.01.004.

*Metformin Ameliorates Ionizing Irradiation-Induced Long-Term Hematopoietic Stem Cell Injury In Mice*, Xu, Wu, Zhang, et al., **Free. Radic. Biol. Med.** 2015; S0891-5849(15)00268-3. doi: 10.1016/j.freeradbiomed.2015.05.045.

*Impact of Glycemia on Survival of Glioblastoma Patients Treated with Radiation and Temozolomide*, Tieu, Lovblom, McNamara, et al., **J. Neurooncol.** 2015; 124: 119–126.

*Berberine Enhances Radiosensitivity of Esophageal Squamous Cancer by Targeting HIF-1 $\alpha$  In Vitro and In Vivo*, Yang, Yang, Cai, et al., **Cancer Biol. Ther.** 2013; 14 (11): 1068–1073.

*Curcumin Stimulates the Antioxidant Mechanisms in Mouse Skin Exposed to Fractionated  $\gamma$ -Irradiation*, Jagetia & Rajanikant, **Antioxidants** (Basel). 2015; 4 (1): 25–41.

*Relationship and Interactions of Curcumin with Radiation Therapy*, Verma, **World J. Clin. Oncol.** 2016; 7 (3): 275-283.

## STEM CELLS & IMMUNE CELLS

*Insights into Breast Cancer Heterogeneity – Stem Cells*, Skinner, **Nat. Rev. Cancer** 2010; 10 (3): 163.  
*Tumour Stem Cells: Rooting Out Resistance*, Rich, et al., **Nat. Rev. Cancer** 2006; 6 (12): 904-905. Medscape article 550020

*On Mammary Stem Cells*, Woodward, Chen, Behbod & Rosen, **J. Cell Sci.** 2005; 118: 3585-3594.  
*Cancer Stem cells: Are We Missing the Target? – Commentary*, Jones, Matsui & Smith, **J. Natl. Cancer Inst.** 2004; 96 (8): 583-585.

*Cancer Stem Cells - Review*, Jordan, Guzman & Noble, **NEJM** 2006; 355 (12): 1253-1261.  
*The Paradox of Response and Survival in Cancer Therapeutics*, Huff, Matsui, Smith & Jones, **Blood** 2006; 107: 4321-434.

*Bone Marrow Derived Cells & Cancer – An Opportunity for Improved Therapy*, Houghton, **Nat. Clin. Pract. Oncol.** 2007; 4 (1): 2-3. Medscape article 551187

*Will Cancer Stem Cell Provide New Therapeutic Targets?- Review*, Behbod & Rosen, **Carcinogenesis** 2004; 26 (4): 703-711.

*The Lymphovascular Embolus of Inflammatory Breast Cancer Expresses a Stem Cell-Like Phenotype*, Xiao, Ye, Yearsley, et al., **Amer. J. Pathol.** 2008; 173 (2): 561-574.

*Leukaemia Stem Cells & the Evolution of Cancer Stem Cell Research*, Huntley & Gilliland, **Nat. Rev. Cancer** 2005; 5: 311-321.

*Human Pancreatic Cancer Stem Cells Identified*, Simenone, et al., **Cancer Res.** 2007 Medscape article 551581

*Targeting Breast Stem Cells with the Cancer Preventive Compounds Curcumin and Piperine*, Kakarala, Brenner, Korkaya, et al., **Breast Cancer Res. Treat.** 2009 [Epub ahead of print] PMID: 19898931

*Variation in Cancer Risk Among Tissues Can Be Explained by the Number of Stem Cell Divisions*, Tomasetti & Vogelstein, **Science** 2015; 347 (6217): 78-81.

*Brain Tumour Cells Lurk in Perivascular Niches*, Gilbertson, **Cancer Cell** 2007; 11: 3-5, 69-82. Medscape article 551315.

*Bone Morphogenetic Proteins Inhibit the Tumourigenic Potential of Human Brain Tumour-initiating Cells*, Piccirillo & Vescovi, **Nature** 2006; 444: 761-765.

*Brain Tumour Stem Cells*, Vescovi, Galli, and Reynolds, **Nat. Rev. Cancer** 2006; 6 (1): 425-436.

*Relation of Tumour Associated Macrophages and Mast Cells of Tumour Interstitium and Angiogenesis in Non-Small Cell Lung Cancer*, Zou & Hu, **Zhong Nan Da Xue Xue Bao** 2007; 32 (6):1037-1041.

*Association of Macrophages, Mast Cells and Eosinophil Leukocytes with Angiogenesis and Tumour Stage in Non-Small Cell Lung Carcinomas (NSCLC)*, Tataroğlu, Kargı, Ozka, et al., **Lung Cancer** 2004; 43 (1): 47-54.

*Inflammatory Cell Infiltration of Tumours: Jekyll or Hyde*, Talmadge, Donkor & Scholar, **Cancer Metastasis Rev.** 2007; 26 (3-4): 373-400.

*Human Macrophages Promote the Motility and Invasiveness of Osteopontin-Knockdown Tumour Cells*, Cheng, Huo, Kuang, et al., **Cancer Res.** 2007; 67( 11): 5141-5147.

*Dynamics of the Immune Reaction to Pancreatic Cancer from Inception to Invasion*, Clark, Hingorani , Mick, et al., **Cancer Res.** 2007;67 (19): 9518-9527.

*Increased Expression of Human Macrophage Metalloelastase (MMP-12) is Associated with the Invasion of Endometrial Adenocarcinoma*, Yang, Dong, Zhao,et al., **Pathol Res Pract.** 2007; 203 (7): 499-505. Epub 2007 Jun 14.

*Role of Tumour-Associated Macrophages in Tumour Progression and Invasion*, Mantovani, Schioppa, Porta, et al., **Cancer Metastasis Rev.** 2006;25( 3): 315-322.

*Co-Opting Macrophage Traits in Cancer Progression: A Consequence of Tumour Cell Fusion?* Pawelek, Chakraborty, Lazova, et al., **Contrib Microbiol.** 2006; 13: 138-155.

*Macrophages: Obligate Partners for Tumour Cell Migration, Invasion, and Metastasis*, Condeelis & Pollard, **Cell** 2006;124 (2): 263-266.

*Prostate Cancer: Genes, Environment, Immunity and the Use of Immunotherapy*, Karan, Thrasher & Lubaroff, **Prostate Cancer Prostatic Dis.** 2008; 11 (3): 230-236.

*ER Alpha Status of Disseminated Tumour Cells in Bone Marrow of Primary Breast Cancer Patients*, Fehm, Krawczyk, Solomayer, et al., **Breast Cancer Res.** 2008; 0 (5): R76.

*Resistance of Cancer Cells to Immune Recognition and Killing*, Lipinski & Egyud, **Med. Hypoth.** 2000; 54 (3): 456-460.

*Molecular Biology of Macrophage Activation: A Pathway Whereby Psychosocial Factors Can Potentially Affect Health*, Adams, **Psychosomat. Med.** 1994; 56: 316-327.

*Disregulation in TH1 and TH2 Subsets of CD4+ T Cells in Peripheral Blood of Colorectal Cancer Patients and Involvement in Cancer Establishment and Progression*, Pellegrini, Berghella, Del Beato, et al., **Cancer Immunol. Immunother.** 1996; 42 (1): 1-8.

*Th1/Th2 balance: The Hypothesis, Its Limitations, and Implications for Health and Disease*, Kidd, **Altern. Med. Rev.** 2003; 8(3):223-46

*Anesthesia, Surgery, and the Immune System*, Kotani, **Curr. Opin. Anesthesiol.** 1993; 6: 562-568.

*Effect of Major Dietary Modifications on the Immune System in Patients with Breast Cancer*, Garritson, Nikaein, Peters, et al., **Cancer Practice** 1995; 3 (4): 239-246.

*In vivo Effect of Ascorbic Acid on Enhancement of Human Natural Killer Cell Activity*, Vojdani & Ghoneum, **Nutr. Res.** 1993; 13: 753-754.

*Enhancement of Human Natural Killer Cytotoxic Activity by Vitamin C in Pure and Augmented Formulations*, Vojdani & Namatalla, **J. Nutr. Environ. Med.** 1997; 7 (3): 187-195.

*Cancer-Expanded Myeloid-Derived Suppressor Cells Induce Anergy of NK Cells Through Membrane-Bound TGF-beta 1*, Li, Han, Guo, et al., **J. Immunol.** 2009; 182 (1): 240-249.

*Toward Integrative Cancer Immunotherapy: - Targeting the Tumour Microenvironment*, Emens Silverstein & Khleif. **J. Transl. Med.** 2012; 10: 70 -75

*Epithelial-to-Mesenchymal Transition in Breast Cancer: A Role For Insulin-Like Growth Factor I and Insulin-Like Growth Factor-Binding Protein 3?*, Zielinska, Bahl, Holly & Perks, **Breast Cancer: Targ. Ther.** 2015;7: 9–19.

#### SUGAR, INSULIN & IGF, METFORMIN

*Insulin and Cancer*, Boyd, **Integr. Cancer Ther.**, 2003; 2 (4): 315-329.

*Insulin-like Growth Factor 1 Tied to Prostate Cancer Risk*, Douglas, **Medscape** 487836 8/25/04.

*Insulin-Like Growth Factor I Receptor Promotes Gastric Cancer* Adachi. et al., **Gut** 2005; 54: 591-600.

*Diabetes, High Glucose Levels Linked to Cancer in Korean Study*, Jee, et al., **JAMA** 2005; 194-202; editorial p. 235-236.

*Diabetes Triples Risk of Liver Cancer*, El-Serag, et al, **Gut**, 2005; 54: 533-539.

*Fructose, Insulin Resistance, and Metabolic Dyslipidemia*, Basciano, Federico & Adeli, **Nutr. Metab.** 2005, 2:5 doi:10.1186/1743-7075-2-5.

*Elevated IGF-1 Linked to Raised Risk of Cancer in Premenopausal Women*, Shi, et al, **Int. J. Cancer** 2004; 111: 418-423.

*High Dietary Glycemic Load May Increase Colorectal Cancer Risk in Women*, Higginbotham, et al, **J. Natl. Cancer Inst.** 2004; 96: 229-233.

*High Dietary Glycemic Load and Insulin Resistance Combine to Increase Pancreatic Cancer Risk*, Michaud, et al., **J. Natl. Cancer Inst.** 2002; 94: 1293-1300.

*Controlling Hyperglycemia as an Adjunct to Cancer Therapy*, Krone & Ely, **Integr. Cancer Ther.** 2005; 4 (1): 25-31.

*Fasting Insulin and Outcome in Early-Stage Breast Cancer- Results of a Prospective Cohort Study*, Goodwin, et al, **J. Clin. Oncol.**, 2002; 20: 42-51.

*Glycemic Index, Glycemic Load and Thyroid Cancer Risk*, Randi, Ferraroni, Talamini, et al., **Annals of Oncol.** 2008; 19(2): 380-383.

*Green Tea Polyphenols Inhibit IGF-1 Signalling in Prostate Cancer Model*, Mukhtar, et al., **Cancer Res.** 2004; 64: 8715-8722.

*Postprandial Hyperinsulinemia Accelerates Growth of Hepatocellular Carcinoma*, Kawata, et al., **Gut** 2002; 51: 100-104.

*Insulin-Like Growth Factor -1 Activates Gene Transcription Programs Strongly Associated with Poor Breast Cancer Prognosis*, Chreighton, Casa, Lazard, et al., **J Clin Oncol** 2008; 26 (25): 4078-4085.

*Insulin, Insulin-Like Growth Factors and Colon Cancer: A Review of the Evidence*, Giovannucci, **J Nutr** 2001; 131 (Suppl. 11): s3109-3120.

*Glycemic Index, Glycemic Load, and Cancer Risk: A Meta-Analysis*, Gnagnarella, Gandini, La Vecchia, & Maisonneuve, **Amer. J. Clin. Nutr.** 2008; 87 (6): 1793-1801.

*Up-regulation of IGF Binding Protein-1 as an Anti-Carcinogenic Strategy: Relevance to Caloric Restriction, Exercise, and Insulin Sensitivity*, McCarty, **Medical Hypotheses** 1997; 48 (4): 297-308.

*The Insulin-like Growth Factor System as a Treatment Target in Breast Cancer*, Yee, **Sem. Oncol.** 2002; 29 (3 Suppl 11): 86-95.

*Cross-Talk Among Estrogen Receptor, Epidermal Growth Factor, and Insulin-like Growth Factor Signaling in Breast Cancer*, Lee, Cui & Oesterreich, **Clin. Cancer Res.** 2001; 7 (12 Suppl): 4429s-4435s.

*Tyrosine Kinase Signalling in Breast Cancer: Insulin-like Growth Factors and Their Receptors in Breast Cancer*, Zhang & Yee, **Breast Cancer Res.** 2000; 2 (3): 170-175.

*Insulin-Like Growth Factors and Cancer*, Furstenberger & Senn, **Lancet Oncol.** 2002; 3 (5): 298-302.

*Insulin-Like Growth Factor (IGF) Family and Prostate Cancer*, Gennigens, Menetrier-Caux & Droz, **Crit. Rev. Oncol. Hematol.** 2006; 58 (2): 124-145.

*Activation of Estrogen Receptor-Mediated Gene Transcription by IGF-I in Human Breast Cancer Cells*, Lee, Weng, Jackson & Yee, **J. Endocrinol.** 1997; 152 (1): 39-47.

*Vitamin D Analogue EB1089-induced Prostate Regression is Associated with Increased Gene Expression of Insulin-like Growth Factor Binding Proteins*, Nickerson T. Huynh H. **J. Endocrinol.** 1999; 160 (2): 223-229.

*Pharmacological Modulation of IGF Serum Concentrations as a Therapeutic Approach to Control the Growth of Malignant Breast Tumours*, Singer, Hudelist, Schreiber & Kubista, **Drugs Today (Barc)**. 2003; 39 (2): 115-125.

*Inhibition of Insulin-like Growth Factor I Receptor Signaling by the Vitamin D Analogue EB1089 in MCF-7 Breast Cancer Cells: A Role for Insulin-like Growth Factor Binding Proteins*, Rozen & Pollak, **Int. J. Oncol.** 1999; 15 (3): 589-594.

*Insulin, Insulin-like Growth Factors, Insulin Resistance, and Neoplasia*, Pollack **Am. J. Clin. Nutr.** 2007; 86 (3): s820-822.

*Insulin-Like Growth Factor-I Axis as a Pathway for Cancer Chemoprevention*, Adhami, Afaq & Mukhtar, **Clin. Cancer Res.** 2006; 212 (19): 5611-5614.

*Role of Sugars in Human Neutrophilic Phagocytosis*, Sanchez, Reeser, Lau, et al., **Am. J. Clin. Nutr.** 1973; 26: 1180-118.

*Associations of Insulin-Like Growth Factor and Insulin-Like Growth Factor Binding Protein-3 with Mortality in Women with Breast Cancer*, Duggan, Wang, Neuhouser, et al., **Int. J. Cancer** 2013; 132: 1191-1200.

*Metformin Inhibits the Inflammatory Response Associated with Cellular Transformation and Cancer Stem Cell Growth*, Hirsch, Iliopoulos & Kevin Struhl, **PNAS** 2013; 110 (3): 972-977.

*Metformin Treatment Exerts Antiinvasive and Antimetastatic Effects in Human Endometrial Carcinoma Cells*, Tan, Adya, Chen, et al., **J. Clin. Endocrinol. Metab.** 2011; 96 (3): 808-816.

*Metformin: Taking Away the Candy for Cancer?*, Gietema, Lefrandt, Jong, et al., **Eur. J. Cancer** 2010; 46: 2369-2380.

*Understanding the Benefit of Metformin Use in Cancer Treatment*, Dowling, Goodwin & Stambolic, **BMC Med.** 2011; 9: 33.

*The Antidiabetic Drug Metformin Suppresses HER2 (erbB--2) Oncoprotein Overexpression Via Inhibition of the mTOR Effector p70S6K1 In Human Breast Carcinoma Cells*, Vazquez-Martin, Oliveras-Ferraro & Menendez, **Cell Cycle** 2009; 8 (1): 88-96. PMID: 19106626.

*Metformin-Induced Preferential Killing of Breast Cancer Initiating CD44+CD24--/Low Cells Is Sufficient To Overcome Primary Resistance To Trastuzumab In HER2+ Human Breast Cancer Xenografts*, Cufi, Corominas-Faja, Vazquez-Martin, et al., **Oncotarget** 2012; 3 (4): 395-398. PMID: 22565037.

*Metformin Selectively Targets Cancer Stem Cells, And Acts Together With Chemotherapy To Block Tumour Growth And Prolong Remission*, Hirsch, Iliopoulos, Tsichlis & Struhl, **Cancer Res.** 2009; 69 (19): 7507-7511. PMID: 19752085.

*Metformin Enhances the Antiproliferative and Apoptotic Effect of Biclutamide in Prostate Cancer*, Colquhoun, Venier, Vandersluis, et al., **Prost. Dis.** 2012; May 22. [Epub ahead of print] PMID: 22614062.

*Systemic Treatment with the Antidiabetic Drug Metformin Selectively Impairs p53-Deficient Tumour Cell Growth*, Buzzai, Jones, Amaravadi, et al. **Cancer Res** 2007; 67: 6745-6752.

*The Influence of Antidiabetic Medications on the Development and Progression of Prostate Cancer*, Hitron, Adams, Talbert & Steinke , **Cancer Epidemiol.** 2012 Mar 12. [Epub ahead of print]

*Managing Lipid Metabolism in Proliferating Cells: New Perspective for Metformin Usage in Cancer Therapy*, Lettieri Barbato, Vegliante, Desideri & Ciriolo, **Biochimica et Biophysica Acta** 2014; 10.1016/j.bbcan.2014.02.003.

*Effects of Metformin on Head and Neck Cancer: A Systematic Review*, Rêgo, Pavan, Elias, et al., **Oral Oncol** 2015 Jan 27;[EPub Ahead of Print].

*C-Peptide, Insulin-Like Growth Factor Binding Protein-1, Glycosylated Hemoglobin, and the Risk of Distal Colorectal Adenoma in Women*, Wei, Ma, Pollak, et al., **Cancer Epidemiol. Biomarkers Prev.** 2006; 15 (4): 750-755.

*Impaired Glucose Metabolism and Diabetes and the Risk of Breast, Endometrial, and Ovarian Cancer*, Lambe, Wigertz, Garmo, et al. **Cancer Causes & Control**. 2011; 228: 1163-1171.

*Diabetes, Pancreatic Cancer, and Metformin Therapy*, Gong, Robbins, Lugea1, et al., **Front. Physiol.** 2014; | doi: 07 November :10.3389/fphys.2014.00426

*Arthralgia Induced by Endocrine Treatment (Tamoxifen) for Breast Cancer: A Prospective Study of Serum Levels of Insulin Like Growth Factor-I, Its Binding Protein and Oestrogens*, Lintermans, Vanderschueren, Verhaeghe, et al., **Eur. J. Cancer** 2014; 50 (17): 2925- 2931.

*Increased Sugar Uptake Promotes Oncogenesis Via EPAC/RAP1 and O-GlcNAc Pathways*, Onodera, Nam & Bissell, **J. Clin. Inv.**, 2013; DOI: 10.1172/JCI63146

*Sweetened Beverage Consumption and Risk of Biliary Tract and Gallbladder Cancer in a Prospective Study*, Larsson, Giovannucci & Wolk, **J. Natl. Cancer Inst.** 2016; 108 (10): pii: djw125. doi: 10.1093/jnci/djw125. PMID: 27281756

*Serum Glucose and Risk of Cancer: A Meta-Analysis*, Crawley, Holmberg, Melvin, et al., **BMC Cancer** 2014; 14:985 doi:10.1186/1471-2407-14-985.

*Low Insulin-like Growth Factor-1 Level Predicts Survival in Humans with Exceptional Longevity*, Milman, Atzmon, Huffman, et al., **Aging Cell** 2014; pp 1-3. doi: 10.1111/acel.12213

*Survival of Patients with Stage IV Lung Cancer with Diabetes Treated with Metformin*, Lin, Gallagher, Sigel K, Mhango, et al., **Am. J. Respir. Crit. Care Med.** 2015 Feb 15; 191 (4):448-454.

*Metformin Use Decreases Distant Metastases in Diabetic Oropharyngeal Cancer Patients*, Spratt, Beadle, Zumsteg, et al., **Int. J. Rad. Oncol. Biol. Physics** 2015 Nov 11; [EPub Ahead of Print] PMID: 26892740.

*Metformin Inhibits the Development and Metastasis of Ovarian Cancer*, Wu, Sheng, Zhu, et al., **Oncol. Rep.** 2102; 28 (3): 903-908.

*Individualizing Chemotherapy Using the Anti-Diabetic Drug, Metformin, As An “Adjuvant”: An Exploratory Study*, Bradford and Khan, **J. Cancer Sci. Ther.** 2013; 5: 120-125.

## SURGERY

*Micrometastases Often Persist in Breast Cancer Patients*, Slade, et al, **Int. J. Cancer** 2005; 114: 94-100.  
*Wounding from Biopsy and Breast Cancer Progression*, Retsky, Demicheli & Hrushesky, **Lancet** 2001; 357 (9261): 1048.

*Port-Sites Excision for Gallbladder Cancer Incidentally Found After Laparoscopic Cholecystectomy*, Giulante, Ardito, Velone, et al., **Am. J. Surg.** 2006; 191 (1): 114-116.

*Primary Tumour Removal Increases Vascular Density in Liver Metastases*, **Int. J. Cancer**, 2004; 112: 554-559.

*Menopausal Status Dependence of the Timing of Breast Cancer Recurrence After Surgical Removal of the Primary Tumour*, Demicheli, et al., **Breast Cancer Res.**, 2004; 6 (6): 689-696.

*A Randomized Clinical Trial of a Brief Hypnosis Intervention to Control Side-Effects in Breast Surgery Patients*, Montgomery, Bovbjerg, Schnur, et al., **J. Natl. Cancer Inst.** 2007; 99 (17): 1304-1312.

*Impact of Psycho-Therapeutic Support for Patients with Gastro-Intestinal Cancer Undergoing Surgery: 10-Year Survival Results of a Randomized Trial*, Kuchler, Bestmann, Rappat, et al., **J. Clin. Oncol.** 2007; 25 (19): 2702-2708.

*Needle Track Seeding Following Biopsy of Liver Lesions in the Diagnosis of Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis*, Silva, Hegab, Hyde, et al., **Gut** 2008; 57 (11): 1592-1596.

*Decrease in Circulating Anti-Angiogenic Factors (Angiostatin and Endostatin) After Surgical Removal of Primary Colorectal Carcinoma Coincides with Increased Metabolic Activity of Liver Metastases*, Peeters, de Geus, Westphal, et al., **Surgery** 2005; 137 (2): 246-249.

*Vascular Density in Colorectal Liver Metastases Increases After Removal of the Primary Tumour in Human Cancer Patients*, Peeters, Westphal, de Waal, et al., **Int. J. Cancer** 2004; 112 (4): 554-559.

*Outgrowth of Human Liver Metastases After Resection of the Primary Colorectal Tumour: A Shift in the Balance Between Apoptosis and Proliferation*, Peeters, de Waal, Wobbes, et al., **Int. J. Cancer** 2006; 119 (6): 1249-1253.

*Does Surgery Unfavourably Perturb the "Natural History" of Early Breast Cancer by Accelerating the Appearance of Distant Metastases?*, Baum, Demicheli, Hrushesky & Retsky **Eur. J. Cancer** 2005; 41 (4): 508-515.

*Does Surgery Induce Angiogenesis in Breast Cancer? Indirect Evidence from Relapse Pattern and Mammography Paradox*, Retsky, Demicheli & Hrushesky, **Int. J. Surg.** 2005; 3 (3): 179-187.

*Surgery for Gastric Cancer Increases Plasma Levels of Vascular Endothelial Growth Factor and von Willebrand Factor*, Ikeda, Furukawa, Imamura, et al., **Gastric Cancer** 2002; 5 (3): 137-141.

*Major Abdominal Surgery Increases Plasma Levels of Vascular Endothelial Growth Factor: Open More So Than Minimally Invasive Methods*, Belizan, Balik, Feingold, et al., **Ann. Surg.** 2006; 244 (5): 792-798.

*Altered Plasma Matrix Metalloproteinase-9/Tissue Inhibitor of Matrix Metalloproteinase-1 Concentration During the Early Postoperative Period in Patients with Colorectal Cancer*, Kirman, Jain, Cekic, et al., **Surg. Endosc.** 2006; 20 (3): 482-486. Erratum in: **Surg. Endosc.** 2006; 20 (4): 706.

*Tumour Dormancy and Surgery-Driven Interruption of Dormancy in Breast Cancer: Learning from Failures*, Demicheli, Retsky, Hrushesky & Baum, **Nat. Clin. Pract. Oncol.** 2007; 4 (12): 699-710. Review.

*The Effects of Surgery on Tumour Growth: A Century of Investigations*, Demicheli, Retsky, Hrushesky, et al., **Ann. Oncol.** 2008; 19 (11): 1821-1828.

*Hematogenous Dissemination of Hepatocytes and Tumour Cells After Surgical Resection of Hepatocellular Carcinoma: A Quantitative Analysis*, Wong, Lau, Leung, et al., **Clin. Cancer Res.** 1999; 4021-4027.

*Hematogenous Dissemination of Prostatic Epithelial Cells During Radical Prostatectomy*, Eschwege, Dumas , Blanchet, et al., **Lancet** 1995; 346, 1528-1530.

*Perioperative Activation of Disseminated Tumour Cells in Bone Marrow of Patients with Prostate Cancer*, Weckermann, Polzer, Ragg, et al., **J. Clin. Oncol.** 2009; 27: 1549-1556.

*Iatrogenic Displacement of Tumour Cells to the Sentinel Node after Surgical Excision Biopsy in Primary Breast Cancer*, Tvedskov, Jensen, Kroman & Balslev, **San Antonio Breast Cancer Symposium**, December 11, 2010; S5-2.

*Endothelial Function is Impaired After a High-Salt Meal in Healthy Subjects*, Dickinson, Clifton & Keogh, **Am. J. Clin. Nutr.** 2011; 93: 500-505.

*The Effect of Paravertebral Block During Surgery on the Recurrence of Breast Cancer*, Oppfeldt, Palle & Carlsson, **Amer. Soc. Anaesth.** 2013, Oct. 15, abstract 4253.

[See Low-Dose Naltrexone section re: peri-operative opioids and tumour recurrence risk.]

## VITAMIN C

*Vitamin C Deficiency in Cancer Patients*, Mayland, Bennett & Allan, **Palliat. Med.** 2005; 19: 17-20.

*High-Dose Vitamin C Selectively Kills Cancer Cells*, Levine, et al., **Proc. Natl. Acad. Sciences USA**, 2005; 102: 13604-13609.

*High-dose Vitamin C Therapy: Renewed Hope or False Promise?* Assouline & Miller, **Can. Med. Assoc. J.** 2006; 174: 956-957.

*Intravenous Ascorbate as a Tumour Cytotoxic Chemotherapeutic Agent*, Riordan, et al., **Med. Hypotheses** 1995; 44: 207-213.

*Prolonged Survival Linked to Intravenous Vitamin C Seen in Three Cancer Patients*, Levine, et al, **Can. Med. Assoc. J.**, 2006; 174: 937-942.

*Changes of Terminal Cancer Patients' Health-Related Quality of Life After High Dose Vitamin C Administration*, Yeom, Jung & Song, **J. Korean Med Sci** 2007; 22 (1): 7-11.

*Intravenously Administered Vitamin C as a Cancer Therapy: Three Cases*, Padayatty, Riordan, Hewitt, et al., **CMAJ** 2006; 174 (7): 937-942.

*A Pilot Clinical Study of Continuous Intravenous Ascorbate in Terminal Cancer Patients*, Riordan, Casciari, Gonzalez, et al., **P R Health Sci J** 2005; 24 (4): 269-276.

*Innovation vs. Quality Control: An 'Unpublishable' Clinical Trial of Supplemental Ascorbate in Incurable Cancer*, Cameron & Campbell, **Med Hypotheses** 1991; 36 (3): 185-189.

*Reticulum Cell Sarcoma: Two Complete 'Spontaneous' Regressions, in Response to High-dose Ascorbic Acid Therapy. A Report on Subsequent Progress*, Campbell, Jack & Cameron, **Oncology** 1991; 48 (6): 495-497.

*Changes of Terminal Cancer Patients' Health-Related Quality of Life After High Dose Vitamin C Administration*, Yeom, Jung & Song, **J. Korean Med Sci** 2007; 22 (1): 7-11.

*Supplemental Ascorbate in the Supportive Treatment of Cancer: Prolongation of Survival Times in Terminal Human Cancer*, Cameron & Pauling, **Proc. Natl Acad Sci USA** 1976; 73 (10): 3685-3689.

*Supplemental Ascorbate in the Supportive Treatment of Cancer: Reevaluation of Prolongation of Survival Times in Terminal Human Cancer*, Cameron & Pauling, **Proc Natl Acad Sci USA** 1978; 75: 4538-4542.

*Vitamin C Inhibits p53-Induced Replicative Senescence Through Suppression of ROS Production and p38 MAPK Activity*, Kim, Jin, Lee, et al., **Biochem Pharmacol.** 2008; 77 (5): 651-655.

*Pharmacological Doses of Ascorbate Act as a Pro-Oxidant and Decrease Growth of Aggressive Tumour Xenografts in Mice*, Chen, Espey, Sun, et al., **Proc. Natl. Acad. Sci. USA** 2008; 105: 11105-11109.

*Pharmacologic Ascorbic Acid Concentrations Selectively Kill Cancer Cells: Action as a Pro-Drug to Deliver Hydrogen Peroxide to Tissues*, Chen, Espey, Krishna, et al., **Proc. Natl. Acad. Sci. U S A** 2005; 102 (38): 13604-13609.

*Vitamin C Pharmacokinetics: Implications for Oral and Intravenous Use*, Padayatty, Sun, Wang, et al., **Ann. Intern. Med.** 2004; 140 (7): 533-537.

*Ascorbate in Pharmacologic Concentrations Selectively Generates Ascorbate Radical and Hydrogen Peroxide in Extracellular Fluid in vivo*, Chen, Espey, Sun, et al., **Proc. Natl. Acad. Sci U S A** 2007; 104 (21): 8749-8754.

*Pharmacological Concentrations of Ascorbate are Achieved by Parenteral Administration and Exhibit Antitumoural Effects*, Verrax & Calderon, **Free Radic. Biol. Med.** 2009; 47 (1): 32-40.

*Phase I Clinical Trial of I.V. Ascorbic Acid in Advanced Malignancy*, Hoffer, Levine, Assouline, et al., **Ann. Oncol.** 2008; [Epub ahead of print]

*Phase I Evaluation of Intravenous Ascorbic Acid in Combination with Gemcitabine and Erlotinib in Patients with Metastatic Pancreatic Cancer*, Monti, Mitchell, Bazzan, et al., **PLoS One** 2012; 7 (1): e29794.

*Emerging Role of Ascorbic Acid in the Management of Advanced Breast Carcinoma as a Chemosensitizer*, Goel, Agarwal, Mandal, et al., **Asian J. Surg.** 1999; 22: 333-336.

*In vivo Effect of Ascorbic Acid on Enhancement of Human Natural Killer Cell Activity*, Vojdani & Ghoneum, **Nutr. Res.** 1993; 13: 753-754.

*Enhancement of Human Natural Killer Cytotoxic Activity by Vitamin C in Pure and Augmented Formulations*, Vojdani & Namatalla, **J. Nutr. Environ. Med.** 1997; 7 (3): 187-195.

*The Orthomolecular Treatment of Cancer II. Clinical Trial of High-Dose Ascorbic Acid Supplements in Advanced Human Cancer*, Cameron & Campbell, **Chem. Biol. Interact.** 1974; 9: 285-315.

*Mega-Dose Vitamin C as Therapy for Human Cancer?* Borst, **Proc Natl Acad Sci USA**; 2008; 105: E95.

*Vitamin C and Cancer Revisited*, Frei & Lawson, **Proc Natl Acad Sci USA** 2008; 105: 11037-11038.

*The Antioxidant Ascorbic Acid Mobilizes Nuclear Copper Leading to a Prooxidant Breakage of Cellular DNA: Implications for Chemotherapeutic Action Against Cancer*, Ullah, Khan, Zubair, et al., **Cancer Chemother. Pharmacol.** 2010 March 6 [Epub ahead of print] PMID: 20213077.

*Catalytic Therapy of Cancer by Ascorbic Acid Involves Redox Cycling of Exogenous/Endogenous Copper Ions and Generation of Reactive Oxygen Species*, Hadi, Ullah, Shamim, Bhatt & Azmi, **Cancer Chemotherapy** 2010; 56 (4): 280-284.

*H(2)O(2)-Mediated Cytotoxicity of Pharmacologic Ascorbate Concentrations to Neuroblastoma Cells: Potential Role of Lactate and Ferritin*, Deubzer, Mayer, Kuçi et al., **Cell Physiol. Biochem.** 2010; 25 (6): 767-774.

*The Effect of Intracellular Antioxidant Delivery (Catalase) on Hydrogen Peroxide and Proinflammatory Cytokine Synthesis: A New Therapeutic Horizon*, Siwale, Yeboah, Addo, et.al. **J.Drug Target.**, 2009; 17 (9) : 710-718.  
doi.org/10.3109/10611860903161328

*New Developments and Novel Therapeutic Perspectives for Vitamin C*, Li & Schellhorn, **J. Nutr.** 2007; 137: 2171-2184.

*The Vitamin C: Vitamin K3 System – Enhancers and Inhibitors of the Anti-Cancer Effect*, Lamson, Gu, Plaza, et al., **Alt. Med. Rev.** 2010; December – pre-publication.

*Cell Cycle Arrest and Autoschizis in a Human Bladder Carcinoma Cell Line Following Vitamin C and Vitamin K3 Treatment*, Jamison, Gilloteaux, Nassiri, et al., **Biochem. Pharmacol.** 2004; 67 (2): 337-351.

*Ascorbate Exerts Anti-Proliferative Effects Through Cell Cycle Inhibition and Sensitizes Tumour Cells Towards Cytostatic Drugs*, Fromberg, Gutsch, Schulze, et .al., **Cancer Chemother. Pharmacol.** 2011; 67: 1157-1166.

*Intravenous Vitamin C Administration Improves Quality of Life in Breast Cancer Patients During Chemo-/Radiotherapy and Aftercare: Results of a Retrospective, Multicentre, Epidemiological Cohort Study in Germany*, Vollbracht, Schneider, Leendert, et al., **In Vivo** 2011; 25 (6): 983-990.

*Sodium Ascorbate Induces Apoptosis in Neuroblastoma Cell Lines by Interfering with Iron Uptake*, Carosio, Zuccari, Orienti, et al., **Mol. Cancer** 2007; 6 (1): 55-65.

*Phase 1 Evaluation of Intravenous Ascorbic Acid in Combination with Gemcitabine and Erlotinib in Patients with Metastatic Pancreatic Cancer*, Monti, Mitchell, Bazzan, et al., **PLoS One** 2012; 7 (1): e29794. Epub 2012 Jan 17.

*Ascorbic Acid Suppresses Drug-Induced Apoptosis in Human Colon Cancer Cells by Scavenging Mitochondrial Superoxide Anions*, **Carcinogenesis** 2004; PMID 14754875.

*The Controversial Place of Vitamin C in Cancer Treatment*, Verrax & Calderon, **Biochem. Pharmacol.** 2008; 76: 1644-1652.

*High-Dose Intravenous Vitamin C in the Treatment of a Patient with Renal Cell Carcinoma of the Kidney*, Riordan, Jackson, Riordan & Schultz, **J. Orthomol. Med.** 1998; 13: 72-73.

*High-Dose Intravenous Vitamin C in the Treatment of a Patient with Adenocarcinoma of the Kidney*, Riordan, Jackson & Schultz, **J. Orthomol. Med.** 1990; 5: 5-7.

*Clinical and Experimental Experiences with Intravenous Vitamin C*, Riordan, Riordan & Casciari, **J. Orthomol. Med.** 2000; 15: 201-203.

*The Concern About B-Vitamins Affecting the Oxidant Effect of Intravenous Ascorbate for Malignancy*, Ochi, Hetherington & Lamson, **Alt. Med. Rev.** 2011; 16 (Suppl.): 1-5S.

*Changes in Terminal Cancer Patients' Health-Related Quality of Life After High Dose Vitamin C Administration*, Yeom, Jung & Song, **J. Korean Med. Sci.** 2007; 22 (1): 7-11.

*Use of Subtherapeutic Dose of Cisplatin and Vitamin C Against Murine Dalton's Lymphoma*, Prasad, Giri & Arjun, **Pol. J. Pharmacol. Pharm.** 1992; 44 (4): 383-391.

*Pharmacological Ascorbate Induces Cytotoxicity in Prostate Cancer Cells Through ATP Depletion and Induction of Autophagy*, Ping, Jun, Chalmers, Drisko, et al., **Anti-Cancer Drugs** 2012; 23 (4): 437-444.

*Intravenous Vitamin C Administration Reduces Fatigue in Office Workers: A Double-Blind Randomized Controlled Trial*, Suh, Bae, Ahn, et al., **Nutr. J.** 2012, 11:7.

*Prospective Randomized Phase I/IIa Pilot Trial to Assess Safety and Benefit Administering High Dose Intravenous Ascorbate in Combination with Chemotherapy in Newly Diagnosed Advanced Stage III or Stage IV Ovarian Cancer*, Sullivan, G. et. al., 2011, November, Moderated Abstract [6] presented at the **Society for Integrative Oncology**, Cleveland, OH.

*Synergistic Effects of Ascorbate with Carboplatin Against Human Ovarian Cancer in Vitro and in Vivo*. Ma, Y. Drisko, J. Poirreddy, K. (2011, November). Moderated Abstract [20] presented at the **Society for Integrative Oncology**, Cleveland, OH.

*The Use of Antioxidants with First-Line Chemotherapy in Two Cases of Ovarian Cancer*, Drisko, Chapman & Hunter, **J. Amer. Coll. Nutr.** 2003; 22 (2): 118-123.

*Chemotherapy Alone vs. Chemotherapy Plus High Dose Multiple Antioxidants in Patients with Advanced Non Small Cell Lung Cancer*, Pathak, Bhutani, Guleria, et al., **J. Am. Coll. Nutr.** 2005; 24: 16–21.

*High-Dose Parenteral Ascorbate Enhanced Chemosensitivity of Ovarian Cancer and Reduced Toxicity of Chemotherapy*, Ma, Levine..Drisko, et al, **Sci. Transl. Med.** 2014; 6 (222): 222ra18.

*Anti-Cancer Effect of Pharmacological Ascorbate and Its Interactions with Supplementary Parenteral Glutathione in Preclinical Cancer Models*, Chen, Stone...Drisko, et al., **Free Rad. Biol. Med.** 2011; 51: 681-687.

*Pharmacological Ascorbate Synergizes with Gemcitabine in Preclinical Models of Pancreatic Cancer*, Esprey, Drisko, Levine,et al., **Free Rad. Biol. Med.** 2011; 50: 1610-1619.

*Pharmacological Ascorbate with Gemcitabine for the Control of Meastatic and Node-Positive Pancreatic Cancer (PACMAN): Results from a Phase 1 Clinical Trial*, Welsh,Wagner,van't Erve, et al., **Cancer Chemother. Pharmacol.** 2013; 71: 765-775.

*Vitamin C: Intravenous Use by Complementary and Alternative Medicine Practitioners and Adverse Effects*, Padayatty, Drisko, Levine, et al., **PLoS ONE** 2010; 5 (7): e11414.

*The Use of IV Vitamin C as an Adjunct to Chemotherapy and Radiation Therapy*, Lander, **CAND Vital Link**, 2014; Fall-Winter: 47-52.

*Vitamin C and Survival Among Women with Breast Cancer: A Meta-Analysis*, Harris, Orsini & Wolk, **Eur. J. Cancer** 2014; 50 (7): 1223-1231.

*Is There a Role for Oral or Intravenous Ascorbate (Vitamin C) in Treating Patients With Cancer?: A Systematic Review*, Jacobs, Hutton, Ng, et al., **Oncologist** 2015; 2014:0381. [Epub ahead of print]

*High Dose Vitamin C Injection to Cancer Patients May Promote Thrombosis Through Procoagulant Activation of Erythrocytes*, Kim, Bae, Koh, et al., **Toxicol. Sci.** 2015 Jul 2. pii: kfv133. [Epub ahead of print]

*Effects of L-Ascorbic Acid on Lysyl Oxidase in the Formation of Collagen Cross-Links*, Kuroyanagi, Shimamura, Kim, et al., **Biosci. Biotechnol. Biochem.** 2002; 66 (10): 2077-2082.

*Metabolomic Alterations in Human Cancer Cells by Vitamin-C-Induced Oxidative Stress*, Uetaki, Tabata, Nakasuka, et al., **Scientific Reports** 2015; 5: 13896. DOI: 10: 1038/srep 13896.

*Vitamin C Uncouples the Warburg Metabolic Switch in KRAS Mutant Colon Cancer*, Aguilera, Muñoz-Sagastibelza, Torrejón, et al., [Epub ahead of print] **Oncotarget** 2016 Jun 15. doi: 1018632/oncotarget.10087.

## VITAMIN D

*Vitamin D and Calcium Supplementation Reduces Cancer Risk: Results of a Randomized Trial*, Lappe, et al., **Am. J. Clin. Nutr.** 2007; 85 (6): 1586-1591.

*All-Trans Retinoic Acid Antagonizes the Action of Calciferol and Its Active Metabolite, 1,25-Dihydroxy-Cholecalciferol, in Rats*, Rohde & DeLuca, **J. Nutr.** 2005; 135: 1647–1652.

*Heterodimeric DNA Binding by the Vitamin D Receptor and Retinoid X Receptors Is Enhanced by 1,25-Dihydroxyvitamin D3 and Inhibited by 9-cis-Retinoic Acid; Evidence for Allosteric Receptor Interactions*, Thompson, Jurutka, Haussler, et al., **J. Biol. Chem.** 1998; 273 (14): 8483–8491.

*Vitamin D and Cancer*, Ali & Vaidya, **J. Cancer Res. Ther.** 2007; 3 (4): 225-230.

*Vitamin D Signalling Pathways in Cancer: Potential for Anti-Cancer Therapeutics*, Deeb, Trump & Johnson, **Nat. Rev. Cancer** 2007; 7 (9): 684-700.

*Induction of Ovarian Cancer Cell Apoptosis by 1,25-Dihydroxy-Vitamin D<sub>3</sub> Through the Down-Regulation of Telomerase*, Jiang, Bao , Li, et al., **Biol. Chem.** 2004; 279 (51): 53213-53221.

*High Vitamin D Levels Linked to Improved Lung Cancer Survival*, Zhou, et al., **J. Clin. Oncol.** 2007; 25: 479-485.

*Vitamin D Supplementation and Total Mortality: A Meta-Analysis of Randomized Controlled Trials*, Autier and Gandini, **Arch. Intern. Med.** 2007; 167 (16): 1730-1737.

*Strong Associations of 25-Hydroxyvitamin D Concentrations With All-Cause, Cardiovascular, Cancer, and Respiratory Disease Mortality in a Large Cohort Study*, Schöttker, Haug, Schomburg, et al., **Am. J. Clin. Nutr.** 2013; 97 (4): 782-793.

*Do Sunlight and Vitamin D Reduce the Likelihood of Colon Cancer?*, Garland & Garland, **Int. J. Epidemiol.** 2006; 35 (2): 217-220.

*Circulating 25-Hydroxy Vitamin D Levels and Survival in Patients with Colorectal Cancer*, Ng, Meyerhardt, Wu, et al., **J Clin Oncol** 2008; 26 (18): 2937-2939.

*Molecular Basis of Potential of Vitamin D to Prevent Cancer*, Ingraham, Bragdon & Nohe, **Curr. Med. Res. & Opin.** 2008; 241: 139-149.

*1{alpha}, 25-Dihydroxyvitamin D<sub>3</sub> Potentiates Cisplatin Anti-Tumour Activity by p73 Induction in a Squamous Cell Carcinoma Model*, Ma, et al., **Mol. Cancer Ther.** 2008; 7 (9): 3047-3055.

*Association Between Serum 25(OH)D and Death from Prostate Cancer*, Tretli, Hernes, Berg, et al., **Br. J. Cancer** 2009; 1003: 450-454.

*Chemotherapy is Linked to Severe Vitamin D Deficiency in Patients with Colorectal Cancer*, Fakih, Trump, Johnson, et al., **Int. J. Colorectal Dis.** 2009; 242: 219-224.

*Dairy Products, Calcium, and Vitamin D and Risk of Prostate Cancer*, Chan & Giovannucci, **Epidemiol. Rev.** 2001; 23 (1): 87-92.

*Vitamin D is Associated with Improved Survival in Early-Stage Non-Small Cell Lung Cancer Patients*, Zhou, Suk, Liu, et al., **Cancer Epidemiol. Biomarkers Prev.** 2005; 14 (10): 2303-2309.

*Vitamin D Analogue EB1089-Induced Prostate Regression is Associated with Increased Gene Expression of Insulin-Like Growth Factor Binding Proteins*, Nickerson T. Huynh H. **J. Endocrinol.** 1999; 160 (2): 223-229.

*Inhibition of Insulin-Like Growth Factor I Receptor Signaling by the Vitamin D Analogue EB1089 in MCF-7 Breast Cancer Cells: A Role for Insulin-like Growth Factor Binding Proteins*, Rozen & Pollak, **Int. J. Oncol.** 1999; 15 (3): 589-594.

*A Combined Pretreatment of 1,25-Dihydroxyvitamin D<sub>3</sub> and SodiumValproate Enhances the Damaging Effect of Ionizing Radiation on Prostate Cancer Cells*, Gavrilov Leibovich, Ariad, Lavrenkov & Shany, **J. Steroid Biochem. Mol. Biol.** 2010

[Epub ahead of print] PMID: 20214985.

*Vitamin D<sub>3</sub> Distribution and Status in the Body*, Heaney, Horst, Cullen & Armas, **J. Am. Coll. Nutr.** 2009; 28 (3): 252-256.

*Vitamin D for Cancer Prevention: Global Perspective*, Garland, Gorham, Mohr & Garland, **Ann. Epidemiol.** 2009; 19 (7): 468-483.

*Meta-Analysis: Longitudinal Studies of Serum Vitamin D and Colorectal Cancer Risk*, Yin, Grandi, Raum, et al., **Aliment. Pharmacol. Ther.** 2009; 30 (2): 113-125.

*Double-Blinded Randomized Study of High-Dose Calcitriol Plus Docetaxol Compared with Placebo Plus Docetaxol in Androgen-independent Prostate Cancer: A Report from the ASCENT Investigators*, Beer, Ryan, Venner, et al., **J. Clin. Oncol.** 2007; 25 (6): 669-674.

*A Phase II Trial of Calcitriol and Naproxen in Recurrent Prostate Cancer*, Srinivas & Feldman, **Anticancer Res.** 2009; 29 (9): 3605-3610.

*Phase II Trial of High-Dose Intermittent Calcitriol (1,25 Dihydroxyvitamin D3) and Dexamethasone in Androgen-Independent Prostate Cancer*, Trump, Potter, Muindi, et al., **Cancer** 2006; 106 (10): 2136-2142.

*Immunomodulatory Effects of Vitamin D: Implications for GVHD*, Rosenblatt, Bissonnette, Ahmad, et al., **Bone Marr. Transplant.** 2010;45 (9): 1463-1468.

*Vitamin D Status is Associated with Disease-Free Survival and Overall Survival Time in Patients with Squamous Cell Carcinoma of the Upper Aerodigestive Tract*, Gugatschka, Kiesler, Obermayer-Pietsch, et al., **Eur Arch Otorhinolaryngol.** 2011 Jan 8. [Epub ahead of print] PMID: 21221617

*Seasonal Variation in Blood Drug Concentrations and a Potential Relationship to Vitamin D*, Lindh, Andersson, Eliasson & Bjorkhem-Bergman, **Drug Metab. Dispos.** 2011; Feb. 24 [Epub ahead of Print].

*Vitamin D Insufficiency and Prognosis in Non-Hodgkin's Lymphoma*, Drake, Maurer, Link, et al., **J. Clin. Oncol.** 2010; 28 (27): 4191-4198.

*Cod Liver Oil, Vitamin A Toxicity, Frequent Respiratory Infections, and the Vitamin D Deficiency Epidemic*, Cannell, Vieth, Willett, et al., **Ann. Otol., Rhinol. & Laryngol.** 2008; 117 (11): 864-870.

*Increased Prevalence of Vitamin D Insufficiency in Patients with Breast Cancer After Neoadjuvant Chemotherapy*, Jacot, Pouderoux, Thezenas, et al., **Breast Cancer Res. Treat.** 2012; 1342: 709 -717.

*Serum 25-Hydroxyvitamin D and Risk of Breast Cancer: Results of a Large Population-Based Case-Control Study in Mexican Women*, Fedirko, Torres-Mejia, Ortega-Olvera, et al. **Cancer Causes Control** 2012; 237: 1149 -1162.

*Vitamin D Status at Breast Cancer Diagnosis: Correlation with Tumour Characteristics, Disease Outcome, and Genetic Determinants of Vitamin D Insufficiency*, Proctor, Morrison, Talwar, et al., **Carcinogenesis** 2012; 337: 1319 - 1326.

*Vitamin D3 Supplementation at 4000 International Units Per Day for One Year Results in a Decrease of Positive Cores at Repeat Biopsy in Subjects with Low-Risk Prostate Cancer Under Active Surveillance*, Marshall, Savage, Garrett-Mayer, et al., **J. Clin. Endocrinol. Met.** 2012; 977: 2315 - 2324.

## VITAMIN K

*The Anticancer Effects of Vitamin K*, Lamson & Plaza, **Alt. Med. Rev.** 2003; 8 (3): 303-318.

*The Mechanisms of Vitamin K2-Induced Apoptosis of Myeloma Cells*, Tsujioka, Miura, otsuki, et al., **Haematologica** 2006, 91 (5): 613-619.

*Oxidative Stress by Ascorbate (Vit C) / Menadione (K3) Association Kills K562 Human Chronic Myelogenous Leukemia Cells and Inhibits its Tumour Growth in Nude Mice*, Verrax, Stockis, Tison, et al., **Biochem. Pharmacol.** 72 (6): 671-680.

*Vitamin K2 Inhibits the Growth and Invasiveness of Hepatocellular Carcinoma Cells Via Protein Kinase A Activation*, Otsuka, Kato, Shao, et al., **Hepatology** 2004; 40 (1): 243-251.

*Phase I Trial of Menadiol Diphosphate (Vitamin K3) in Advanced Malignancy*, Lim, et al., **Invest. New Drugs** 2005; 23: 235–239.

*The Vitamin C: Vitamin K3 System – Enhancers and Inhibitors of the Anticancer Effect*, Lamson, Gu, Plaza, et al., **Alt Med. Rev.** 2010; 15 (4): 345-351.

Vitamin K2 Therapy for Myelodysplastic Syndrome, Abe, Muta, Choi, et al., **Rinsho Ketsueki** 2002; 43 (2): 117-121. [Article in Japanese]

---

**Bibliography / Suggested reading:**

*Life Over Cancer*, Keith Block, MD 2009 Random House

*The Paleolithic Prescription – A Program of Diet and Exercise and a Design for Living*, Eaton, Shostak, and Konner, 1988.

*Dietary Options for Cancer Survivors – A Guide to Research on Foods, Food Substances, Herbals and Dietary Regimens That Might Influence Cancer*, Weldon, et al, American Institute for Cancer Research, 2002.

*Stopping Cancer Before It Starts – The American Institute for Cancer Research's Program for Cancer Prevention*, The American Institute for Cancer Research, 1999.

*Guns, Germs and Steel – the Fates of Human Societies*, Jared Diamond, 1997.

*Foods That Fight Cancer, Preventing Cancer by Diet*, Richard Beliveau and Denis Gingras, 2007

*Cooking with Foods That Fight Cancer*, Richard Beliveau and Denis Gingras, 2007

*The Complete Natural Medicine Guide to Breast Cancer – A Practical Manual for Understanding, Prevention and Care*, Sat Dharam Kaur, ND 2003.

*Natural Compounds in Cancer Therapy – Promising Non-toxic Anti-tumour Agents from Plants and Other Natural Sources*, John Boik, Oregon Medical Press 2001.

*An Alternative Medicine Definitive Guide to Cancer*, Diamond, Cowden & Goldberg, Future Medicine Publishing, 1997.

*The Whole Life Nutrition Cookbook – Whole foods recipes for personal and planetary health*, 2<sup>nd</sup> edition, Segersten and Malterre, 2008; Whole Lfe Press.

*Healing the Planet- One Patient at a Time, A Primer in Environmental Medicine*, Jozef Krop, 2000.

*Healing with Whole Foods - Asian Traditions and Modern Nutrition*, Paul Pritchard, 2003.

*Breast Cancer – Beyond Convention*, edited by Tafliaferri, Cohen & Tripathy, 2002, Atria Books.

*Iscador- Mistletoe preparations used in anthroposophically extended cancer treatment*, Gorter, 1998, Erlag fur GanzheitsMedizin.

*Iscador Mistletoe and Cancer Therapy*, edited by Christine Murphy, 2001, Lantern Books.

*Staying Alive Cookbook for Cancer Free Living*, Sally Errey, 2004, Belissimo Books.

*The Complete Cancer Cleanse*, Calbom, Calbom & Mahaffey, 2003, Thomas Nelson, Inc.

*Cancer as a Turning Point*, Lawrence LeShan, 1994, Plume/Penguin.

*You Can Fight for Your Life*, Lawrence LeShan, 1977, M. Evans & Co.

*Questioning Chemotherapy*, Ralph Moss, 1995, Equinox Press.

*Antioxidants Against Cancer*, Ralph Moss, 2000, Equinox Press.

*Cancer and Vitamin C*, Cameron & Pauling, revised ed. 1993, Camino Books.

*Healing Cancer- Complementary Vitamin & Drug Treatments*, Hoffer & Pauling, 2004, CCNM Press.

*Nutrition After Cancer*, 2002, American Institute for Cancer Research.

*Alternatives in Cancer Therapy*, Pelton & Overholser, 1994, Fireside.

*The Biology of Cancer*, Robert A. Weinberg, 2007; Garland Science

*Comprehensive Cancer Care – Integrating Alternative, Complementary and Conventional Therapies*, Gordon & Curtin, 2001, Perseus Publishing.

*Clinical Oncology*, American Cancer Society, 2000.

*Cancer Medicine* 7: Holland, Frei et al., editors, 7<sup>th</sup> edition, BC Decker, 2006.

*Robbins Pathologic Basis of Disease*, Sixth edition, R. Cotran, V. Kumar, & T. Collins, W.B. Saunders Company

*Cancer & Natural Medicine - a Textbook of Basic Science and Clinical Research*, John Boik, 1996, Oregon Medical Press

*Natural Compounds in Cancer Therapy – Promising Non-toxic Anti-tumour Agents from Plants and Other Natural Sources*, John Boik, 2001, Oregon Medical Press.

*Cancer and Natural Medicine – a Textbook of Basic Science and Clinical Research*, John Boik, 1996 Oregon Medical Press.

*You Don't Have to Die*, Harry Hoxsey, N.D., 1956 Milestone Books

*The Cancer Industry -Unravelling the Politics*, Ralph W. Moss, 1989, Paragon

*A Family Guide - Coping with Chemotherapy Using Homeopathy*, Laura Fenton, 2003, Health Harmony Books.

*An Introduction to Integrated Healing - Participants' guide to self-care, healthful nutrition, vitamins, supplements, complementary medical therapies and healing*, Center for Integrated Healing, 1998

*Third Opinion: An International Directory to Alternative Therapy Centres for the Treatment and Prevention of Cancer and Other Degenerative Diseases*, Second edition, J. M. Fink, 1992; Avery Publishing Group.

*A Guide to Unconventional Cancer Therapies*, Ontario Breast Cancer Information Exchange Project, 1994

*Breast Cancer - What you should know (but may not be told) about prevention, diagnosis and treatment*, Steve Austin, N.D. and Cathy Hitchcock, M.S.W., 1994, Prima Health Publishing

*Breast Cancer - The Complete Guide*, Third edition, Yashar Hirshaut & Peter Pressman, 2000, Bantam Books.

*Breast Cancer - A Nutritional Approach*, Carlton Fredericks, Ph.D., 1977, Grosset & Dunlap

*Beating Cancer with Nutrition*, Patrick Quillan, 1994, Nutrition times Press.

*Secrets to Great Health*, Jonn Matsen, N.D., 2001, Prima Publishing

*The Schwarzbein Principle*, Diana Schwarzbein, MD, 1999, Health Communications

*A Holistic Approach to Cancer Therapy*, Wolfgang Woepel, 1995, Pascoe

*Nutritional Management of Cancer Patients*, Abby S. Block, Aspen Publishers

*Love, Medicine & Miracles - Lessons learned about self-healing from a surgeon's experience with exceptional patients*, Bernie. S. Siegel, M.D., 1986, Harper & Row

*Cancer Therapy – The Independent Consumer's Guide to Non-toxic Treatment and Prevention* , Ralph Moss 1992/6 Equinox Press.

*Homeopathic Medical Repertory*, Robin Murphy, N.D., 1993; Hahnemann Academy of North America

*How to Prevent and Treat Cancer with Natural Medicine*, Michael Murray, Tim Birdsall, Joseph E. Pizzorno & Paul Reilly, 2002, Riverhead Books

*Cancer and Vitamin C*, Ewan Cameron & Linus Pauling, 1979, Linus Pauling Institute of Science and Medicine

*Everyone's Guide to Cancer Therapy*, M. Dollinger, E. Rosebaum, & G. Cable, Andrews-McMeel Publishers

*The Wheatgrass Book*, Ann Wigmore, 'Doctor of Natural Laws', 1985, Avery Publishing Group.

*Healing Words – The Power of Prayer and the Practice of Medicine*, Larry Dossey 1993.

*Head First – The Biology of Hope*, Norman Cousins, 1989.

*Cancer Principles and Practices*, V. DeVita, S. Hellman,& S. Rosenberg, 9<sup>th</sup> Ed. 2011, Lipincott-Raven Publishers

*Handbook of Cancer Chemotherapy*, Roland T. Skeel, 1999, Lipincott.

*Manual of Clinical Oncology*,3<sup>rd</sup> Ed. 1995, D. Casciato & B. Lowitz, Little Brown

*FDA Supplement Warnings - Misleading, Exaggerated or Unproven*, Zoltan Rona, June/July 1998, Health Naturally.

*Increasing and Improving Research in Complementary and Alternative Medicine*, Carlo Calabrese, 2000, NIH Office of Alternative Medicine.

*The Cancer Blackout - A history of denied and suppressed remedies*, Maurice Natenberg, 1959, Regent House.

*The Medical Mafia - How to get out of it alive and take back our health & wealth*, Ghislaine Lanctot, 2002 edition, self-published.

*Hard to Swallow – The Truth About Food Additives*, Sargeant and Evans, 1995, Alive Books

*Fight for Your Health*, Byron Richards, 2006, Walter Publishing.

*Cancer - A Healing Crisis - the whole-body approach to cancer therapy*, Jack Tropp, 1980, Exposition Press.

*The Healing of Cancer - The cures, the cover-ups and the solution now*, Barry Lynes, 1989, Marcus Books.

*7-Day Detox Miracle 2<sup>nd</sup> ed.,*, Bennett & Barrie , 2001; Three Rivers Press.

*Cancer Treatment with Fu Zheng Pei Ben Principle*, Pan Mingji, et al, 1992, Fujian Science & Technology Publishing House.

*Living Downstream: An Ecologist Looks at Cancer and the Environment*, Steingraber, 1997, published by Addison-Wesley.

*Our Toxic World – A Wake-up Call - Chemicals damage your body, brain, behaviour and sex*, Doris Rapp, 2004.

*Toxic Deception - How the chemicals industry manipulates science, bends the law and endangers your health*, Dan Fagin, Marianne Lavelle, 2002, Common Courage Press.

*The CancerSmart Consumer Guide- How to eliminate toxins from your home and garden products and how to make healthy choices for your family and the environment*, Labour Environmental Alliance Society, Vancouver, B.C., [www.leas.ca](http://www.leas.ca)

*Clinical Purification, A Complete Treatment and Reference Manual*, Gina Nick, 2001, Longevity Through Prevention.

*Cancer Therapy – The Independent Consumer’s Guide to Non-Toxic Treatment and Prevention*, Ralph Moss 1992/6 Equinox Press.

*The Promise of Low-Dose Naltrexone Therapy*, Moore & Wilkinson, 2009; McFarland ISBN 978-0-7864-3715-3.  
*Dismantling Cancer*, Contreras, Baroso-Arnanda & Kennedy, 2004; Interpacific Press.

*Cannabis – A History*, Martin Booth, 2003, Picador – St. Martin’s Press.

*Oral Vs. Inhaled Cannabinoids for Nausea/Vomiting from Cancer Chemotherapy*”, New Mexico State Department of Health Nov. 1986.

*Cannabis and Cannabinoids: Pharmacology, Toxicology and Therapeutic Potential*. Grotenhermen, Franjo (2002). New York City: Hawthorne Integrative Healing Press

*Hempology 101- The History and Uses of Cannabis Sativa*, 4<sup>th</sup> edition, Ted Smith, 2012, The International Hempology 101 Society.

*Integrative Oncology*, ed. Donald Abrams and Andrew Weil, see “Cannabis and Cancer” Abrams and Guzman, 2009, Oxford University Press.

*Marijuana – Gateway to Health – How Cannabis Protects Us from Cancer and Alzheimer’s Disease*, Clint Werner, 2011, Dachstar Press.

*The Pot Book, A Complete Guide to Cannabis – It’s Role in Medicine, Politics, Science and Culture*, Julie Holland, ed., 2010, Park Street Press.

*Tripping Over the Truth: The Return of the Metabolic Theory of Cancer Illuminates a New and Hopeful Path to a Cure*, Travis Christofferson, 2014; CreateSpace Independent Publishing Platform.

*Cancer As A Metabolic Disease – On the Origin, Management and Prevention of Cancer*, Thomas Seyfried, PhD, 2012, John Wiley & Sons.

*Vitamin K2 and the Calcium Paradox – How a Little-Known Vitamin Could Save Your Life*, K. Rheaume-Bleue, ND , 2012, Harper-Collins Publishing.

#### **RECOMMENDED JOURNALS**

- Cancer
- Nutrition & Cancer
- Journal of Clinical Oncology
- Journal of the National Cancer Institute
- Cancer Research
- Integrative Cancer Therapies
- American Journal of Clinical Nutrition
- Alternative Medicine Review